<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vaccines for preventing influenza in healthy adults - Demicheli, V - 2018 | Cochrane Library</title> <meta content="Vaccines for preventing influenza in healthy adults - Demicheli, V - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001269.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vaccines for preventing influenza in healthy adults - Demicheli, V - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001269.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001269.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Vaccines for preventing influenza in healthy adults" name="citation_title"/> <meta content="Vittorio Demicheli" name="citation_author"/> <meta content="Azienda Sanitaria Locale ASL AL" name="citation_author_institution"/> <meta content="vittorio.demicheli@libero.it" name="citation_author_email"/> <meta content="Tom Jefferson" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Eliana Ferroni" name="citation_author"/> <meta content="Regional Center for Epidemiology, Veneto Region" name="citation_author_institution"/> <meta content="Alessandro Rivetti" name="citation_author"/> <meta content="ASL CN2 Alba Bra" name="citation_author_institution"/> <meta content="Carlo Di Pietrantonj" name="citation_author"/> <meta content="Local Health Unit Alessandria‐ ASL AL" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD001269.pub6" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001269.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001269.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001269.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Absenteeism; Drug Industry; Health Status; Hospitalization [statistics &amp; numerical data]; Influenza A virus; Influenza B virus; Influenza Vaccines [adverse effects, *therapeutic use]; Influenza, Human [*prevention &amp; control, virology]; Nausea [chemically induced]; Pregnancy Complications, Infectious [prevention &amp; control, virology]; Publication Bias; Research Support as Topic; Vomiting [chemically induced]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001269.pub6&amp;doi=10.1002/14651858.CD001269.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="1pyM3CVc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001269\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001269\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","pl","fr","de","hr","fa","th","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001269.pub6",title:"Vaccines for preventing influenza in healthy adults",firstPublishedDate:"Feb 1, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001269.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001269.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001269.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001269.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001269.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001269.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001269.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001269.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001269.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001269.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>64531 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001269.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-sec-0144"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-sec-0082"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-sec-0134"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/appendices#CD001269-sec-0149"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/table_n/CD001269StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/table_n/CD001269StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vaccines for preventing influenza in healthy adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#CD001269-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vittorio Demicheli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#CD001269-cr-0003">Tom Jefferson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#CD001269-cr-0004">Eliana Ferroni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#CD001269-cr-0005">Alessandro Rivetti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information#CD001269-cr-0006">Carlo Di Pietrantonj</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information/en#CD001269-sec-0227">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001269.pub6">https://doi.org/10.1002/14651858.CD001269.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001269-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001269-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001269-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001269-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001269-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001269-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001269-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001269-abs-0001" lang="en"> <section id="CD001269-sec-0001"> <h3 class="title" id="CD001269-sec-0001">Background</h3> <p>The consequences of influenza in adults are mainly time off work. Vaccination of pregnant women is recommended internationally. This is an update of a review published in 2014. Future updates of this review will be made only when new trials or vaccines become available. Observational data included in previous versions of the review have been retained for historical reasons but have not been updated due to their lack of influence on the review conclusions. </p> </section> <section id="CD001269-sec-0002"> <h3 class="title" id="CD001269-sec-0002">Objectives</h3> <p>To assess the effects (efficacy, effectiveness, and harm) of vaccines against influenza in healthy adults, including pregnant women. </p> </section> <section id="CD001269-sec-0003"> <h3 class="title" id="CD001269-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 12), MEDLINE (January 1966 to 31 December 2016), Embase (1990 to 31 December 2016), the WHO International Clinical Trials Registry Platform (ICTRP; 1 July 2017), and ClinicalTrials.gov (1 July 2017), as well as checking the bibliographies of retrieved articles. </p> </section> <section id="CD001269-sec-0004"> <h3 class="title" id="CD001269-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) or quasi‐RCTs comparing influenza vaccines with placebo or no intervention in naturally occurring influenza in healthy individuals aged 16 to 65 years. Previous versions of this review included observational comparative studies assessing serious and rare harms cohort and case‐control studies. Due to the uncertain quality of observational (i.e. non‐randomised) studies and their lack of influence on the review conclusions, we decided to update only randomised evidence. The searches for observational comparative studies are no longer updated. </p> </section> <section id="CD001269-sec-0005"> <h3 class="title" id="CD001269-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. We rated certainty of evidence for key outcomes (influenza, influenza‐like illness (ILI), hospitalisation, and adverse effects) using GRADE. </p> </section> <section id="CD001269-sec-0006"> <h3 class="title" id="CD001269-sec-0006">Main results</h3> <p>We included 52 clinical trials of over 80,000 people assessing the safety and effectiveness of influenza vaccines. We have presented findings from 25 studies comparing inactivated parenteral influenza vaccine against placebo or do‐nothing control groups as the most relevant to decision‐making. The studies were conducted over single influenza seasons in North America, South America, and Europe between 1969 and 2009. We did not consider studies at high risk of bias to influence the results of our outcomes except for hospitalisation. </p> <p>Inactivated influenza vaccines probably reduce influenza in healthy adults from 2.3% without vaccination to 0.9% (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.36 to 0.47; 71,221 participants; moderate‐certainty evidence), and they probably reduce ILI from 21.5% to 18.1% (RR 0.84, 95% CI 0.75 to 0.95; 25,795 participants; moderate‐certainty evidence; 71 healthy adults need to be vaccinated to prevent one of them experiencing influenza, and 29 healthy adults need to be vaccinated to prevent one of them experiencing an ILI). The difference between the two number needed to vaccinate (NNV) values depends on the different incidence of ILI and confirmed influenza among the study populations. Vaccination may lead to a small reduction in the risk of hospitalisation in healthy adults, from 14.7% to 14.1%, but the CI is wide and does not rule out a large benefit (RR 0.96, 95% CI 0.85 to 1.08; 11,924 participants; low‐certainty evidence). Vaccines may lead to little or no small reduction in days off work (‐0.04 days, 95% CI ‐0.14 days to 0.06; low‐certainty evidence). Inactivated vaccines cause an increase in fever from 1.5% to 2.3%. </p> <p>We identified one RCT and one controlled clinical trial assessing the effects of vaccination in pregnant women. The efficacy of inactivated vaccine containing pH1N1 against influenza was 50% (95% CI 14% to 71%) in mothers (NNV 55), and 49% (95% CI 12% to 70%) in infants up to 24 weeks (NNV 56). No data were available on efficacy against seasonal influenza during pregnancy. Evidence from observational studies showed effectiveness of influenza vaccines against ILI in pregnant women to be 24% (95% CI 11% to 36%, NNV 94), and against influenza in newborns from vaccinated women to be 41% (95% CI 6% to 63%, NNV 27). </p> <p>Live aerosol vaccines have an overall effectiveness corresponding to an NNV of 46. The performance of one‐ or two‐dose whole‐virion 1968 to 1969 pandemic vaccines was higher (NNV 16) against ILI and (NNV 35) against influenza. There was limited impact on hospitalisations in the 1968 to 1969 pandemic (NNV 94). The administration of both seasonal and 2009 pandemic vaccines during pregnancy had no significant effect on abortion or neonatal death, but this was based on observational data sets. </p> </section> <section id="CD001269-sec-0007"> <h3 class="title" id="CD001269-sec-0007">Authors' conclusions</h3> <p>Healthy adults who receive inactivated parenteral influenza vaccine rather than no vaccine probably experience less influenza, from just over 2% to just under 1% (moderate‐certainty evidence). They also probably experience less ILI following vaccination, but the degree of benefit when expressed in absolute terms varied across different settings. Variation in protection against ILI may be due in part to inconsistent symptom classification. Certainty of evidence for the small reductions in hospitalisations and time off work is low. Protection against influenza and ILI in mothers and newborns was smaller than the effects seen in other populations considered in this review. </p> <p>Vaccines increase the risk of a number of adverse events, including a small increase in fever, but rates of nausea and vomiting are uncertain. The protective effect of vaccination in pregnant women and newborns is also very modest. We did not find any evidence of an association between influenza vaccination and serious adverse events in the comparative studies considered in this review. Fifteen included RCTs were industry funded (29%). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001269-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001269-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001269-abs-0014">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001269-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001269-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001269-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001269-abs-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001269-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001269-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001269-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD001269-abs-0020">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001269-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001269-abs-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001269-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001269-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001269-abs-0005" lang="en"> <h3>Vaccines to prevent influenza in healthy adults</h3> <p><b>Review aim</b> </p> <p>The aim of this Cochrane Review, first published in 1999, was to summarise research that looks at the effects of immunising healthy adults with influenza vaccines during influenza seasons. We used information from randomised trials comparing vaccines with dummy vaccines or nothing. We focused on the results of studies looking at vaccines based on inactivated influenza viruses, which are developed by killing the influenza virus with a chemical and are given by injection through the skin. We evaluated the effects of vaccines on reducing the number of adults with confirmed influenza and the number of adults who had influenza‐like symptoms such as headache, high temperature, cough, and muscle pain (influenza‐like illness, or ILI). We also evaluated hospital admission and harms arising from the vaccines. Observational data included in previous versions of the review have been retained for historical reasons but have not been updated due to their lack of influence on the review conclusions. </p> <p><b>What was studied in this review?</b> </p> <p>Over 200 viruses cause ILI, which produces the same symptoms (fever, headache, aches, pains, cough, and runny nose) as influenza. Without laboratory tests, doctors cannot distinguish between ILI and influenza because both last for days and rarely cause serious illness or death. The types of virus contained in influenza vaccines are usually those that are expected to circulate in the following influenza seasons, according to recommendations of the World Health Organization (seasonal vaccine). Pandemic vaccine contains only the virus strain that is responsible of the pandemic (i.e. the type A H1N1 for the 2009 to 2010 pandemic). </p> <p><b>Main results</b> </p> <p>We found 52 clinical trials of over 80,000 adults. We were unable to determine the impact of bias on about 70% of the included studies due to insufficient reporting of details. Around 15% of the included studies were well designed and conducted. We focused on reporting of results from 25 studies that looked at inactivated vaccines. Injected influenza vaccines probably have a small protective effect against influenza and ILI (moderate‐certainty evidence), as 71 people would need to be vaccinated to avoid one influenza case, and 29 would need to be vaccinated to avoid one case of ILI. Vaccination may have little or no appreciable effect on hospitalisations (low‐certainty evidence) or number of working days lost. </p> <p>We were uncertain of the protection provided to pregnant women against ILI and influenza by the inactivated influenza vaccine, or this was at least very limited. </p> <p>The administration of seasonal vaccines during pregnancy showed no significant effect on abortion or neonatal death, but the evidence set was observational. </p> <p><b>Key messages</b> </p> <p>Inactivated vaccines can reduce the proportion of healthy adults (including pregnant women) who have influenza and ILI, but their impact is modest. We are uncertain about the effects of inactivated vaccines on working days lost or serious complications of influenza during influenza season. </p> <p><b>How up to date is this review?</b> </p> <p>The evidence is current to 31 December 2016.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001269-sec-0144" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001269-sec-0144">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001269-sec-0283">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001269-sec-0144"></div> <h3 class="title" id="CD001269-sec-0145">Implications for practice</h3> <section id="CD001269-sec-0145"> <p>Healthy adults who receive inactivated parenteral influenza vaccine rather than no vaccine probably have a 1% lower risk of experiencing influenza over a single influenza season (2.3% versus 1%, moderate‐certainty evidence) and probably have a 3.4% lower risk of experiencing influenza‐like illness (ILI) (21.5% versus 18.1%, moderate‐certainty evidence). The numbers needed to vaccinate (NNVs) for influenza and ILI were 71 and 29, respectively, reflecting high rates of ILI in the control groups for many of the trials. The NNV of 29 conceals variation in the absolute reduction in ILI for low‐ and high‐risk groups, and the degree of benefit may vary at least in part due to inconsistent symptom classification. Extrapolatiing these effects to settings other than those of the studies is challenging due to uncertain methods for confirming influenza and variation in the absolute reductions in ILI following vaccination. </p> <p>We found low‐certainty evidence that hospitalisation rates and time off work may be comparable between vaccinated and unvaccinated adults, although the confidence interval around the effect for hospital admission is wide and there was substantial variation in the direction of effect on time off work. Vaccines increase the risk of a number of adverse events, including a small increase in fever, but the effect on nausea or vomiting is less clear. </p> </section> <h3 class="title" id="CD001269-sec-0146">Implications for research</h3> <section id="CD001269-sec-0146"> <p>When a new vaccination or preventive technology becomes available, an adequately powered, publicly funded, high‐quality, placebo‐controlled trial run over several seasons should be undertaken. New insights on the role of viruses and other agents in the genesis of influenza and ILI are also needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001269-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001269-sec-0043"></div> <div class="table" id="CD001269-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Inactivated parenteral influenza vaccine compared to placebo or 'do nothing' for preventing influenza in healthy adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inactivated parenteral influenza vaccine compared to placebo or 'do nothing' for preventing influenza in healthy adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults<br/> <b>Setting:</b> community‐based studies in North America, South America, and Europe (1969 to 2009)<br/> <b>Intervention:</b> inactivated parenteral influenza vaccine<br/> <b>Comparison:</b> placebo or 'do nothing' </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or 'do nothing'</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactivated parenteral influenza vaccine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Influenza</b><br/> assessed by laboratory confirmation </p> <p>Timing of assessment: most studies tested vaccines over a single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/> (0.36 to 0.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71,221<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (8 to 11) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Influenza‐like illness</b><br/> assessed by subjective report </p> <p>Timing of assessment: most studies tested vaccines over a single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.84<br/> (0.75 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>25,795<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/> (30 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000<br/> (161 to 205) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>910 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>764 per 1000<br/> (683 to 864) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hospitalisations</b> </p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.85 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,924<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>147 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/> (125 to 158) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time off work</b> </p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3726</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average number of days lost per person ranged from 0.2 to 2 days over the season.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average reduction in working days lost following vaccination was 0.04 days fewer (0.14 fewer to 0.06 days more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fever</b> </p> <p>assessed by subjective report</p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.55<br/> (1.26 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23,850<br/> (13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (19 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea or vomiting</b><br/> assessed by subjective report </p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.80<br/> (0.65 to 5.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6315<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (24 to 185) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk calculated as the sum of events over total sample size from the control groups. For the outcome of influenza‐like illness, control group risk was stratified as low, moderate (or median), and high due to variation in risk groups across the studies. For the remaining outcomes, the control group risk was taken as aggregate.<br/> <sup>2</sup>Sensitivity analysis by excluding studies with two or more domains at unclear risk of bias did not meaningfully alter the direction, size, or precision of effect. We are confident that bias is unlikely to exaggerate the intervention effect because the absolute reduction in influenza and relative reduction in the risk of influenza‐like illness are small with vaccination.<br/> <sup>3</sup>Downgraded one level due to serious indirectness. Uncertainty over definition, surveillance and testing of influenza in older trials.<br/> <sup>4</sup>Downgraded one level for serious inconsistency. There is discordance between the direction and size of effects across the studies. Different definitions of influenza‐like illness across the studies could explain why there is variation in the event rates across the control arms.<br/> <sup>5</sup>Downgraded one level due to serious risk of bias. Meta‐analysis heavily influenced by a large study with high risk of bias across several domains.<br/> <sup>6</sup>Downgraded one level due to serious imprecision. Confidence interval includes meaningful reduction and increase in effect.<br/> <sup>7</sup>Downgraded one level due to serious risk of bias. Effect is influenced by studies judged to be at unclear risk of bias.<br/> <sup>8</sup>Downgraded one level due to serious inconsistency. Direction and magnitude of effect differed across the studies (I<sup>2</sup> = 82%). Wide confidence interval reflects the range of study effect sizes. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001269-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001269-sec-0044">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001269-sec-0235">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD001269-sec-0044"></div> <section id="CD001269-sec-0045"> <h3 class="title" id="CD001269-sec-0045">Description of the condition</h3> <p>Viral respiratory disease imposes a heavy burden on society. The majority of viral respiratory disease (influenza‐like illness (ILI)) is caused by many different agents that are not clinically distinguishable from one another. A variable proportion of ILI (7% to 15% on average) is caused by influenza viruses and is known as influenza (<a href="./references#CD001269-bbs2-0336" title="JeffersonTO . Mistaken identity: seasonal influenza versus influenza‐like illness. Clinical Evidence2009;329:1‐4. ">Jefferson 2009a</a>). </p> <p>Influenza is an acute respiratory infection caused by a virus of the <i>Orthomyxoviridae</i> family. Three serotypes are known (A, B, and C). Influenza causes an acute febrile illness with myalgia, headache, and cough. Although the median duration of the acute illness is three days, cough and malaise can persist for weeks. Complications of influenza include otitis media, pneumonia, secondary bacterial pneumonia, exacerbations of chronic respiratory disease, and bronchiolitis in children. Additionally, influenza can cause a range of non‐respiratory complications, including febrile convulsions, Reye's syndrome, and myocarditis (<a href="./references#CD001269-bbs2-0349" title="TreanorJJ . Influenza vaccination. New England Journal of Medicine2016;375(13):1261‐8. [DOI: 10.1056/NEJMcp1512870] ">Treanor 2016</a>; <a href="./references#CD001269-bbs2-0351" title="WiselkaM . Influenza: diagnosis, management and prophylaxis. BMJ1994;308:1341‐5. ">Wiselka 1994</a>). Efforts to prevent or minimise the impact of seasonal influenza in the second part of the 20th century were centred on the use of vaccines. Due to the yearly changes in viral antigenic configuration and the lack of carry‐over protection from year to year, a new vaccination campaign needs to be organised annually, with a huge scientific and logistic effort to ensure production and delivery of the vaccines. </p> </section> <section id="CD001269-sec-0046"> <h3 class="title" id="CD001269-sec-0046">Description of the intervention</h3> <p>There are currently three types of influenza vaccines:</p> <p> <ol id="CD001269-list-0001"> <li> <p>whole‐virion vaccines, which consist of complete viruses that have been 'killed' or inactivated, so that they are not infectious but retain their strain‐specific antigenic properties; </p> </li> <li> <p>subunit vaccines, which are made of surface antigens (H and N) only; and</p> </li> <li> <p>split‐virion vaccines, in which the viral structure is broken up by a disrupting agent.</p> </li> </ol> </p> <p>These vaccines contain both surface and internal antigens. In addition, a variety of non‐European manufacturers produce live attenuated vaccines. Whole‐virion vaccines are traditionally thought to be less well tolerated due to the presence of a lipid stratum on the surface of the viral particles (a remnant of the host cell membrane coating the virion, when budding from the host cell). </p> <p>The US Food and Drug Administration (FDA) recently approved a new recombinant vaccine (Flublok) consisting of purified haemagglutinin proteins produced in inset cells for use in adults aged between 18 and 49 years with a known history of egg allergy (<a href="./references#CD001269-bbs2-0325" title="Advisory Committee on Immunization Practices. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015‐16 influenza season. Morbidity and Mortality Weekly Report2015;64(30):818‐25. ">ACIP 2015</a>). </p> <p>Influenza vaccines are produced worldwide. Periodic antigenic drifts and shifts pose problems for vaccine production and procurement, as a new vaccine closely matching the circulating antigenic configuration must be produced and procured for the beginning of each new influenza 'season'. To achieve this, the World Health Organization (WHO) has established a worldwide surveillance system, allowing the identification and isolation of viral strains circulating the different parts of the globe. Sentinel practices recover viral particles from the nasopharynx of patients with influenza‐like symptoms, and the samples are sent swiftly to the laboratories of the national influenza centres (110 laboratories in 79 countries). When new strains are detected, the samples are sent to one of the four WHO reference centres (London, Atlanta, Tokyo, and Melbourne) for antigenic analysis. Information on the circulating strain is then sent to the WHO, which in February of each year recommends through a committee the strains to be included in the vaccine for the forthcoming 'season'. Individual governments may or may not follow the WHO recommendations. Australia, New Zealand, and more recently South Africa have followed their own recommendations for vaccine content. Surveillance and early identification thus play a central part in the composition of the vaccine. </p> </section> <section id="CD001269-sec-0047"> <h3 class="title" id="CD001269-sec-0047">How the intervention might work</h3> <p>Vaccines work by simulating an infection and stimulating the body to produce antibodies against the threat and activate other defence mechanisms. Every vaccination campaign has stated aims against which the effects of the campaign must be measured. Perhaps the most detailed document presenting the rationale for a comprehensive preventive programme was that by the US Advisory Committee on Immunization Practice (ACIP), published in 2006 (<a href="./references#CD001269-bbs2-0323" title="Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendations and Reports: Morbidity and Mortality Weekly Report2006;55:1‐41. ">ACIP 2006</a>). The document identified 11 categories of people at high risk of complications from influenza, among which are healthy adults 50 to 65 years of age and healthcare workers. The rationale for policy choices rests on the heavy burden that influenza imposes on the populations and on the benefits accruing from vaccinating them. Reductions in cases and complications (such as excess hospitalisations, absence from work, mortality, and healthcare contacts) and the interruption of transmission are the principal arguments for extending vaccination to healthy adults aged 50 to 65 years (<a href="./references#CD001269-bbs2-0323" title="Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendations and Reports: Morbidity and Mortality Weekly Report2006;55:1‐41. ">ACIP 2006</a>). </p> <p>The <a href="./references#CD001269-bbs2-0325" title="Advisory Committee on Immunization Practices. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015‐16 influenza season. Morbidity and Mortality Weekly Report2015;64(30):818‐25. ">ACIP 2015</a> document update recommends routine vaccination for all people aged six months and older without contraindications. It underlines the importance of focusing vaccination efforts, when vaccination supplies are limited, on healthy adults who are at increased risk of developing severe complications from influenza, such as: </p> <p> <ul id="CD001269-list-0002"> <li> <p>people aged 50 years or over;</p> </li> <li> <p>women who are or who will be pregnant during the influenza season;</p> </li> <li> <p>healthcare personnel;</p> </li> <li> <p>household contacts and caregivers of children aged below five years and adults aged 50 years or over, with particular emphasis on vaccinating contacts of children younger than six months of age; and </p> </li> <li> <p>household contacts and caregivers of people with medical conditions that put them at higher risk of severe complications from influenza (<a href="./references#CD001269-bbs2-0324" title="FioreAE , UyekiTM , BroderK , FinelliL , EulerGL , SingletonJA , et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report2010;59(RR‐8):1‐62. ">ACIP 2010</a>; <a href="./references#CD001269-bbs2-0325" title="Advisory Committee on Immunization Practices. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015‐16 influenza season. Morbidity and Mortality Weekly Report2015;64(30):818‐25. ">ACIP 2015</a>; <a href="./references#CD001269-bbs2-0334" title="GrohskopfLA , SokolowLZ , BroderKR , OlsenSJ , KarronRA , JerniganDB , et al. Prevention and control of seasonal influenza with vaccines. Morbidity and Mortality Weekly Report2016;65(5):1‐54. [DOI: 10.15585/mmwr.rr6505a1] ">Grohskopf 2016</a>). </p> </li> </ul> </p> <p>Pregnant women are included among priority recipients for seasonal influenza immunisation in many countries due to the risk of influenza‐associated morbidity during pregnancy and the possible adverse neonatal outcomes associated with maternal influenza infections (<a href="./references#CD001269-bbs2-0326" title="Australian Technical Advisory Group on Immunisation (ATAGI). The Australian Immunisation Handbook. 10th Edition. Australian Government: National Health and Medical Research Council, 2013. ">AIH 2013</a>; <a href="./references#CD001269-bbs2-0330" title="Department of Health, UK . Influenza. Immunisation Against Infectious Diseases: The Green Book. Vol. 19, Department of Health, UK, 2015:18‐9. ">DoH 2015</a>; <a href="./references#CD001269-bbs2-0343" title="National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Commitee on Immunization: statement on seasonal influenza vaccine for 2014‐2015. Canada Communicable Diseases Report, 2014. http:/www.phac‐aspc.gcca/naci‐ccni/assets/pdf/flu‐grippe‐eng.pdf (accessed September 3, 2015). ">NACI 2014</a>; <a href="./references#CD001269-bbs2-0347" title="Ständigen Impfkommission (STIKO) am RobertKoch‐Institut . Recommendations update for immunisation against influenza [Änderung der Empfehlungen zur Impfung gegen Influenza]. Epidemiologisches Bulletin2010;31:299‐308. ">STIKO 2010</a>), and based on evidence that vaccination of pregnant women protects their newborns from influenza and influenza‐related hospitalisations (<a href="./references#CD001269-bbs2-0343" title="National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Commitee on Immunization: statement on seasonal influenza vaccine for 2014‐2015. Canada Communicable Diseases Report, 2014. http:/www.phac‐aspc.gcca/naci‐ccni/assets/pdf/flu‐grippe‐eng.pdf (accessed September 3, 2015). ">NACI 2014</a>). </p> <p>Inactivated influenza vaccine may be administered at any stage of pregnancy, whereas live vaccine is not licensed for use during pregnancy as the available data about safety and efficacy in mothers and babies are very limited (<a href="./references#CD001269-bbs2-0324" title="FioreAE , UyekiTM , BroderK , FinelliL , EulerGL , SingletonJA , et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report2010;59(RR‐8):1‐62. ">ACIP 2010</a>; <a href="./references#CD001269-bbs2-0330" title="Department of Health, UK . Influenza. Immunisation Against Infectious Diseases: The Green Book. Vol. 19, Department of Health, UK, 2015:18‐9. ">DoH 2015</a>). </p> <p>The European Medicines Agency (EMA) recently made changes to the registration of seasonal, pre‐pandemic, and pandemic influenza vaccines (<a href="./references#CD001269-bbs2-0331" title="Committee for Medicinal Products for Human Use. Guideline on influenza vaccines. Non‐clinical and clinical module. European Medicines Agency, 2014, EMA/CHMP/VWP/457259/2014. [web:: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211324.pdf] ">EMA 2014</a>; <a href="./references#CD001269-bbs2-0350" title="WijnansL , VoordouwB . A review of the changes to the licensing of influenza vaccines in Europe. Viruses2016;10(1):2‐8. ">Wijnans 2016</a>). The changes were introduced in 2014, triggered by the realisation that antibody responses are not sufficient predictors of field protection, as our reviews have consistently shown over the years. Most of the data for influenza vaccines included in our reviews are from registered vaccines, and yet the field protection afforded is modest or negligible. In addition, the methods of standardisation of antibody titres were lacking. The new rules for adults and the elderly require demonstration of non‐inferiority of antibody response (immunogenicity) by a candidate seasonal influenza vaccine compared to an established one. In addition, whenever a demonstration of clinical efficacy is necessary (see <a href="./appendices#CD001269-sec-0150">Appendix 1</a>), the EMA encourages minimisation of the use of placebo and encourages the use of active controls (such a non‐influenza vaccines) with ILI (and relevant polymerase chain reaction (PCR) results) as a primary endpoint. Clinical effectiveness should be tested by carrying out (preferably prospective) cohort studies or nested so‐called test‐negative case‐control studies following the European Centre for Disease Prevention and Control (ECDC) protocol (<a href="./references#CD001269-bbs2-0340" title="KisslingE , MorenA , ValencianoM . Protocol for case‐control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. ECDC Technical Document. Paris: European Centre for Disease Prevention and Control, 2009. [web: http://ecdc.europa.eu/en/publications/Publications/0907_TED_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Case_Control_Studies.pdf last accessed on May 25th, 2017] ">Kissling 2009a</a>; <a href="./references#CD001269-bbs2-0341" title="KisslingE , MorenA , ValencianoM . Protocol for cohort database studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. ECDC Technical Document. Paris: European Centre for Disease Prevention and Control, 2009. [web: http://ecdc.europa.eu/en/publications/Publications/0907_TER_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Cohort_Database_Studies.pdf Last accessed on May 25th, 2017] ">Kissling 2009b</a>). </p> <p>Harms surveillance is now required with a follow‐up of at least six months duration and in the general elderly population a database of at least 3000 people exposed to the vaccine. Enhanced vaccine vigilance data should be collected as soon as possible at the beginning of the vaccination campaign each year. </p> </section> <section id="CD001269-sec-0048"> <h3 class="title" id="CD001269-sec-0048">Why it is important to do this review</h3> <p>Due to the unique production cycle of influenza vaccines (they are tested using surrogate outcomes ‐ antibody stimulation ‐ ahead of each influenza 'season'), past performance is probably the only reliable way to predict future performance. </p> <p>An accurate assessment of the effects (efficacy, effectiveness, and safety profile) of influenza vaccines is essential to allow rational choice between alternative strategies. This review with its two companion reviews, <a href="./references#CD001269-bbs2-0328" title="DemicheliV , JeffersonT , Al‐AnsaryLA , FerroniE , RivettiA , DiPietrantonjC . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD001269.pub5] ">Demicheli 2014</a> and <a href="./references#CD001269-bbs2-0338" title="JeffersonT , RivettiA , DiPietrantonjC , DemicheliV , FerroniE . Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD004879.pub4] ">Jefferson 2012</a>, are long‐running reviews. They are among the most consistently accessed in the Cochrane Database of Systematic Reviews, confirming the importance of the topic and interest in it. Periodic updates, some stretching back almost two decades, have allowed us to include an increasing number of studies on the effects of influenza vaccines and monitor their impact on our reviews (<a href="#CD001269-tbl-0002">Table 1</a>). </p> <div class="table" id="CD001269-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies included in the various versions of this review and their impact on our conclusions</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review version (searches date)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials (RCTs/CCTs)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included observational studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Estimates of effect (RCTs/CCTs only)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions (1‐2 lines from abstract)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 1</p> <p><a href="./references#CD001269-bbs2-0353" title="DemicheliV , RivettiD , DeeksJJ , JeffersonTO . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD001269] ">Demicheli 1999</a> </p> <p>(6 July 1999)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical influenza</b> </p> <p>TIV = 24% (95% CI 15% to 32%)</p> <p>LAIV = 13% (95% CI 5% to 20%)</p> <p>IAV = 40% (95% CI 13% to 59%)</p> <p><b>Laboratory‐confirmed influenza</b> </p> <p>TIV = 68% (95% CI 49% to 79%)</p> <p>LAIV = 48% (95% CI 24% to 64%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines are effective in reducing serologically confirmed cases of influenza A. However, they are not as effective in reducing cases of clinical influenza. The use of WHO recommended vaccines appears to enhance their effectiveness in practice. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 2<br/> <a href="./references#CD001269-bbs2-0355" title="DemicheliV , RivettiD , DeeksJJ , JeffersonTO . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD001269.pub2] ">Demicheli 2004</a> </p> <p>(24 May 2004)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical influenza</b> </p> <p>TIV = 25% (95% CI 13% to 35%)</p> <p>LAIV = 15% (95% CI 8% to 21%)</p> <p>IAV = 40% (95% CI 13% to 59%)</p> <p><b>Laboratory‐confirmed influenza</b> </p> <p>TIV = 70% (95% CI 56% to 80%)</p> <p>LAIV = 48% (95% CI 24% to 64%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines are effective in reducing serologically confirmed cases of influenza. However, they are not as effective in reducing cases of clinical influenza and number of working days lost. Universal immunisation of healthy adults is not supported by the results of this review. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 3<br/> <a href="./references#CD001269-bbs2-0356" title="JeffersonTO , RivettiD , DiPietrantonjC , RivettiA , DemicheliV . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD001269.pub3] ">Jefferson 2007</a> </p> <p>(16 February 2007)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(for harms only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ILI</b> </p> <p>TIV = 30% (95% CI 17% to 41%)</p> <p>LAIV = n.s.</p> <p>IAV = n.s.</p> <p><b>Influenza</b> </p> <p>TIV = 80% (95% CI 56% to 81%)</p> <p>LAIV = 56% (95% CI 19% to 76%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines are effective in reducing cases of influenza, especially when the content accurately predicts circulating types and circulation is high. However, they are less effective in reducing cases of influenza‐like illness and have a modest impact on working days lost. There is insufficient evidence to assess their impact on complications. Whole‐virion monovalent vaccines may perform best in a pandemic. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 4<br/> <a href="./references#CD001269-bbs2-0357" title="JeffersonTO , DiPietrantonjC , RivettiA , BawazeerGA , Al‐AnsaryLA , FeroniE . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD001269.pub4] ">Jefferson 2010</a> </p> <p>(15 June 2010)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(for harms only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ILI</b> </p> <p>TIV = 30% (95% CI 17% to 41%)</p> <p>LAIV = n.s.</p> <p>IAV = n.s.</p> <p><b>Influenza</b> </p> <p>TIV = 73% (95% CI 54% to 84%)</p> <p>LAIV = 56% (95% CI 19% to 76%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines have a modest effect in reducing influenza symptoms and working days lost. There is no evidence that they affect complications, such as pneumonia, or transmission. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 5<br/> <a href="./references#CD001269-bbs2-0358" title="JeffersonT , DiPietrantonjC , RivettiA , BawazeerGA , Al‐AnsaryLA , FerroniE . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD001269.pub5] ">Jefferson 2014</a> </p> <p>(4 March 2014)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ILI</b> </p> <p>TIV = 17% (95% CI 11% to 23%)</p> <p>LAIV = n.s.</p> <p>IAV = n.s.</p> <p><b>Influenza</b> </p> <p>TIV = 63% (95% CI 55% to 69%)</p> <p>LAIV = 45% (95% CI 18% to 63%)</p> <p>IAV = n.s.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines have a very modest effect in reducing influenza symptoms and working days lost in the general population, including pregnant women. No evidence of association between influenza vaccination and serious adverse events was found in the comparative studies considered in the review. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/> CI: confidence interval<br/> IAV: inactivated aerosol vaccines<br/> ILI: influenza‐like illness<br/> LAIV: live attenuated vaccines<br/> n.s.: not statistically significant<br/> RCT: randomised controlled trial<br/> TIV: trivalent inactivated vaccines<br/> WHO: World Health Organization<br/> <br/> <b>Versions 1 and 2</b> </p> <p>Effect estimates are from Comparison 02 (At least one vaccine recommended for that year versus placebo or other vaccine). </p> <p>A clinically defined case was assumed as any case definition based on symptoms without further specification. </p> <p>A clinically defined case (specific definition) was defined as:</p> <p> <ul id="CD001269-list-0003"> <li> <p>'flu‐like illness' according to a predefined list of symptoms (including the Centers for Disease Control and Prevention case definition for surveillance); </p> </li> <li> <p>'upper respiratory illness' according to a predefined list of symptoms.</p> </li> </ul> </p> <p>When more than one definition was given for the same trial, data related to the more specific definition were included. </p> <p>In Analysis 2.1 from versions 1 and 2, studies with both definitions are included.</p> <p>Evidence about effectiveness of aerosol inactivated vaccine comes only from studies carried out during the 1968‐69 pandemic. From version 3 onwards, specific comparisons have been added. </p> <p><b>Versions 3, 4, 5</b> </p> <p>Recommended vaccine matching circulating strains.</p> <p><b>Version 5</b> </p> <p>Out of the 42 included observational studies, 8 assessed efficacy or effectiveness of vaccine, or both, when administered during pregnancy (6 cohort and 2 case‐control studies). </p> <p><b>Version 6 (current)</b> </p> <p>In two new RCTs included in this version, vaccination was performed during pregnancy.</p> <p>Regarding efficacy/effectiveness of TIV administered in general population, estimates assessed by applying random‐effects model were 16% (95% CI 9% to 23%) against ILI and 62% (95% CI 52% to 69%) against influenza, respectively. </p> <p>In a previous interim unpublished update before the decision to stabilise the review was made, a further 16 observational studies were included: 3 case‐control and 2 cohort studies assessing the safety of influenza vaccine administration in general population, 10 cohort studies assessing the safety of influenza vaccine administration during pregnancy, and one cohort study assessing efficacy/effectiveness of the vaccine administration during pregnancy. In this 2016 updated review, we included a total of 160 studies (137 data sets), while we no longer updated searches for observational comparative studies. </p> </div> </div> <p>The reviews are not methodologically homogeneous, as their methods reflect the history and development of Cochrane Reviews. In particular, the inclusion of observational studies, which was initially favoured for the assessment of harms, has been a source of discussion. In this review, randomised evidence represents 44% of studies considered. To enhance the relevance of the review to decision‐makers, in the <a href="./references#CD001269-bbs2-0356" title="JeffersonTO , RivettiD , DiPietrantonjC , RivettiA , DemicheliV . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD001269.pub3] ">Jefferson 2007</a> update, we included comparative non‐randomised studies reporting evidence of serious or rare harms (or both). </p> <p>Historically, observational studies have been of poor methodological quality, often reporting conflicting or paradoxical results, preventing the drawing of firm conclusions. However, inclusion of particular study types and increasing size of the data sets has not led to a change in the conclusion of the reviews, while leading to a greatly increased workload. This is the main reason why the authors, the review group, and the Cochrane editors have decided to stabilise all three reviews, that is not to carry out routine updates of the observational data set and update the randomised data set if certain conditions are fulfilled in the future. </p> <p>For the same reason we have retained the observational content of this review and its companions as historical evidence of the life cycle of the reviews. </p> <p>Since the 2014 update of this review (<a href="./references#CD001269-bbs2-0358" title="JeffersonT , DiPietrantonjC , RivettiA , BawazeerGA , Al‐AnsaryLA , FerroniE . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD001269.pub5] ">Jefferson 2014</a>), we have included evidence about influenza vaccination in pregnant women and newborns. </p> <p>We plan to update the randomised evidence in this review if any or all of these conditions are fulfilled in the future: </p> <p> <ul id="CD001269-list-0004"> <li> <p>a trial assessing the clinical effects of the evolution of current technologies becomes available; </p> </li> <li> <p>a new type of vaccine is developed; or</p> </li> <li> <p>a new credible causal paradigm for influenza is formulated.</p> </li> </ul> </p> <p>For an overview of the three reviews, see the covering editorial at <a href="https://community.cochrane.org/news/why-have-three-long-running-cochrane-reviews-influenza-vaccines-been-stabilised" target="_blank">https://community.cochrane.org/news/why‐have‐three‐long‐running‐cochrane‐reviews‐influenza‐vaccines‐been‐stabilised</a>. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001269-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001269-sec-0049">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001269-sec-0240">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001269-sec-0049"></div> <p>To assess the effects (efficacy, effectiveness, and harm) of vaccines against influenza in healthy adults, including pregnant women. </p> <p>We defined 'effects' as follows:</p> <p> <ol id="CD001269-list-0005"> <li> <p>efficacy as the capacity of the vaccines to prevent influenza A or B and its complications;</p> </li> <li> <p>effectiveness as the capacity of the vaccines to prevent influenza‐like illness and its consequences; and </p> </li> <li> <p>harm as any harmful event potentially associated with exposure to influenza vaccines.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001269-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001269-sec-0050">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001269-sec-0241">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001269-sec-0050"></div> <section id="CD001269-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001269-sec-0052"> <h4 class="title">Types of studies</h4> <p>Any randomised controlled trial (RCT) or quasi‐RCT comparing influenza vaccines in humans with placebo or no intervention, or comparing types, doses, or schedules of influenza vaccine. We only considered studies assessing protection from exposure to naturally occurring influenza. </p> <p>To enhance the relevance of the review to decision‐makers, in the <a href="./references#CD001269-bbs2-0356" title="JeffersonTO , RivettiD , DiPietrantonjC , RivettiA , DemicheliV . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD001269.pub3] ">Jefferson 2007</a> update, we included comparative non‐randomised studies if they reported evidence on the association between influenza vaccines and serious adverse effects, such as Guillain‐Barré syndrome or oculo‐respiratory syndromes, or if they reported effectiveness or efficacy data for vaccine administration during pregnancy. </p> <p>We defined as RCTs studies in which it appeared that the individuals (or other experimental units) included in the study were definitely or possibly assigned prospectively to one of two (or more) alternative forms of health care using random allocation. A study was quasi‐randomised when it appeared that the individuals (or other experimental units) followed in the study were definitely or possibly assigned prospectively to one of two (or more) alternative forms of health care using some quasi‐random method of allocation (such as by alternation, date of birth, or case record number). </p> </section> <section id="CD001269-sec-0053"> <h4 class="title">Types of participants</h4> <p>Healthy individuals aged 16 to 65 years, irrespective of influenza immune status. We excluded studies considering more than 25% of individuals outside this age range. We also included pregnant women together with their newborns. </p> </section> <section id="CD001269-sec-0054"> <h4 class="title">Types of interventions</h4> <p>Live, attenuated, or killed vaccines, or fractions thereof, administered by any route, irrespective of antigenic configuration. </p> </section> <section id="CD001269-sec-0055"> <h4 class="title">Types of outcome measures</h4> <section id="CD001269-sec-0056"> <h5 class="title">Primary outcomes</h5> <section id="CD001269-sec-0057"> <h6 class="title">Clinical</h6> <p> <ol id="CD001269-list-0006"> <li> <p>Numbers and seriousness (complications and working days lost) of symptomatic influenza and influenza‐like illness (ILI) cases occurring in vaccine and placebo groups. </p> </li> </ol> </p> </section> <section id="CD001269-sec-0058"> <h6 class="title">Harms</h6> <p> <ol id="CD001269-list-0007"> <li> <p>Number and seriousness of adverse effects (systemic and severe). Systemic adverse effects included cases of malaise, nausea, fever, arthralgia, rash, headache and more generalised and serious signs, such as neurological harms. </p> </li> <li> <p>Maternal outcomes and outcomes related to the course of pregnancy. These included abortion (spontaneous, internal, foetal death, and stillbirth), preterm birth (less than 37 weeks), and maternal death. </p> </li> <li> <p>Neonatal outcomes: congenital malformations (minor and major), neonatal death.</p> </li> </ol> </p> </section> </section> <section id="CD001269-sec-0059"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001269-list-0008"> <li> <p>Local adverse effects including induration, soreness, and redness at the site of inoculation.</p> </li> </ol> </p> </section> </section> </section> <section id="CD001269-sec-0060"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001269-sec-0061"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 12) searched 31 December 2016 via the Cochrane Library), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (PubMed) (January 1966 to 31 December 2016); Embase (Elsevier) (1990 to 31 December 2016); WHO International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp/en" target="_blank">www.who.int/ictrp/en</a>, 1 July 2017); and ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, 1 July 2017). See <a href="./appendices#CD001269-sec-0155">Appendix 2</a> for the search strategies used to identify trials. </p> <p>See <a href="./appendices#CD001269-sec-0156">Appendix 3</a> for search strategies used prior to this 2017 update to identify observational studies. See <a href="./appendices#CD001269-sec-0157">Appendix 4</a> for strategies used in the 2010 update, and <a href="./appendices#CD001269-sec-0158">Appendix 5</a> for the MEDLINE search strategy used in 2004. </p> </section> <section id="CD001269-sec-0062"> <h4 class="title">Searching other resources</h4> <p>In order to identify further trials, we read the bibliographies of retrieved articles and handsearched the journal <i>Vaccine</i> from its first issue to the end of 2009. The results of the handsearches are included in CENTRAL. In order to locate unpublished trials for the first edition of this review, we wrote to manufacturers and first or corresponding trial authors of studies in the review. </p> </section> </section> <section id="CD001269-sec-0063"> <h3 class="title" id="CD001269-sec-0063">Data collection and analysis</h3> <section id="CD001269-sec-0064"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AR, CDP) independently excluded all initially identified and retrieved articles not fulfilling the inclusion criteria. In the case of disagreement, one review author (VD) acted as arbitrator. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (<a href="./references#CD001269-bbs2-0342" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>). </p> </section> <section id="CD001269-sec-0065"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AR, CDP) performed data extraction using a data extraction form (<a href="./appendices#CD001269-sec-0159">Appendix 6</a>). We checked and entered the data into Review Manager 5 software (<a href="./references#CD001269-bbs2-0345" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We extracted data on the following: </p> <p> <ul id="CD001269-list-0009"> <li> <p>methodological quality of studies;</p> </li> <li> <p>study design (<a href="./appendices#CD001269-sec-0197">Appendix 7</a>); </p> </li> <li> <p>description of setting;</p> </li> <li> <p>characteristics of participants;</p> </li> <li> <p>description of vaccines (content and antigenic match);</p> </li> <li> <p>description of outcomes;</p> </li> <li> <p>publication status;</p> </li> <li> <p>date of study;</p> </li> <li> <p>location of study.</p> </li> </ul> </p> <p>One review author (CDP) carried out statistical analyses.</p> <p>We assumed an ILI case (specific definition) to be the same as a 'flu‐like illness' according to a predefined list of symptoms (such as the Centers for Disease Control and Prevention (CDC) case definition for surveillance) or 'upper respiratory illness' according to a predefined list of symptoms. </p> <p>The laboratory confirmations of influenza cases we found were:</p> <p> <ol id="CD001269-list-0010"> <li> <p>virus isolation from culture;</p> </li> <li> <p>four‐fold antibody increase (haemagglutinin) in acute‐ or convalescent‐phase sera;</p> </li> <li> <p>four‐fold antibody increase (haemagglutinin) in postvaccination‐ or postepidemic‐phase sera. </p> </li> </ol> </p> </section> <section id="CD001269-sec-0066"> <h4 class="title">Assessment of risk of bias in included studies</h4> <section id="CD001269-sec-0067"> <h5 class="title">Experimental studies (trials)</h5> <p>Two review authors (CDP, AR) independently assessed the methodological quality of the included studies using criteria from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001269-bbs2-0335" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). In case of disagreement, one review author (VD) acted as arbitrator in assigning quality judgements. </p> <p>We classified studies according to the following key domains for assessing risk of bias (<a href="./references#CD001269-bbs2-0335" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <section id="CD001269-sec-0068"> <h6 class="title">Random sequence generation</h6> <p> <ul id="CD001269-list-0011"> <li> <p>Low risk of bias: e.g. a table of random numbers or computer‐generated random numbers.</p> </li> <li> <p>High risk of bias: e.g. alternation, date of birth, day of the week, or case record number. </p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ul> </p> </section> <section id="CD001269-sec-0069"> <h6 class="title">Allocation concealment</h6> <p> <ul id="CD001269-list-0012"> <li> <p>Low risk of bias: e.g. numbered or coded identical containers were administered sequentially; an onsite computer system that could only be accessed after entering the characteristics of an enrolled participant; or serially numbered, opaque, sealed envelopes, or sealed envelopes that were not sequentially numbered. </p> </li> <li> <p>High risk of bias: e.g. an open table of random numbers.</p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ul> </p> </section> <section id="CD001269-sec-0070"> <h6 class="title">Blinding</h6> <p> <ul id="CD001269-list-0013"> <li> <p>Low risk of bias: if adequate double‐blinding (e.g. placebo vaccine) or single‐blinding (i.e. blinded outcome assessment) was used. </p> </li> <li> <p>High risk of bias: if there was no blinding.</p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ul> </p> </section> <section id="CD001269-sec-0071"> <h6 class="title">Incomplete outcome data</h6> <p>Number of losses to follow‐up:</p> <p> <ul id="CD001269-list-0014"> <li> <p>Low risk of bias: no missing data or the proportion of missing data compared with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate. </p> </li> <li> <p>High risk of bias: when the proportion of missing data compared with observed event risk was large enough to induce clinically relevant bias in the intervention effect estimate. </p> </li> <li> <p>Unclear risk of bias: if insufficient information was provided.</p> </li> </ul> </p> </section> </section> <section id="CD001269-sec-0072"> <h5 class="title">Non‐experimental studies</h5> <p>We carried out quality assessment of non‐randomised studies in relation to the presence of potential confounders, which could make interpretation of the results difficult. We evaluated the quality of case‐control (prospective and retrospective) and cohort studies using the appropriate Newcastle‐Ottawa Scales (NOS) (<a href="./appendices#CD001269-sec-0198">Appendix 8</a>). </p> <p>Using quality at the analysis stage as a means of interpreting the results, we assigned 'Risk of bias' categories (<a href="./references#CD001269-bbs2-0335" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>): </p> <p> <ul id="CD001269-list-0015"> <li> <p>Low risk of bias: plausible bias unlikely to seriously alter the results.</p> </li> <li> <p>Unclear risk of bias: plausible bias that raises some doubt about the results.</p> </li> <li> <p>High risk of bias: plausible bias that seriously weakens confidence in the results.</p> </li> </ul> </p> </section> </section> <section id="CD001269-sec-0073"> <h4 class="title">Measures of treatment effect</h4> <p>We used the risk ratio (RR) and its 95% confidence interval (CI) as the summary measure. We calculated vaccine efficacy (or effectiveness) as VE = 1 ‐ RR, expressed as a percentage, for cohort and RCT/controlled clinical trial (CCT) studies. For case‐control studies we adopted an odds ratio (OR) with 95% CIs. </p> <p>To enhance relevance to everyday practice, we also expressed the summary measure of the most reliable and significant comparisons (those from RCTs with influenza cases as an outcome by age group) as a risk difference (RD). This is a measure of absolute efficacy of the vaccines, which incorporates significant information such as the incidence in the control arm and allows the calculation of its reciprocal, the number needed to treat for an additional beneficial outcome (NNTB), or in this case, the number needed to vaccinate (NNV). </p> <p>The NNV expresses the number of children needed to be vaccinated to prevent one case of influenza. The NNV can be computed as 1/RD. Since meta‐analysis estimates from RD are affected by statistical heterogeneity, we preferred to compute the NNV from the RD between assumed and corresponding risks. We used aggregate or median of the control group risks, giving a formula of: 1/(control event rate (CER) ‐ CER*RR). </p> <p>We conducted quantitative synthesis of the evidence from observational studies using adjusted estimates, when these were available; in some cases we also used original data (unadjusted data) in order to compare meta‐analysis results from adjusted and unadjusted estimates. </p> <p>We calculated hospital admission rates as the proportion of cases hospitalised for respiratory causes. We considered complications as the proportion of cases complicated by bronchitis, pneumonia, or otitis. We also considered working days lost due to episodes of sickness absence regardless of cause. Only five trials used working days lost as an outcome measure, of which four trials measured the work absence in terms of the difference in the average number of days lost in two arms of the trial (<a href="./references#CD001269-fig-0010" title="">Analysis 1.7</a>). These studies presented a standard error value measured accordingly. The remainder expressed work absence in terms of rate ratio, which does not allow the recalculation of the correct estimate of the standard error (<a href="./references#CD001269-bbs2-0031" title="NicholKL , MendelmanPM , MallonKP , JacksonLA , GorseGJ , BelsheRB , et al. Effectiveness of live attenuated intranasal influenza virus vaccine in healthy working adults, a randomized controlled trial. JAMA1999;282(2):137‐44. ">aa Nichol 1999a</a>). We therefore excluded this study from the pooled analysis. </p> <p>We presented local symptoms separately from systemic symptoms. We have considered individual harms in the analysis, as well as a combined endpoint (any or highest symptom). We used all data included in the analysis as presented by the authors in the primary study, regardless of the number of dropouts. We decided on this approach (complete‐case scenario) because the majority of the included studies did not attempt to use an intention‐to‐treat analysis or mention the reasons for the loss to follow‐up, and they did not contain detailed information to allow estimations of the real number of participants. </p> </section> <section id="CD001269-sec-0074"> <h4 class="title">Unit of analysis issues</h4> <p>Several trials included more than one active vaccine arm. Where several active arms from the same trial were included in the same analysis, we split the placebo group equally between the different arms, so that the total number of participants in a single analysis did not exceed the actual number in the trials. </p> <p>We found four different definitions of the 'epidemic period'.</p> <p> <ol id="CD001269-list-0016"> <li> <p>Interval between the first and the last virus isolation in the community.</p> </li> <li> <p>Interval during which the influenza virus was recovered from more than a stated percentage of ill participants. </p> </li> <li> <p>Period during which an increase of respiratory illness of more than a stated percentage was recorded. </p> </li> <li> <p>Winter period, taken as a proxy for the epidemic period.</p> </li> </ol> </p> <p>We included data regardless of the definition of epidemic period used in the primary study. When data were presented for the epidemic period and the entire follow‐up period, we considered those that occurred during the former. </p> </section> <section id="CD001269-sec-0075"> <h4 class="title">Dealing with missing data</h4> <p>For the first publication of this review (<a href="./references#CD001269-bbs2-0353" title="DemicheliV , RivettiD , DeeksJJ , JeffersonTO . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD001269] ">Demicheli 1999</a>), we wrote to the trial authors and manufacturers to identify possible unpublished studies and missing data. The response was disappointing, and we desisted from any further attempts. Our analysis relies on existing data. Whenever possible we used the intention‐to‐treat population. </p> </section> <section id="CD001269-sec-0076"> <h4 class="title">Assessment of heterogeneity</h4> <p>We calculated the I<sup>2</sup> statistic for each pooled estimate to assess the impact on statistical heterogeneity. The I<sup>2</sup> statistic can be interpreted as the proportion of total variation among effect estimates that is due to heterogeneity rather than sampling error, and it is intrinsically independent from the number of studies. When the I<sup>2</sup> statistic is less than 30%, there is little concern about statistical heterogeneity (<a href="./references#CD001269-bbs2-0335" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We used random‐effects models throughout to take into account the between‐study variance in our findings (<a href="./references#CD001269-bbs2-0335" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Variance is to be expected in influenza vaccine trials, as there are unpredictable systematic differences between trials regarding the circulating strains, degree of antigenic matching of the vaccine, type of vaccine, and the levels of immunity presented by different populations in different settings. Not all studies reported sufficient details to enable a full analysis of the sources of heterogeneity, but we were able to take into account vaccine matching and circulating strain. </p> </section> <section id="CD001269-sec-0077"> <h4 class="title">Assessment of reporting biases</h4> <p>Due to the limited number of studies in each comparison or subgroup, assessment of publication bias was not applicable, since the evidence presented in this review originated mainly from published data. For this reason, our results could be affected by publication bias. </p> <p>The overall quality of the retrieved studies was poor and was affected by poor reporting or limited descriptions of the studies' designs. A detailed description is provided in the <a href="#CD001269-sec-0099">Risk of bias in included studies</a> section of the review. </p> <p>The main problems with influenza vaccine studies are their poor quality and discrepancies between the data presented, their conclusions, and the authors' recommendations. </p> </section> <section id="CD001269-sec-0078"> <h4 class="title">Data synthesis</h4> <p>We calculated all meta‐analyses using a random‐effects model due to expected variation in the efficacy and effectiveness of viral strain matching, and seasonal variation in virulence of the circulating influenza virus. We summarised evidence from non‐randomised studies (cohort and case‐control) according to <a href="./references#CD001269-bbs2-0335" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>. </p> </section> <section id="CD001269-sec-0079"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out subgroup analyses according to the degree of matching with that year's World Health Organization (WHO) recommended content and with circulating viruses ("WHO recommended and matching" when known). WHO recommendations on the content of vaccines have been published since 1973. Different dosages and schedules of the vaccine and the presence of different adjuvants were not compared. We pooled data from the arms of trials comparing only vaccine composition or dosage in the analysis. We checked compliance of the study vaccine with the official antigenic content and potency recommendations by reviewing the WHO records whenever possible. In case of uncertainty due to ambiguity in the wording used (in the oldest trials), we took into account the opinion given by the trial authors. We classified the compliance of a live attenuated vaccine with the recommendations according to the antigenic comparability of the wild strains. </p> <p>Since the degree of matching between vaccine and circulating strains could affect the effectiveness/efficacy of the vaccine, we analysed the data in separate subgroups according to this parameter. For serious adverse events, whenever possible we analysed data from pregnant women and the general population in separate subgroups. When case‐control studies reported safety outcomes, whenever possible we performed analyses in separate subgroups according to time since exposure. Finally, we carried out a separate analysis of trials carried out during the 1968 to 1969 (H3N2) pandemic and the 2009 to 2010 (H1N1) pandemic. </p> </section> <section id="CD001269-sec-0080"> <h4 class="title">Sensitivity analysis</h4> <p>As it was not possible to identify all sources of heterogeneity, we decided to carry out a sensitivity analysis by applying fixed‐effect and random‐effects models to assess the impact of heterogeneity on our results. In order to assess the robustness of our conclusions, we performed a sensitivity analysis by excluding studies judged to be at high risk of bias for one domain or unclear risk of bias for two or more domains. We restricted sensitivity analyses to <a href="./full#CD001269-tbl-0001">summary of findings Table for the main comparison</a> outcomes (see below). Historical versions of this review compared the results from the crude data with those from the adjusted data from observational studies (historical versions of this review only). </p> <section id="CD001269-sec-0081"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>We restricted our focus in the 'Summary of findings' tables to the comparison of inactivated parenteral influenza vaccine with placebo or do nothing, which we regarded as the most commonly adopted strategy. We created a <a href="./full#CD001269-tbl-0001">summary of findings Table for the main comparison</a> using the following outcomes: ILI, influenza, hospitalisations, time off work, fever, and nausea/vomiting. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD001269-bbs2-0327" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001269-bbs2-0335" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), employing GRADEpro GDT software (<a href="./references#CD001269-bbs2-0333" title="GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). We used the results from randomised studies and justified all decisions to down‐ or upgrade the quality of studies using footnotes, making comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001269-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001269-sec-0082"></div> <section id="CD001269-sec-0083"> <h3 class="title">Description of studies</h3> <section id="CD001269-sec-0084"> <h4 class="title">Results of the search</h4> <p>The first publication of this review contained 20 trials (<a href="./references#CD001269-bbs2-0353" title="DemicheliV , RivettiD , DeeksJJ , JeffersonTO . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD001269] ">Demicheli 1999</a>). In the second publication we included five additional trials (<a href="./references#CD001269-bbs2-0355" title="DemicheliV , RivettiD , DeeksJJ , JeffersonTO . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD001269.pub2] ">Demicheli 2004</a>), and the third publication included 48 trials in total (<a href="./references#CD001269-bbs2-0356" title="JeffersonTO , RivettiD , DiPietrantonjC , RivettiA , DemicheliV . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD001269.pub3] ">Jefferson 2007</a>). The fourth published update, <a href="./references#CD001269-bbs2-0357" title="JeffersonTO , DiPietrantonjC , RivettiA , BawazeerGA , Al‐AnsaryLA , FeroniE . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD001269.pub4] ">Jefferson 2010</a>, included two new trials (<a href="./references#CD001269-bbs2-0002" title="BeranJ , WertzovaV , HonegrK , KaliskovaE , HavlickovaM , HavlikJ , et al. Challenge of conducting a placebo‐controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infectious Diseases2009;9:2. [DOI: 10.1186/1471‐2334‐9‐2] ">aa Beran 2009a</a>; <a href="./references#CD001269-bbs2-0003" title="BeranJ , VesikariT , WertzovaV , KarvonenA , HonegrK , LindbladN , et al. Efficacy of inactivated split‐virus influenza vaccine against culture‐confirmed influenza in healthy adults: a prospective, randomized, placebo‐controlled trial. Journal of Infectious Diseases2009;200:1861‐9. ">aa Beran 2009b</a>), and excluded three new trials (<a href="./references#CD001269-bbs2-0161" title="BelongiaEA , KiekeBA , DonahueJG , GreenleeRT , BalishA , FoustA , et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004‐2005 season to the 2006‐2007 season. Journal of Infectious Diseases2009;199(2):159‐67. ">Belongia 2009</a>; <a href="./references#CD001269-bbs2-0175" title="ChouCH , LiouWP , HuKI , LohCH , ChouCC , ChenYH . Bell’s palsy associated with influenza vaccination: two case reports. Vaccine2007;25:2839–41. ">Chou 2007</a>; <a href="./references#CD001269-bbs2-0228" title="KhazeniN , HuttonD , GarberA , HupertN , OwensD . Effectiveness and cost‐effectiveness of vaccination against pandemic influenza (H1N1) 2009. Annals of Internal Medicine2009;151:829‐39. ">Khazeni 2009</a>). The fourth update included 41 new study reports and excluded 63 new trials (<a href="./references#CD001269-bbs2-0358" title="JeffersonT , DiPietrantonjC , RivettiA , BawazeerGA , Al‐AnsaryLA , FerroniE . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD001269.pub5] ">Jefferson 2014</a>). In this 2016 update we have included 20 new studies, excluded 21 new trials, and added two further trials (three data sets). One was newly identified (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=637899081614140966%26versionPK1=z1501112345395670904484709322696%26versionPK2=z1707191901334959418051266427983#STD-aa-Mc-Bride-2016a" target="_blank">aa Mc Bride 2016a</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=637899081614140966%26versionPK1=z1501112345395670904484709322696%26versionPK2=z1707191901334959418051266427983#STD-aa-Mc-Bride-2016b" target="_blank">aa Mc Bride 2016b</a>), and one was included from the 'awaiting assessment' category (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=637899081614140966%26versionPK1=z1501112345395670904484709322696%26versionPK2=z1707191901334959418051266427983#STD-aa-Treanor-2011" target="_blank">aa Treanor 2011</a>). </p> <p>Some of the included studies had more than two arms, comparing different vaccines, routes of administration, schedules, or dosages, or reported data from different settings and epidemic seasons. We split these studies into substudies (data sets). For the remainder of this review, the term 'study report' refers to the original study report, while the word 'data set' refers to the substudy; these substudies could refer either to different study arms, different influenza seasons, or different study designs. Risk of bias may be independently assessed for each substudy (or data set) study design. </p> <p>More information about the division of study reports into data sets is given in the <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=637899081614140966%26versionPK1=z1501112345395670904484709322696%26versionPK2=z1707191901334959418051266427983#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table. In this 2016 updated review, we included a total of 160 studies (137 data sets), while we no longer updated searches for observational comparative studies (<a href="#CD001269-fig-0001">Figure 1</a>). Trial register searches identified 18 completed trials with one or more corresponding publications, reporting methods and study design. All 18 trials had been identified and dealt with appropriately in our searches of journal publication databases. </p> <div class="figure" id="CD001269-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001269-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001269-sec-0085"> <h4 class="title">Included studies</h4> <p>We coded each trial on the basis of study design and the type of data contributed to the review as follows. The letter preceding the study represents the study design: (a) denotes RCTs, (b) denotes case‐control studies, and (c) denotes cohort studies. The second letter indicates the contribution to the evidence in the data set: (a) efficacy/effectiveness or (b) harms. So, for example, a case‐control study contributing safety or harms data is coded as (bb), and a trial contributing efficacy/effectiveness data is coded as (aa). A (p) code has been added to refer to the studies on vaccination during pregnancy. </p> <section id="CD001269-sec-0086"> <h5 class="title">Seasonal vaccines: efficacy or effectiveness</h5> <p> <ol id="CD001269-list-0017"> <li> <p><b>RCTs on inactivated parenteral vaccine:</b> (22 studies/32 data sets) (<a href="./references#CD001269-bbs2-0001" title="BarrettPN , BerezukG , FritschS , AichingerG , HartMK , El‐AminW , et al. Efficacy, safety, and immunogenicity of a Vero‐cell‐culture‐derived trivalent influenza vaccine: a multicentre, double‐blind, randomised, placebo‐controlled trial. Lancet2011;377(9767):751‐9. EhrlichHJ , BerezukG , FritschS , AichingerG , SingerJ , PortsmouthD , et al. Clinical development of a Vero cell culture‐derived seasonal influenza vaccine. Vaccine2011;30(29):4377‐86. EhrlichHJ , SingerJ , BerezukG , FritschS , AichingerG , HartMK , et al. A cell culture‐derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clinical Infectious Diseases2012;54(7):946‐54. ">aa Barrett 2011</a>; <a href="./references#CD001269-bbs2-0002" title="BeranJ , WertzovaV , HonegrK , KaliskovaE , HavlickovaM , HavlikJ , et al. Challenge of conducting a placebo‐controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infectious Diseases2009;9:2. [DOI: 10.1186/1471‐2334‐9‐2] ">aa Beran 2009a</a>; <a href="./references#CD001269-bbs2-0003" title="BeranJ , VesikariT , WertzovaV , KarvonenA , HonegrK , LindbladN , et al. Efficacy of inactivated split‐virus influenza vaccine against culture‐confirmed influenza in healthy adults: a prospective, randomized, placebo‐controlled trial. Journal of Infectious Diseases2009;200:1861‐9. ">aa Beran 2009b</a>; <a href="./references#CD001269-bbs2-0004" title="Buxton BridgesC , ThompsonVV , MeltzerMI , ReeveGR , TalamontiVJ , CoxNJ , et al. Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA2000;284(13):1655‐63. ">aa Bridges 2000a</a>; <a href="./references#CD001269-bbs2-0005" title="Buxton BridgesC , ThompsonVV , MeltzerMI , ReeveGR , TalamontiVJ , CoxNJ . Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA2000;284(13):1655‐63. ">aa Bridges 2000b</a>; <a href="./references#CD001269-bbs2-0006" title="EddyTS , DaviesNA . The effect of vaccine on a closed epidemic of Hong Kong influenza. South African Medical Journal1970;44(8):214‐6. ">aa Eddy 1970</a>; <a href="./references#CD001269-bbs2-0011" title="FreyS , VesikariT , Szymczakiewicz‐MultanowskaA , LattanziM , IzuA , GrothN , et al. Clinical efficacy of cell culture‐derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clinical Infectious Diseases2010;51(9):997‐1004. ">aa Frey 2010</a>; <a href="./references#CD001269-bbs2-0012" title="HammondML , FerrisAA , FaineS . Effective protection against influenza after vaccination with subunit vaccine. Medical Journal of Australia1978;1(6):301‐3. ">aa Hammond 1978</a>; <a href="./references#CD001269-bbs2-0013" title="JacksonLA , GaglaniMJ , KeyserlingHL , BalserJ , BouveretN , FriesL , et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomised, placebo‐controlled trial over two influenza seasons. BMC Infectious Diseases2010;10:71. ">aa Jackson 2010a</a>; <a href="./references#CD001269-bbs2-0014" title="JacksonLA , GaglaniMJ , KeyserlingHL , BalserJ , BouveretN , FriesL , et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomised, placebo‐controlled trial over two influenza seasons. BMC Infectious Diseases2010;10:71. ">aa Jackson 2010b</a>; <a href="./references#CD001269-bbs2-0015" title="KeitelWA , CateTR , CouchRB . Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. American Journal of Epidemiology1988;127(2):353‐64. ">aa Keitel 1988a</a>; <a href="./references#CD001269-bbs2-0016" title="KeitelWA , CateTR , CouchRB . Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. American Journal of Epidemiology1988;127(2):353‐64. ">aa Keitel 1988b</a>; <a href="./references#CD001269-bbs2-0017" title="KeitelWA , CateTR , CouchRB , HugginsLL , HessKR . Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine1997;15(10):1114‐22. ">aa Keitel 1997a</a>; <a href="./references#CD001269-bbs2-0018" title="KeitelWA , CateTR , CouchRB , HugginsLL , HessKR . Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine1997;15(10):1114‐22. ">aa Keitel 1997b</a>; <a href="./references#CD001269-bbs2-0019" title="KeitelWA , CateTR , CouchRB , HugginsLL , HessKR . Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine1997;15(10):1114‐22. ">aa Keitel 1997c</a>; <a href="./references#CD001269-bbs2-0021" title="LeibovitzA , CoultripRL , KilbourneED , LegtersLJ , SmithCD , ChinJ , et al. Correlated studies of a recombinant influenza‐virus vaccine. IV. Protection against naturally occurring influenza in military trainees. Journal of Infectious Diseases1971;124(5):481‐7. ">aa Leibovitz 1971</a>; <a href="./references#CD001269-bbs2-0022" title="McbrideWJ , AbhayaratnaWP , BarrI , BooyR , CarapetisJ , CarsonS , et al. Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: a randomized, placebo‐controlled trial. Vaccine2016;34(41):4991‐7. ">aa Mcbride 2016a</a>; <a href="./references#CD001269-bbs2-0023" title="McbrideWJ , AbhayaratnaWP , BarrI , BooyR , CarapetisJ , CarsonS , et al. Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: a randomized, placebo‐controlled trial. Vaccine2016;34(41):4991‐7. ">aa Mcbride 2016b</a>; <a href="./references#CD001269-bbs2-0024" title="Mesa DuqueSS , MorenoAP , HurtadoG , Arbelàaz MontoyaMP . Effectiveness of an influenza vaccine in a working population in Colombia [Effectividad de una vacuna anti gripal en una poblaciòn laboral colombiana]. Pan American Journal of Public Health2001;10(4):232‐9. ">aa Mesa Duque 2001</a>; <a href="./references#CD001269-bbs2-0025" title="MixéuMA , VespaGN , Forleo‐NetoE , Toniolo‐NetoJ , AlvesPM . Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviation, Space, and Environmental Medicine2002;73(9):876‐80. ">aa Mixéu 2002</a>; <a href="./references#CD001269-bbs2-0029" title="MontoAS , OhmitSE , PetrieJG , JohnsonE , TrusconR , TeichE , et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. New England Journal of Medicine2009;361(13):1260‐7. ">aa Monto 2009</a>; <a href="./references#CD001269-bbs2-0030" title="NicholKL , LindA , MargolisKL , MurdochM , McFaddenR , HaugeM . The effectiveness of vaccination against influenza in healthy, working adults. New England Journal of Medicine1995;333(14):889‐93. ">aa Nichol 1995</a>; <a href="./references#CD001269-bbs2-0032" title="OhmitSE , VictorJC , RotthoffJR , TeichER , TrusconRK , BaumLL , et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. New England Journal of Medicine2006;355(24):2513‐22. ">aa Ohmit 2006</a>; <a href="./references#CD001269-bbs2-0033" title="OhmitSE , VictorJC , TeichER , TrusconRK , RotthoffJR , NewtonDW , et al. Prevention of symptomatic seasonal influenza in 2005‐2006 by inactivated and live attenuated vaccines. Journal of Infectious Diseases2008;198(3):312‐7. ">aa Ohmit 2008</a>; <a href="./references#CD001269-bbs2-0034" title="PowersDC , SmithGE , AndersonEL , KennedyDJ , HackettCS , WilkinsonBE , et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases1995;171(6):1595‐9. ">aa Powers 1995a</a>; <a href="./references#CD001269-bbs2-0035" title="PowersDC , SmithGE , AndersonEL , KennedyDJ , HackettCS , WilkinsonBE , et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases1995;171(6):1595‐9. ">aa Powers 1995b</a>; <a href="./references#CD001269-bbs2-0036" title="PowersDC , SmithGE , AndersonEL , KennedyDJ , HackettCS , WilkinsonBE , et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases1995;171:1595‐9. ">aa Powers 1995c</a>; <a href="./references#CD001269-bbs2-0039" title="TannockGA , BryceDA , HensleyMJ , SaundersNA , GillettRS , KennedyWS . Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population. Vaccine1984;2(1):100‐5. ">aa Tannock 1984</a>; <a href="./references#CD001269-bbs2-0040" title="TreanorJJ , ElSahlyH , KingJ , GrahamI , IziksonR , KohbergerR , et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomised, placebo‐controlled trial. Vaccine2011;29(44):7733‐9. ">aa Treanor 2011</a>; <a href="./references#CD001269-bbs2-0049" title="WeingartenS , StaniloffH , AultM , MilesP , BambergerM , MeyerRD . Do hospital employees benefit from the influenza vaccine?. Journal of General Internal Medicine1988;3(1):32‐7. ">aa Weingarten 1988</a>; <a href="./references#CD001269-bbs2-0050" title="ZhilovaGP , Ignat'evaGS , OrlovVA , MalikovaEV , MaksakovaVL . Results of a study of the effectiveness of simultaneous immunization against influenza with live and inactivated vaccines (1980 ‐ 1983). Voprosy Virusologii1986;31(1):40‐4. ">aa Zhilova 1986a</a>; <a href="./references#CD001269-bbs2-0051" title="ZhilovaGP , Ignat'evaGS , OrlovVA , MalikovaEV , MaksakovaVL . Results of a study of the effectiveness of simultaneous immunization against influenza with live and inactivated vaccines (1980 ‐ 1983). Voprosy Virusologii1986;31(1):40‐4. ">aa Zhilova 1986b</a>). </p> </li> <li> <p><b>RCTs on live aerosol vaccine:</b> (8 studies/12 data sets) (<a href="./references#CD001269-bbs2-0007" title="EdwardsKM , DupontWD , WestrichMK , PlummerWDJr , PalmerPS , WrightPF . A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases1994;169(1):68‐76. ">aa Edwards 1994a</a>; <a href="./references#CD001269-bbs2-0008" title="EdwardsKM , DupontWD , WestrichMK , PlummerWDJr , PalmerPS , WrightPF . A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases1994;169(1):68‐76. ">aa Edwards 1994b</a>; <a href="./references#CD001269-bbs2-0009" title="EdwardsKM , DupontWD , WestrichMK , PlummerWDJr , PalmerPS , WrightPF . A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases1994;169(1):68‐76. ">aa Edwards 1994c</a>; <a href="./references#CD001269-bbs2-0010" title="EdwardsKM , DupontWD , WestrichMK , PlummerWDJr , PalmerPS , WrightPF . A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases1994;169(1):68‐76. ">aa Edwards 1994d</a>; <a href="./references#CD001269-bbs2-0028" title="MontoAS , DeWolfe MillerF , MaassabHF . Evaluation of an attenuated, cold recombinant influenza B virus vaccine. Journal of Infectious Diseases1982;145(1):57‐64. ">aa Monto 1982</a>; <a href="./references#CD001269-bbs2-0029" title="MontoAS , OhmitSE , PetrieJG , JohnsonE , TrusconR , TeichE , et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. New England Journal of Medicine2009;361(13):1260‐7. ">aa Monto 2009</a>; <a href="./references#CD001269-bbs2-0031" title="NicholKL , MendelmanPM , MallonKP , JacksonLA , GorseGJ , BelsheRB , et al. Effectiveness of live attenuated intranasal influenza virus vaccine in healthy working adults, a randomized controlled trial. JAMA1999;282(2):137‐44. ">aa Nichol 1999a</a>; <a href="./references#CD001269-bbs2-0032" title="OhmitSE , VictorJC , RotthoffJR , TeichER , TrusconRK , BaumLL , et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. New England Journal of Medicine2006;355(24):2513‐22. ">aa Ohmit 2006</a>; <a href="./references#CD001269-bbs2-0033" title="OhmitSE , VictorJC , TeichER , TrusconRK , RotthoffJR , NewtonDW , et al. Prevention of symptomatic seasonal influenza in 2005‐2006 by inactivated and live attenuated vaccines. Journal of Infectious Diseases2008;198(3):312‐7. ">aa Ohmit 2008</a>; <a href="./references#CD001269-bbs2-0037" title='RytelMW , JacksonLJ , NiebojewskiRA , HaagensenJL , RosenkranzMA . Field trial of live attenuated influenza A/B ("Alice"/R‐75) vaccine. American Journal of Epidemiology1977;105(1):49‐55. '>aa Rytel 1977</a>; <a href="./references#CD001269-bbs2-0050" title="ZhilovaGP , Ignat'evaGS , OrlovVA , MalikovaEV , MaksakovaVL . Results of a study of the effectiveness of simultaneous immunization against influenza with live and inactivated vaccines (1980 ‐ 1983). Voprosy Virusologii1986;31(1):40‐4. ">aa Zhilova 1986a</a>; <a href="./references#CD001269-bbs2-0051" title="ZhilovaGP , Ignat'evaGS , OrlovVA , MalikovaEV , MaksakovaVL . Results of a study of the effectiveness of simultaneous immunization against influenza with live and inactivated vaccines (1980 ‐ 1983). Voprosy Virusologii1986;31(1):40‐4. ">aa Zhilova 1986b</a>). </p> </li> <li> <p><b>RCTs on inactivated aerosol vaccine:</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0020" title="LangleyJM , AokiF , WardBJ , McGeerA , AngelJB , StiverG , et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine2011;29(10):1921‐8. ">aa Langley 2011</a>). </p> </li> </ol> </p> </section> <section id="CD001269-sec-0087"> <h5 class="title">Seasonal vaccines: safety (local and systemic harms)</h5> <p> <ol id="CD001269-list-0018"> <li> <p><b>RCTs on inactivated parenteral vaccine:</b> (21 studies/22 data sets) (<a href="./references#CD001269-bbs2-0001" title="BarrettPN , BerezukG , FritschS , AichingerG , HartMK , El‐AminW , et al. Efficacy, safety, and immunogenicity of a Vero‐cell‐culture‐derived trivalent influenza vaccine: a multicentre, double‐blind, randomised, placebo‐controlled trial. Lancet2011;377(9767):751‐9. EhrlichHJ , BerezukG , FritschS , AichingerG , SingerJ , PortsmouthD , et al. Clinical development of a Vero cell culture‐derived seasonal influenza vaccine. Vaccine2011;30(29):4377‐86. EhrlichHJ , SingerJ , BerezukG , FritschS , AichingerG , HartMK , et al. A cell culture‐derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clinical Infectious Diseases2012;54(7):946‐54. ">aa Barrett 2011</a>; <a href="./references#CD001269-bbs2-0004" title="Buxton BridgesC , ThompsonVV , MeltzerMI , ReeveGR , TalamontiVJ , CoxNJ , et al. Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA2000;284(13):1655‐63. ">aa Bridges 2000a</a>; <a href="./references#CD001269-bbs2-0005" title="Buxton BridgesC , ThompsonVV , MeltzerMI , ReeveGR , TalamontiVJ , CoxNJ . Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA2000;284(13):1655‐63. ">aa Bridges 2000b</a>; <a href="./references#CD001269-bbs2-0011" title="FreyS , VesikariT , Szymczakiewicz‐MultanowskaA , LattanziM , IzuA , GrothN , et al. Clinical efficacy of cell culture‐derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clinical Infectious Diseases2010;51(9):997‐1004. ">aa Frey 2010</a>; <a href="./references#CD001269-bbs2-0013" title="JacksonLA , GaglaniMJ , KeyserlingHL , BalserJ , BouveretN , FriesL , et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomised, placebo‐controlled trial over two influenza seasons. BMC Infectious Diseases2010;10:71. ">aa Jackson 2010a</a>; <a href="./references#CD001269-bbs2-0024" title="Mesa DuqueSS , MorenoAP , HurtadoG , Arbelàaz MontoyaMP . Effectiveness of an influenza vaccine in a working population in Colombia [Effectividad de una vacuna anti gripal en una poblaciòn laboral colombiana]. Pan American Journal of Public Health2001;10(4):232‐9. ">aa Mesa Duque 2001</a>; <a href="./references#CD001269-bbs2-0029" title="MontoAS , OhmitSE , PetrieJG , JohnsonE , TrusconR , TeichE , et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. New England Journal of Medicine2009;361(13):1260‐7. ">aa Monto 2009</a>; <a href="./references#CD001269-bbs2-0030" title="NicholKL , LindA , MargolisKL , MurdochM , McFaddenR , HaugeM . The effectiveness of vaccination against influenza in healthy, working adults. New England Journal of Medicine1995;333(14):889‐93. ">aa Nichol 1995</a>; <a href="./references#CD001269-bbs2-0032" title="OhmitSE , VictorJC , RotthoffJR , TeichER , TrusconRK , BaumLL , et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. New England Journal of Medicine2006;355(24):2513‐22. ">aa Ohmit 2006</a>; <a href="./references#CD001269-bbs2-0033" title="OhmitSE , VictorJC , TeichER , TrusconRK , RotthoffJR , NewtonDW , et al. Prevention of symptomatic seasonal influenza in 2005‐2006 by inactivated and live attenuated vaccines. Journal of Infectious Diseases2008;198(3):312‐7. ">aa Ohmit 2008</a>; <a href="./references#CD001269-bbs2-0034" title="PowersDC , SmithGE , AndersonEL , KennedyDJ , HackettCS , WilkinsonBE , et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases1995;171(6):1595‐9. ">aa Powers 1995a</a>; <a href="./references#CD001269-bbs2-0039" title="TannockGA , BryceDA , HensleyMJ , SaundersNA , GillettRS , KennedyWS . Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population. Vaccine1984;2(1):100‐5. ">aa Tannock 1984</a>; <a href="./references#CD001269-bbs2-0040" title="TreanorJJ , ElSahlyH , KingJ , GrahamI , IziksonR , KohbergerR , et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomised, placebo‐controlled trial. Vaccine2011;29(44):7733‐9. ">aa Treanor 2011</a>; <a href="./references#CD001269-bbs2-0049" title="WeingartenS , StaniloffH , AultM , MilesP , BambergerM , MeyerRD . Do hospital employees benefit from the influenza vaccine?. Journal of General Internal Medicine1988;3(1):32‐7. ">aa Weingarten 1988</a>; <a href="./references#CD001269-bbs2-0055" title="CaplanES , HughesTP , O'DonnelS , LevineMM , HornickRB . Reactogenicity and immunogenicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults. Journal of Infectious Diseases1977;136(Suppl):484‐90. ">ab Caplan 1977</a>; <a href="./references#CD001269-bbs2-0056" title="El'shinaGA , MasalinIM , ShervaliVI , GorbunovMA , LonskaiaNI , AgafonovaLV , et al. The trivalent polymer‐subunit influenza vaccine Grippol studied in a controlled epidemiological trial. Voenno‐Meditsinskii Zhurnal1996;317(8):57‐60. ">ab El'shina 1996</a>; <a href="./references#CD001269-bbs2-0058" title="ForsythJR . An assessment of oil adjuvant and aqueous influenza vaccines. I. Reactions to the vaccines. Journal of Hygiene1967;65(4):485‐95. ">ab Forsyth 1967</a>; <a href="./references#CD001269-bbs2-0059" title="GoodeveA , PotterCW , ClarkA , JenningsR , SchildGC , YettsR . A graded‐dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. Journal of Hygiene1983;90(1):107‐15. ">ab Goodeve 1983</a>; <a href="./references#CD001269-bbs2-0066" title="PyrhönenS , SuniJ , RomoM . Clinical trial of a subunit influenza vaccine. Scandinavian Journal of Infectious Diseases1981;13:95‐9. ">ab Pyrhönen 1981</a>; <a href="./references#CD001269-bbs2-0068" title="RocchiG , RagonaG , PigaC , PelosioA , VolpiA , VellaS , et al. Influenza vaccination with live‐attenuated and inactivated virus‐vaccines during an outbreak of disease. Journal of Hygiene1979;83(3):383‐90. ">ab Rocchi 1979a</a>; <a href="./references#CD001269-bbs2-0070" title="SaxenH , VirtanenM . Randomized, placebo‐controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatric Infectious Disease Journal1999;18(9):779‐83. ">ab Saxen 1999</a>; <a href="./references#CD001269-bbs2-0071" title="ScheifeleDW , DuvalB , RussellML , WarringtonR , DeSerresG , SkowronskiDM , et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clinical Infectious Diseases2003;36(7):850‐7. ">ab Scheifele 2003</a>). </p> </li> <li> <p><b>RCTs on live aerosol vaccine:</b> (13 studies/14 data sets) (<a href="./references#CD001269-bbs2-0028" title="MontoAS , DeWolfe MillerF , MaassabHF . Evaluation of an attenuated, cold recombinant influenza B virus vaccine. Journal of Infectious Diseases1982;145(1):57‐64. ">aa Monto 1982</a>; <a href="./references#CD001269-bbs2-0031" title="NicholKL , MendelmanPM , MallonKP , JacksonLA , GorseGJ , BelsheRB , et al. Effectiveness of live attenuated intranasal influenza virus vaccine in healthy working adults, a randomized controlled trial. JAMA1999;282(2):137‐44. ">aa Nichol 1999a</a>; <a href="./references#CD001269-bbs2-0032" title="OhmitSE , VictorJC , RotthoffJR , TeichER , TrusconRK , BaumLL , et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. New England Journal of Medicine2006;355(24):2513‐22. ">aa Ohmit 2006</a>; <a href="./references#CD001269-bbs2-0033" title="OhmitSE , VictorJC , TeichER , TrusconRK , RotthoffJR , NewtonDW , et al. Prevention of symptomatic seasonal influenza in 2005‐2006 by inactivated and live attenuated vaccines. Journal of Infectious Diseases2008;198(3):312‐7. ">aa Ohmit 2008</a>; <a href="./references#CD001269-bbs2-0037" title='RytelMW , JacksonLJ , NiebojewskiRA , HaagensenJL , RosenkranzMA . Field trial of live attenuated influenza A/B ("Alice"/R‐75) vaccine. American Journal of Epidemiology1977;105(1):49‐55. '>aa Rytel 1977</a>; <a href="./references#CD001269-bbs2-0052" title="AtmarRL , BloomK , KeitelW , CouchRB , GreenbergSB . Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine1990;8(3):217‐24. ">ab Atmar 1990</a>; <a href="./references#CD001269-bbs2-0053" title="BettsRF , DouglasRGJr , RothFK , LittleJW3rd . Efficacy of live attenuated influenza A/Scotland/74 (H3N2) virus vaccine against challenge with influenza A/Victoria/3/75 (H3N2) virus. Journal of Infectious Diseases1977;136(6):746‐53. ">ab Betts 1977a</a>; <a href="./references#CD001269-bbs2-0057" title="EvansAE , LetleyE , FerrisRD , FreestoneDS . WRL 105 strain live attenuated influenza vaccine; comparison of one and two dose schedules. Journal of Hygiene1976;77(3):327‐32. ">ab Evans 1976</a>; <a href="./references#CD001269-bbs2-0060" title="HrabarA , VodopijaI , AndreFE , MitchellJR , MaassabHF , HennessyAV , et al. A placebo‐controlled dose‐response study of the reactogenicity and immunogenicity of a cold‐adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Developments in Biological Standardization1977;39:53‐60. ">ab Hrabar 1977</a>; <a href="./references#CD001269-bbs2-0061" title="KeitelWA , CouchRB , QuarlesJM , CateTR , BaxterB , MaassabHF . Trivalent attenuated cold‐adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. Journal of Infectious Diseases1993;167(2):305‐11. ">ab Keitel 1993a</a>; <a href="./references#CD001269-bbs2-0062" title="KeitelWA , CouchRB , QuarlesJM , CateTR , BaxterB , MaassabHF . Trivalent attenuated cold‐adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. Journal of Infectious Diseases1993;167(2):305‐11. ">ab Keitel 1993b</a>; <a href="./references#CD001269-bbs2-0064" title="LauteriaSF , KantzlerGB , HighPC , LeeJD , WaldmanRH . An attenuated influenza virus vaccine: reactogenicity, transmissibility, immunogenicity, and protective efficacy. Journal of Infectious Diseases1974;130(4):380‐3. ">ab Lauteria 1974</a>; <a href="./references#CD001269-bbs2-0065" title="MillerLW , TogoY , HornickRB . Clinical and serologic effects of live attenuated serum inhibitor‐resistant influenza B vaccine in seronegative adults. Journal of Medical Virology1977;1(3):193‐9. ">ab Miller 1977</a>; <a href="./references#CD001269-bbs2-0069" title="RocchiG , RagonaG , PigaC , PelosioA , VolpiA , VellaS , et al. Influenza vaccination with live‐attenuated and inactivated virus‐vaccines during an outbreak of disease. Journal of Hygiene1979;83(3):383‐90. ">ab Rocchi 1979b</a>). </p> </li> <li> <p><b>RCTs on inactivated aerosol vaccine:</b> (three studies/three data sets) (<a href="./references#CD001269-bbs2-0020" title="LangleyJM , AokiF , WardBJ , McGeerA , AngelJB , StiverG , et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine2011;29(10):1921‐8. ">aa Langley 2011</a>; <a href="./references#CD001269-bbs2-0054" title="BoyceTG , HsuHH , SannellaEC , Coleman‐DockerySD , BaylisE , ZhuY , et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine2000;19(2‐3):217‐26. ">ab Boyce 2000</a>; <a href="./references#CD001269-bbs2-0063" title="LangleyJM , HalperinSA , McNeilS , SmithB , JonesT , BurtD , et al. Safety and immunogenicity of a Proteosome‐trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine2005;24(10):1601‐8. ">ab Langley 2005</a>). </p> </li> </ol> </p> <p>We could not introduce two studies with live aerosol vaccine, <a href="./references#CD001269-bbs2-0067" title="ReeveP , PibermannM , BachmayerH , LiehlE , MoritzA , GanzingerU , et al. Studies in man with a cold‐recombinant live influenza B virus vaccine. Journal of Medical Virology1982;9(1):1‐9. ">ab Reeve 1982</a> and <a href="./references#CD001269-bbs2-0072" title='SpencerMJ , CherryJD , PowellKR . Clinical trial with "R‐75" strain live, attenuated, serum inhibitor‐resistant intranasal influenza B vaccine. Journal of Clinical Microbiology1977;5(6):584‐7. '>ab Spencer 1977</a>, (each one a data set) into the harms analysis (secondary effects) because the data did not allow for quantitative analysis (systemic and local harms were reported given as cumulative in <a href="./references#CD001269-bbs2-0072" title='SpencerMJ , CherryJD , PowellKR . Clinical trial with "R‐75" strain live, attenuated, serum inhibitor‐resistant intranasal influenza B vaccine. Journal of Clinical Microbiology1977;5(6):584‐7. '>ab Spencer 1977</a> and data were not clearly reported in <a href="./references#CD001269-bbs2-0067" title="ReeveP , PibermannM , BachmayerH , LiehlE , MoritzA , GanzingerU , et al. Studies in man with a cold‐recombinant live influenza B virus vaccine. Journal of Medical Virology1982;9(1):1‐9. ">ab Reeve 1982</a>). </p> </section> <section id="CD001269-sec-0088"> <h5 class="title">Administration during pregnancy ‐ efficacy/effectiveness in mothers</h5> <p> <ol id="CD001269-list-0019"> <li> <p><b>Seasonal trivalent inactivated vaccine containing pH1N1 ‐ RCTs</b>: (one study/one data set) (<a href="./references#CD001269-bbs2-0103" title="MadhiSA , CutlandCL , KuwandaL , WeinbergA , HugoA , JonesS , et al. Influenza vaccination of pregnant women and protection of their infants. New England Journal of Medicine2014;371(10):918‐31. ">paa Madhi 2014</a>). </p> </li> <li> <p><b>2009 to 2010 pandemic: inactivated vaccine ‐ CCTs:</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0102" title="MaF , ZhangL , JiangR , ZhangJ , WangH , GaoX , et al. Prospective cohort study of the safety of an influenza A (H1N1) vaccine in pregnant Chinese women. Clinical and Vaccine Immunology2014;21(9):1282‐7. ">paa Ma 2014</a>). </p> </li> <li> <p><b>Seasonal inactivated vaccine ‐ cohort studies:</b> (three studies/three data sets) (<a href="./references#CD001269-bbs2-0107" title="AhrensKA , LouikC , KerrS , MitchellAA , WerlerMM . Seasonal influenza vaccination during pregnancy and the risks of preterm delivery and small for gestational age birth. Paediatric and Perinatal Epidemiology2014;28(6):498‐509. ">pca Ahrens 2014</a>; <a href="./references#CD001269-bbs2-0108" title="BlackSB , ShinefieldHR , FranceEK , FiremanBH , BlattST , ShayD . Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. American Journal of Perinatology2004;21(6):333‐9. ">pca Black 2004</a>; <a href="./references#CD001269-bbs2-0111" title="HulkaJF . Effectiveness of polyvalent influenza vaccine in pregnancy. Report of a controlled study during an outbreak of Asian influenza. Obstetrics and Gynecology1964;23:830‐7. ">pca Hulka 1964</a>). </p> </li> <li> <p><b>2009 to 2010 pandemic: inactivated vaccines ‐ cohort studies:</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0113" title="YamadaT , YamadaT , MorikawaM , ChoK , EndoT , SatoSS , et al. Pandemic (H1N1) 2009 in pregnant Japanese women in Hokkaido. Journal of Obstetrics and Gynaecology Research2012;38(1):130‐6. ">pca Yamada 2012</a>). </p> </li> </ol> </p> </section> <section id="CD001269-sec-0089"> <h5 class="title">Administration during pregnancy ‐ efficacy/effectiveness in newborns</h5> <p> <ol id="CD001269-list-0020"> <li> <p><b>Seasonal trivalent inactivated vaccine containing pH1N1 ‐ RCTs</b>: (one study/one data set) (<a href="./references#CD001269-bbs2-0103" title="MadhiSA , CutlandCL , KuwandaL , WeinbergA , HugoA , JonesS , et al. Influenza vaccination of pregnant women and protection of their infants. New England Journal of Medicine2014;371(10):918‐31. ">paa Madhi 2014</a>). </p> </li> <li> <p><b>Seasonal inactivated vaccine ‐ cohort studies on effectiveness (ILI):</b> (three studies/three data sets) (<a href="./references#CD001269-bbs2-0108" title="BlackSB , ShinefieldHR , FranceEK , FiremanBH , BlattST , ShayD . Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. American Journal of Perinatology2004;21(6):333‐9. ">pca Black 2004</a>; <a href="./references#CD001269-bbs2-0109" title="EickAA , UyekiTM , KlimovA , HallH , ReidR , SantoshamM , et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Archives of Pediatrics and Adolescent Medicine2011;165(2):104‐11. ">pca Eick 2011</a>; <a href="./references#CD001269-bbs2-0110" title="FranceEK , Smith‐RayR , McClureD , HambidgeS , XuS , YamasakiK , et al. Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Archives of Pediatrics and Adolescent Medicine2006;160(12):1277‐83. ">pca France 2006</a>). </p> </li> <li> <p><b>Seasonal inactivated vaccine ‐ cohort studies on efficacy (laboratory‐confirmed):</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0109" title="EickAA , UyekiTM , KlimovA , HallH , ReidR , SantoshamM , et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Archives of Pediatrics and Adolescent Medicine2011;165(2):104‐11. ">pca Eick 2011</a>). </p> </li> <li> <p><b>Seasonal inactivated vaccine ‐ case‐control on effectiveness (ILI):</b> (two studies/two data sets) (<a href="./references#CD001269-bbs2-0104" title="BenowitzI , EspositoDB , GraceyKD , ShapiroED , VázquezM . Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clinical Infectious Diseases2010;51(12):1355‐61. ">pba Benowitz 2010</a>; <a href="./references#CD001269-bbs2-0105" title="PoehlingKA , SzilagyiPG , StaatMA , SnivelyBM , PayneDC , BridgesCB , et al. Impact of maternal immunization on influenza hospitalizations in infants. American Journal of Obstetrics and Gynecology2001;204(Suppl 6):141‐8. ">pba Poehling 2011</a>). </p> </li> </ol> </p> </section> <section id="CD001269-sec-0090"> <h5 class="title">Administration during pregnancy ‐ pregnancy‐related outcomes (abortion, congenital malformation, prematurity, neonatal death) </h5> <p> <ol id="CD001269-list-0021"> <li> <p><b>Seasonal inactivated vaccine ‐ cohort studies:</b> (seven studies/seven data sets) (<a href="./references#CD001269-bbs2-0107" title="AhrensKA , LouikC , KerrS , MitchellAA , WerlerMM . Seasonal influenza vaccination during pregnancy and the risks of preterm delivery and small for gestational age birth. Paediatric and Perinatal Epidemiology2014;28(6):498‐509. ">pca Ahrens 2014</a>; <a href="./references#CD001269-bbs2-0108" title="BlackSB , ShinefieldHR , FranceEK , FiremanBH , BlattST , ShayD . Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. American Journal of Perinatology2004;21(6):333‐9. ">pca Black 2004</a>; <a href="./references#CD001269-bbs2-0112" title="MunozFM , GreisingerAJ , WehmanenOA , MouzoonME , HoyleJC , SmithFA , et al. Safety of influenza vaccination during pregnancy. American Journal of Obstetrics and Gynecology2005;192(4):1098‐106. ">pca Munoz 2005</a>; <a href="./references#CD001269-bbs2-0119" title="DoddsL , MacdonaldN , ScottJ , SpencerA , AllenVM , McNeilS . The association between influenza vaccine in pregnancy and adverse neonatal outcomes. Journal of Obstetrics and Gynaecology Canada2012;34(8):714‐20. ">pcb Dodds 2012</a>; <a href="./references#CD001269-bbs2-0129" title="NordinJD , KharbandaEO , Vazquez BenitezG , LipkindH , VellozziC , DestefanoF . Maternal influenza vaccine and risks for preterm or small for gestational age birth. Journal of Pediatrics2014;164(5):1051‐7.e2. ">pcb Nordin 2014</a>; <a href="./references#CD001269-bbs2-0130" title="OmerSB , GoodmanD , SteinhoffMC , RochatR , KlugmanKP , StollBJ , et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Medicine2011;8(5):e1000441. ">pcb Omer 2011</a>; <a href="./references#CD001269-bbs2-0135" title="SheffieldJS , GreerLG , RogersVL , RobertsSW , LytleH , McIntireDD , et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstetrics and Gynecology2012;120(3):532‐7. ">pcb Sheffield 2012</a>). </p> </li> <li> <p><b>2009 to 2010 pandemic: inactivated vaccine ‐ cohort studies:</b> (14 studies/14 data sets) (<a href="./references#CD001269-bbs2-0114" title="BeauAB , Hurault‐DelarueC , VidalS , GuitardC , VayssiereC , PetiotD . Pandemic A/H1N1 influenza vaccination during pregnancy: a comparative study using the EFEMERIS database. Vaccine2014;32(11):1254‐8. ">pcb Beau 2014</a>; <a href="./references#CD001269-bbs2-0117" title="ClearyBJ , RiceU , EoganM , MetwallyN , McAuliffeF . 2009 A/H1N1 influenza vaccination in pregnancy: uptake and pregnancy outcomes ‐ a historical cohort study. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2014;178:163‐8. ">pcb Cleary 2014</a>; <a href="./references#CD001269-bbs2-0120" title="FellDB , SpragueAE , LiuN , YasseenAS3rd , WenSW , SmithG , et al. Better Outcomes Registry &amp; Network (BORN) Ontario. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. American Journal of Public Health2012;102(6):e33‐40. ">pcb Fell 2012</a>; <a href="./references#CD001269-bbs2-0121" title="HåbergSE , TrogstadL , GunnesN , WilcoxAJ , GjessingHK , SamuelsenSO , et al. Risk of fetal death after pandemic influenza virus infection or vaccination. New England Journal of Medicine2013;368(4):333‐40. HåbergSE , TrogstadL , GunnesN , WilcoxAJ , GjessingHK , SamuelsenSO , et al. Risk of fetal death after pandemic influenza virus infection or vaccination. Obstetrical and Gynecological Survey2013;68(5):348‐9. ">pcb Håberg 2013</a>; <a href="./references#CD001269-bbs2-0122" title="HeikkinenT , YoungJ , vanBeekE , FrankeH , VerstraetenT , WeilJG , et al. Safety of MF59‐adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. American Journal of Obstetrics &amp; Gynecology2012;207(3):177.e1‐8. ">pcb Heikkinen 2012</a>; <a href="./references#CD001269-bbs2-0123" title="KällénB , OlaussonPO . Vaccination against H1N1 influenza with Pandemrix during pregnancy and delivery outcome: a Swedish register study. British Journal of Obstetrics and Gynaecology2012;119(13):1583‐90. ">pcb Källén 2012</a>; <a href="./references#CD001269-bbs2-0124" title="LaunayO , KrivineA , CharlierC , TrusterV , TsatsarisV , LepercqJ , et al. Low rate of pandemic A/H1N1 2009 influenza infection and lack of severe complication of vaccination in pregnant women: a prospective cohort study. PLoS ONE2012;7(12):e52303. ">pcb Launay 2012</a>; <a href="./references#CD001269-bbs2-0125" title="LinTH , LinSY , LinCH , LinRI , LinHC , ChiuTH , et al. AdimFlu‐S influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine2012;30(16):2671‐5. ">pcb Lin 2012</a>; <a href="./references#CD001269-bbs2-0127" title="LudvigssonJF , ZugnaD , CnattingiusS , RichiardiL , EkbomA , OrtqvistA , et al. Influenza H1N1 vaccination and adverse pregnancy outcome. European Journal of Epidemiology2013;28(7):579‐88. ">pcb Ludvigsson 2013</a>; <a href="./references#CD001269-bbs2-0131" title="OppermannM , FritzscheJ , Weber‐SchoendorferC , Keller‐StanislawskiB , AllignolA , MeisterR , et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine2012;30(30):4445‐52. ">pcb Oppermann 2012</a>; <a href="./references#CD001269-bbs2-0132" title="PasternakB , SvanströmH , Mølgaard‐NielsenD , KrauseTG , EmborgHD , MelbyeM , et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A (H1N1) vaccine during pregnancy. JAMA2012;308(2):165‐74. ">pcb Pasternak 2012</a>; <a href="./references#CD001269-bbs2-0133" title="RichardsJL , HansenC , BredfeldtC , BednarczykRA , SteinhoffMC , Adjaye‐GbewonyoD , et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clinical Infectious Diseases2013;56(9):1216‐22. ">pcb Richards 2013</a>; <a href="./references#CD001269-bbs2-0134" title="RubinsteinF , MiconeP , BonottiA , WainerV , SchwarczA , AugustovskiF . Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ Online2013;346(7896):f393. ">pcb Rubinstein 2013</a>; <a href="./references#CD001269-bbs2-0137" title="TrottaF , DaCasR , Spila AlegianiS , GramegnaM , VenegoniM , ZocchettiC , et al. Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. BMJ2014;348:g3361. ">pcb Trotta 2014</a>). </p> </li> <li> <p><b>Seasonal trivalent inactivated vaccine containing pH1N1 ‐ cohort studies:</b> (two studies/two data sets) (<a href="./references#CD001269-bbs2-0116" title="ChambersCD , JohnsonD , XuR , LuoY , LouikC , MitchellAA , et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine2013;31(44):5026‐32. ">pcb Chambers 2013</a>; <a href="./references#CD001269-bbs2-0126" title="LouikC , AhrensK , KerrS , PyoJ , ChambersC , JonesKL , et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. Vaccine2013;31(44):5033‐40. ">pcb Louik 2013</a>). </p> </li> <li> <p><b>Seasonal inactivated vaccine ‐ case‐control:</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0106" title="IrvingSA , KiekeBA , DonahueJG , MascolaMA , BaggsJ , DestefanoF , et al. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstetrics and Gynecology2013;121(1):159‐65. ">pbb Irving 2013</a>). </p> </li> </ol> </p> <p>We did not introduce one study in the quantitative synthesis because it is the only study on the A/NJ/8/76 vaccine (<a href="./references#CD001269-bbs2-0118" title="DeinardAS , OgburnPJr . A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. American Journal of Obstetrics and Gynecology1981;140(3):240‐5. ">pcb Deinard 1981</a>). We also did not include the retrospective cohort study of <a href="./references#CD001269-bbs2-0136" title="TobackSL , BeigiR , TennisP , SifakisF , CalingaertB , AmbroseCS . Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza and Other Respiratory Viruses2012;6(1):44‐51. ">pcb Toback 2012</a> in the analysis because it did not contain useful outcomes. Results of one cohort study was not included in the analysis as it was only commented on (<a href="./references#CD001269-bbs2-0115" title="CantuJ , BiggioJ , JaukV , WettaL , AndrewsW , TitaA . Selective uptake of influenza vaccine and pregnancy outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2013;26(12):1207‐11. ">pcb Cantu 2013</a>). </p> </section> <section id="CD001269-sec-0091"> <h5 class="title">Administration during pregnancy ‐ severe harms</h5> <p>One included cohort study assessed the association between seasonal vaccine exposure during pregnancy and the following harms within 42 days from administration: Guillain‐Barré syndrome, demyelinating diseases, and immune thrombocytopenic purpura (<a href="./references#CD001269-bbs2-0128" title="NordinJD , KharbandaEO , BenitezGV , NicholK , LipkindH , NalewayA , et al. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. Obstetrics and Gynecology2013;121(3):519‐25. ">pcb Nordin 2013</a>). </p> </section> <section id="CD001269-sec-0092"> <h5 class="title">Severe harms ‐ general population</h5> <section id="CD001269-sec-0093"> <h6 class="title">Guillain‐Barré syndrome</h6> <p> <ol id="CD001269-list-0022"> <li> <p><b>2009 to 2010 pandemic ‐ case‐control:</b> (two studies/six data sets) (<a href="./references#CD001269-bbs2-0075" title="DielemanJ , RomioS , JohansenK , WeibelD , BonhoefferJ , SturkenboomM , et al. Guillain‐Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case‐control study in Europe. BMJ2012;343:d3908. ">bb Dieleman 2011a</a>; <a href="./references#CD001269-bbs2-0076" title="DielemanJ , RomioS , JohansenK , WeibelD , BonhoefferJ , SturkenboomM , et al. Guillain‐Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case‐control study in Europe. BMJ2012;343:d3908. ">bb Dieleman 2011b</a>; <a href="./references#CD001269-bbs2-0077" title="DielemanJ , RomioS , JohansenK , WeibelD , BonhoefferJ , SturkenboomM , et al. Guillain‐Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case‐control study in Europe. BMJ2012;343:d3908. ">bb Dieleman 2011c</a>; <a href="./references#CD001269-bbs2-0078" title="DielemanJ , RomioS , JohansenK , WeibelD , BonhoefferJ , SturkenboomM , et al. Guillain‐Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case‐control study in Europe. BMJ2012;343:d3908. ">bb Dieleman 2011d</a>; <a href="./references#CD001269-bbs2-0079" title="DielemanJ , RomioS , JohansenK , WeibelD , BonhoefferJ , SturkenboomM , et al. Guillain‐Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case‐control study in Europe. BMJ2012;343:d3908. ">bb Dieleman 2011e</a>; <a href="./references#CD001269-bbs2-0082" title="Grimaldi‐BensoudaL , AlpérovitchA , BessonG , VialC , CuissetJM , PapeixC , et al. Guillain‐Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. American Journal of Epidemiology2011;174(3):326‐35. ">bb Grimaldi‐Bensouda 2011</a>). </p> </li> <li> <p><b>Seasonal inactivated vaccine ‐ case‐control:</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0080" title="GaleottiF , MassariM , D'AlessandroR , BeghiE , ChiòA , LogroscinoG , et al. Risk of Guillain‐Barré syndrome after 2010‐2011 influenza vaccination. European Journal of Epidemiology2013;28(5):433‐44. ">bb Galeotti 2013</a>). </p> </li> <li> <p><b>Seasonal inactivated vaccine ‐ cohort studies:</b> (two studies/four data sets) (<a href="./references#CD001269-bbs2-0095" title="KaplanJE , KatonaP , HurwitzES , SchonbergerLB . Guillain‐Barre syndrome in the United States, 1979‐1980 and 1980‐1981. Lack of an association with influenza vaccination. JAMA1982;248(6):698‐700. ">cb Kaplan 1982</a>; <a href="./references#CD001269-bbs2-0096" title="LaskyT , TerraccianoGJ , MagderL , KoskiCL , BallesterosM , NashD , et al. The Guillain‐Barre syndrome and the 1992‐1993 and 1993‐1994 influenza vaccines. New England Journal of Medicine1998;339(25):1797‐802. ">cb Lasky 1998</a>). </p> </li> </ol> </p> <p>We did not introduce one cohort study assessing the association between the A/NJ/8/76 vaccine and Guillain‐Barré syndrome into the analysis (<a href="./references#CD001269-bbs2-0101" title="SchonbergerLB , BregmanDJ , Sullivan‐BolyaiJZ , KeenlysideRA , ZieglerDW , RetailliauHF , et al. Guillain‐Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976 ‐ 1977. American Journal of Epidemiology1979;110(2):105‐23. ">cb Shonberger 1979</a>). </p> </section> <section id="CD001269-sec-0094"> <h6 class="title">Demyelinating diseases (optic neuritis or multiple sclerosis)</h6> <p> <ol id="CD001269-list-0023"> <li> <p><b>Seasonal inactivated vaccine ‐ case‐control:</b> (four studies/four data sets) (<a href="./references#CD001269-bbs2-0074" title="DeStefanoF , VerstraetenT , JacksonLA , OkoroCA , BensonP , BlackSB , et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Archives of Neurology2003;60(4):504‐9. ">bb DeStefano 2003</a>; <a href="./references#CD001269-bbs2-0084" title="HernanMA , JickSS , OlekMJ , JickH . Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology2004;63(5):838‐42. ">bb Hernan 2004</a>; <a href="./references#CD001269-bbs2-0088" title="PayneDC , RoseCEJr , KerrisonJ , AranasA , DuderstadtS , McNeilMM . Anthrax vaccination and risk of optic neuritis in the United States military, 1998‐2003. Archives of Neurology2006;63(6):871‐5. ">bb Payne 2006</a>; <a href="./references#CD001269-bbs2-0092" title="ZorzonM , ZivadinovR , NasuelliD , DolfiniP , BoscoA , BratinaA , et al. Risk factors of multiple sclerosis: a case‐control study. Neurological Sciences2003;24(4):242‐7. ">bb Zorzon 2003</a>). </p> </li> <li> <p><b>2009 to 2010 pandemic ‐ cohort study:</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0097" title="MoroML , NobilioL , VociC , DiMarioS , CandelaS , MagriniN . A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia‐Romagna region, Italy ‐ part two. Vaccine2013;31(10):1438‐46. ">cb Moro 2013</a>). </p> </li> </ol> </p> </section> <section id="CD001269-sec-0095"> <h6 class="title">Immune thrombocytopenic purpura</h6> <p> <ol id="CD001269-list-0024"> <li> <p><b>Seasonal inactivated vaccine ‐ case‐control:</b> (two studies/two data sets) (<a href="./references#CD001269-bbs2-0081" title="GarbeE , AndersohnF , BronderE , KlimpelA , ThomaeM , KurtalH . Association between drug use and acute immune thrombocytopenia in adults: results from the Berlin case‐control surveillance study. Pharmacoepidemiology and Drug Safety2011;20:S147. GarbeE , AndersohnF , BronderE , SalamaA , KlimpelA , ThomaeM , et al. Drug‐induced immune thrombocytopaenia: results from the Berlin Case‐Control Surveillance Study. European Journal of Clinical Pharmacology2012;68(5):821‐32. ">bb Garbe 2012</a>; <a href="./references#CD001269-bbs2-0083" title="Grimaldi‐BensoudaL , MichelM , AubrunE , LeightonP , ViallardJF , AdoueD , et al. A case‐control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood2012;120(25):4938‐44. Grimaldi‐BensoudaL , MichelM , ViallardJ‐F , AdoueD , Magy‐BertrandN , KhellafM , et al. A multicenter case‐control prospective study to assess the risk of immune thrombocytopenia (ITP) associated with vaccines in adults using the PGRx‐ITP registry. Blood2011;118(21):1169. ">bb Grimaldi‐Bensouda 2012</a>). </p> </li> </ol> </p> </section> <section id="CD001269-sec-0096"> <h6 class="title">Other serious adverse events</h6> <p> <ol id="CD001269-list-0025"> <li> <p><b>Oculo‐respiratory syndrome:</b> randomised cross‐over trial (one study) (<a href="./references#CD001269-bbs2-0071" title="ScheifeleDW , DuvalB , RussellML , WarringtonR , DeSerresG , SkowronskiDM , et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clinical Infectious Diseases2003;36(7):850‐7. ">ab Scheifele 2003</a>) and one case‐control study (<a href="./references#CD001269-bbs2-0090" title="RouleauI , DeSerresG , SkowronskiDM , DroletJP , LemireC , TothE , et al. Risk factors associated with anaphylaxis and other allergic‐like events following receipt of 2009 monovalent AS03‐adjuvanted pandemic influenza vaccine in Quebec, Canada. Vaccine2014;32(28):3480‐7. ">bb Rouleau 2014</a>). </p> </li> <li> <p><b>Respiratory function</b>: RCT (<a href="./references#CD001269-bbs2-0052" title="AtmarRL , BloomK , KeitelW , CouchRB , GreenbergSB . Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine1990;8(3):217‐24. ">ab Atmar 1990</a>). </p> </li> <li> <p><b>Cutaneous melanoma:</b> case‐control (<a href="./references#CD001269-bbs2-0086" title="MastrangeloG , RossiCR , PfahlbergA , MarziaV , BarbaA , BaldoM , et al. Is there a relationship between influenza vaccinations and risk of melanoma? A population‐based case‐control study. European Journal of Epidemiology2000;16(9):777‐82. ">bb Mastrangelo 2000</a>). </p> </li> <li> <p><b>Bell's palsy:</b> case‐control (<a href="./references#CD001269-bbs2-0087" title="MutschM , ZhouW , RhodesP , BoppM , ChenRT , LinderT , et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New England Journal of Medicine2004;350(9):896‐903. ">bb Mutsch 2004</a>). </p> </li> <li> <p><b>Cardiac arrest:</b> case‐control (<a href="./references#CD001269-bbs2-0091" title="SiscovickDS , RaghunathanTE , LinD , WeinmannS , ArbogastP , LemaitreRN , et al. Influenza vaccination and the risk of primary cardiac arrest. American Journal of Epidemiology2000;152(7):674‐7. ">bb Siscovick 2000</a>). </p> </li> <li> <p><b>Acute myocardial infarction</b>: case‐control (<a href="./references#CD001269-bbs2-0085" title="MacIntyreCR , HeywoodAE , KovoorP , RiddaI , SealeH , TanT , et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. Heart2013;99(24):1843‐8. ">bb MacIntyre 2013</a>) </p> </li> <li> <p><b>Rheumatoid arthritis</b>: case‐control (<a href="./references#CD001269-bbs2-0089" title="RayP , BlackS , ShinefieldH , DillonA , CarpenterD , LewisE , et al. Vaccine Safety Datalink Team. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15‐59 years of age. Vaccine2011;29(38):6592‐7. ">bb Ray 2011</a>). </p> </li> <li> <p><b>Neurological and autoimmune disorders</b>: three cohort studies (<a href="./references#CD001269-bbs2-0093" title="BardageC , PerssonI , OrtqvistA , BergmanU , LudvigssonJF , GranathF . Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ2011;343:d5956. ">cb Bardage 2011</a>; <a href="./references#CD001269-bbs2-0098" title="O'FlanaganD , BarretAS , FoleyM , CotterS , BonnerC , CroweC , et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009‐December 2010. Eurosurveillance2014;19(17):15‐25. ">cb O'Flanagan 2014</a>; <a href="./references#CD001269-bbs2-0099" title="PerssonI , GranathF , AsklingJ , LudvigssonJF , OlssonT , FelteliusN . Risks of neurological and immune‐related diseases, including narcolepsy, after vaccination with Pandemrix: a population‐ and registry‐based cohort study with over 2 years of follow‐up. Journal of Internal Medicine2014;275(2):172‐90. ">cb Persson 2014</a>) and one case‐control (<a href="./references#CD001269-bbs2-0073" title="DauvilliersY , ArnulfI , LecendreuxM , Monaca CharleyC , FrancoP , DrouotX , et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain2013;139(Pt 8):2486‐96. ">bb Dauvilliers 2013</a>). </p> </li> <li> <p><b>Other serious adverse events:</b> cohort study (<a href="./references#CD001269-bbs2-0094" title="BaxterR , TobackSL , SifakisF , HansenJ , BartlettJ , AukesL , et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18‐49 years of age. Vaccine2012;30(20):3053‐60. ">cb Baxter 2012</a>). </p> </li> </ol> </p> </section> </section> <section id="CD001269-sec-0097"> <h5 class="title">Pandemic vaccine: efficacy or effectiveness</h5> <p> <ol id="CD001269-list-0026"> <li> <p><b>RCT on inactivated parenteral vaccine:</b> (four studies/seven data sets) (<a href="./references#CD001269-bbs2-0006" title="EddyTS , DaviesNA . The effect of vaccine on a closed epidemic of Hong Kong influenza. South African Medical Journal1970;44(8):214‐6. ">aa Eddy 1970</a>; <a href="./references#CD001269-bbs2-0026" title="MogabgabWJ , LeidermanE . Immunogenicity of 1967 polyvalent and 1968 Hong Kong influenza vaccines. JAMA1970;211(10):1672‐6. ">aa Mogabgab 1970a</a>; <a href="./references#CD001269-bbs2-0027" title="MogabgabWJ , LeidermanE . Immunogenicity of 1967 polyvalent and 1968 Hong Kong influenza vaccines. JAMA1970;211(10):1672‐6. ">aa Mogabgab 1970b</a>; <a href="./references#CD001269-bbs2-0041" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969a</a>; <a href="./references#CD001269-bbs2-0042" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969b</a>; <a href="./references#CD001269-bbs2-0046" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972b</a>; <a href="./references#CD001269-bbs2-0048" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972d</a>). </p> </li> <li> <p><b>RCT on inactivated aerosol vaccine:</b> (two studies/four data sets) (<a href="./references#CD001269-bbs2-0043" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969c</a>; <a href="./references#CD001269-bbs2-0044" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969d</a>; <a href="./references#CD001269-bbs2-0045" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972a</a>; <a href="./references#CD001269-bbs2-0047" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972c</a>). </p> </li> <li> <p><b>RCT on live aerosol vaccine</b> (one study/one data set) (<a href="./references#CD001269-bbs2-0038" title="SumarokowAA , PopovVF , NefedovaLA , SalminLV , LazorenkoNF . A study of live influenza vaccines in a controlled trial. Zhumal Mikrobiologii Epidemiologii Immunobiologii1971;48(2):46‐52. ">aa Sumarokow 1971</a>). </p> </li> </ol> </p> </section> </section> <section id="CD001269-sec-0098"> <h4 class="title">Excluded studies</h4> <p>We excluded 183 studies (see <a href="./references#CD001269-sec-0234" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD001269-sec-0099"> <h3 class="title">Risk of bias in included studies</h3> <p>Out of the 137 included studies (substudy or data set), we classified 16.1% (22/137) as at low risk of bias (12 RCTs, two case‐control, eight cohort studies); 17.5% (24/137) as at high risk of bias (seven RCTs, three case‐control, 14 cohorts); and 66.4% (91/137) either did not present sufficient information in one or more key domains or, although presenting a low risk of bias in a specific domain, scored at high risk of bias in one or more items used in the quality evaluation. <a href="#CD001269-tbl-0003">Table 2</a> shows the summary quality assessment of all included studies, and graphical displays of the quality assessment are presented in <a href="#CD001269-fig-0002">Figure 2</a> and <a href="#CD001269-fig-0003">Figure 3</a>. We have highlighted that each 'paper' could include more than one study (data set), and these different studies required separate quality assessment. The funding source can be referred only to a single paper. </p> <div class="figure" id="CD001269-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001269-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001269-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001269-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="table" id="CD001269-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unclear risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case‐control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cohort</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RCT/CCT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/> RCT: randomised controlled trial </p> <p>This table displays the overall methodological quality assessment of the included studies described in the text and represented in extended form (with all items of the tools) in <a href="#CD001269-fig-0001">Figure 1</a>. </p> </div> </div> <section id="CD001269-sec-0100"> <h4 class="title">Allocation</h4> <p>In the included trials allocation concealment was adequate (low risk of bias) in 21 studies (28.4%), inadequate (high risk of bias) in seven studies (9.5%), and unclear (unclear risk of bias) in 46 studies (62.2%). </p> </section> <section id="CD001269-sec-0101"> <h4 class="title">Blinding</h4> <p>We judged blinding as at low risk of bias in 17 RCTs/CCTs (23%), high risk of bias in three RCTs/CCTs (4.1%), and unclear in 54 RCTs/CCTs (73%). </p> </section> <section id="CD001269-sec-0102"> <h4 class="title">Incomplete outcome data</h4> <p>The majority of the included RCTs/CCTs reported insufficient information about loss to follow‐up (64 studies; 86.5%). </p> </section> <section id="CD001269-sec-0103"> <h4 class="title">Selective reporting</h4> <p>The assessment of selective reporting bias presents several difficulties and would require review of the original study protocols for the included studies, which are mainly unavailable. </p> </section> <section id="CD001269-sec-0104"> <h4 class="title">Other potential sources of bias</h4> <p>Few studies reported information on influenza circulation in the surrounding community, making interpretation of the results and assessment of their generalisability difficult. </p> <p>It is now known that industry funding of influenza vaccine studies determines publication in high‐prestige journals and higher citation rates than other types of funding. In addition, industry funding is associated with optimistic conclusions, but the quality of the majority of influenza vaccine studies is low, irrespective of funding (<a href="#CD001269-tbl-0004">Table 3</a>). A previously cited review showed a complex web of interrelationships between these variables (<a href="./references#CD001269-bbs2-0337" title="JeffersonT , DiPietrantonjC , DebaliniMG , RivettiA , DemicheliV . Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ2009;338:b354. [DOI: 10.1136/bmj.b354] ">Jefferson 2009b</a>), but the impact of this on policymaking is unknown. </p> <div class="table" id="CD001269-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Funding source of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Government, institutional, or public</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Industry</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mixed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case‐control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cohort</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RCT/CCT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/> RCT: randomised controlled trial </p> </div> </div> <section id="CD001269-sec-0105"> <h5 class="title">Case‐control studies ‐ quality assessment</h5> <p> <ul id="CD001269-list-0027"> <li> <p><b>Case selection (definition/representativeness)</b>: case identification is mainly performed by means of registers maintained at several healthcare organisations (HMO, Kaiser Permanente) or by hospital or GP (general practice) registers. A further case ascertainment is conducted by specialists in order to verify the agreement with the chosen case definition. In studies assessing vaccine efficacy, cases were identified using a laboratory test performed on all participants having symptoms. For 21 out of 23 (91%), we classified case selection and definition as at low risk of bias. </p> </li> <li> <p><b>Control selection (definition):</b> controls were selected from within the same registers used for case identification or from among participants living in the same catchment area of the hospitals in which the cases were identified. We classified control selection and definition as at low risk of bias for 10 out of 23 studies (43.4%), and unclear risk of bias for 11 out of 23 (47.8%). </p> </li> <li> <p><b>Comparability:</b> the most frequent method used to ensure comparability between cases and controls consisted of matching for age, gender, and index date (onset of symptoms for cases and GP visit for controls). Less frequently matching was also done for other possible parameters, such as the number of GP visits within a certain time interval, or by resorting to the use of a propensity score or multivariate models in order to reduce the impact of other possible confounders. Nevertheless, many studies (18 out of 23 (78.3%)) provided insufficient information to judge how comparable cases and controls effectively are. </p> </li> <li> <p><b>Exposure ascertainment (same method of ascertainment for cases and controls/non‐response rate):</b> for studies based on healthcare organisations or insurance registers, assessment of vaccine exposure was certified in the same registers. In other studies vaccine exposure was ascertained with a structured interview, and less frequently also with the recovering of the vaccination records. In many studies (15 out of 23 (65.2%)), ascertainment of the vaccine exposure was not fully reliable. For 7 out of 23 studies (30.4%), we judged exposure ascertainment as at low risk of bias. </p> </li> </ul> </p> </section> <section id="CD001269-sec-0106"> <h5 class="title">Cohort studies ‐ quality assessment</h5> <p> <ul id="CD001269-list-0028"> <li> <p><b>Selection exposed cohort (definition/representativeness):</b> the majority of the studies were retrospective and used a data linkage method to select the exposed cohort. In 20 out of 40 studies (50%), this procedure was insufficiently described. </p> </li> <li> <p><b>Selection non‐exposed cohort (definition/ascertainment):</b> most of the studies were based on record linkage and the identification of the non‐exposed cohort was done by considering the absence of vaccination records. However, insufficient detail was provided, therefore we classified such studies as at unclear risk of bias (18 out of 40 (45%)). </p> </li> <li> <p><b>Comparability:</b> in most of the included cohort studies matching procedures for the most probable confounders were applied using a multivariate model to ensure comparability between exposed and unexposed cohorts. A propensity score procedure was also sometimes used. Therefore in some studies only a few confounders were used to ensure comparability between exposed and non‐exposed cohorts. We classified seven studies as at low risk of bias (17.5%). </p> </li> <li> <p><b>Assessment of outcome (demonstration that outcome of interest was not present at the start of the study/whether follow‐up was long enough for outcomes to occur/adequacy of follow‐up of cohorts):</b> outcomes of interest were generally documented in the registries used to identify the study population, and consequently were almost always retrospectively assessed, thus we classified 11 out of 40 (27.5%) as at low risk of bias. </p> </li> </ul> </p> </section> </section> </section> <section id="CD001269-sec-0107"> <h3 class="title" id="CD001269-sec-0107">Effects of interventions</h3> <p>See: <a href="./full#CD001269-tbl-0001"><b>Summary of findings for the main comparison</b> Inactivated parenteral influenza vaccine compared to placebo or 'do nothing' for preventing influenza in healthy adults</a> </p> <p>We constructed the <a href="./references#CD001269-sec-0148" title="">Data and analyses</a> tables according to the following criteria. </p> <p> <ol id="CD001269-list-0029"> <li> <p>Inactivated parenteral influenza vaccine versus placebo or 'do nothing' (Comparison 01). </p> </li> <li> <p>Live aerosol influenza vaccine versus placebo or 'do nothing' (Comparison 02).</p> </li> <li> <p>Inactivated aerosol influenza vaccine versus placebo or 'do nothing' (Comparison 03).</p> </li> <li> <p>Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy (Comparison 04). </p> </li> <li> <p>Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies (Comparison 05). </p> </li> <li> <p>Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies (Comparison 06). </p> </li> <li> <p>Serious adverse events: Guillain‐Barré syndrome ‐ cohort studies (Comparison 07).</p> </li> <li> <p>Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies (Comparison 08). </p> </li> <li> <p>Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies (Comparison 09). </p> </li> <li> <p>Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies (Comparison 10). </p> </li> <li> <p>Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies (Comparison 11). </p> </li> <li> <p>Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies (Comparison 12). </p> </li> <li> <p>1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo (Comparison 13). </p> </li> <li> <p>1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo (Comparison 14). </p> </li> <li> <p>1968 to 1969 pandemic: inactivated polyvalent aerosol influenza vaccine versus placebo (Comparison 15). </p> </li> <li> <p>1968 to 1969 pandemic: inactivated monovalent aerosol influenza vaccine versus placebo (Comparison 16). </p> </li> <li> <p>1968 to 1969 pandemic: live aerosol influenza vaccine versus placebo (Comparison 17).</p> </li> </ol> </p> <p>Evidence from RCTs/CCTs on vaccine efficacy/effectiveness in the general population is reported in Analyses 1 to 3. Evidence from RCTs/CCTs on vaccine efficacy/effectiveness in pregnancy is reported in Comparison 4. Evidence from observational studies in pregnancy is reported in Analyses 5 and 6. </p> <p>Studies investigating the association between influenza vaccination and Guillain‐Barré syndrome were included in Comparison 7 (cohort on seasonal vaccine) and Comparison 8 (case‐control on H1N1 vaccine). In Comparison 8, we stratified studies according to three different exposure definitions according to the time between vaccination to onset of symptoms (any time, within seven weeks, over seven weeks). We have presented evidence for the association between seasonal vaccine and Guillain‐Barré syndrome from cohort studies in Comparison 7. </p> <p>Studies investigating the association between influenza vaccination and multiple sclerosis and optic neuritis are included in Analyses 9 and 10 (cohort and case‐control studies ‐ demyelinating diseases). </p> <p>Studies investigating the association between influenza vaccination and immune thrombocytopenic purpura are included in Analyses 11 and 12 (cohort and case‐control studies ‐ immune thrombocytopenic purpura). </p> <p>We have constructed a 'Summary of findings' table for key outcomes (see <a href="./full#CD001269-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD001269-sec-0108"> <h4 class="title">Inactivated parenteral influenza vaccine versus placebo or 'do nothing' (Comparison 01) </h4> <p>Inactivated parenteral vaccines probably have 59% efficacy in preventing confirmed influenza (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.36 to 0.47; 71,221 participants; 25 studies, moderate‐certainty evidence) (<a href="./references#CD001269-fig-0004" title="">Analysis 1.1</a>). Based on the control group risk of 2.3%, 71 healthy adults need to be vaccinated in order to prevent one of them experiencing influenza. The effects were very similar when matching was absent or unknown. Since heterogeneity was very low (I<sup>2</sup> = 17% for Analysis 1.2.1; I<sup>2</sup> = 14% for Analysis 1.1.2), there were no differences when comparing the estimates obtained by using a fixed‐effect model with those from a random‐effects model. Restricting the analysis to studies at low risk of bias did not affect the direction or size of effect (see <a href="#CD001269-tbl-0005">Table 4</a>). </p> <div class="table" id="CD001269-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for 'Summary of findings' table outcomes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome (analysis)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All studies (primary analysis)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies at low risk of bias (sensitivity analysis)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza (<a href="./references#CD001269-fig-0004" title="">Analysis 1.1</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.41 (0.36 to 0.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.34 (0.25 to 0.45)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza‐like illness (<a href="./references#CD001269-fig-0005" title="">Analysis 1.2</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.84 (0.75 to 0.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.82 (0.69 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisations (<a href="./references#CD001269-fig-0011" title="">Analysis 1.8</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96 (0.85 to 1.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.89 (0.12 to 70.68)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever (<a href="./references#CD001269-fig-0014" title="">Analysis 1.11</a>.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.55 (1.26 to 1.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.59 (1 to 2.53)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting (<a href="./references#CD001269-fig-0014" title="">Analysis 1.11</a>.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80 (0.65 to 5.04)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 7.05 (1.61 to 30.87)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RR: risk ratio</p> </div> </div> <p>Inactivated parenteral vaccines probably have 16% effectiveness in preventing ILI (RR 0.84, 95% CI 0.75 to 0.95; 25,795 participants; 16 studies; moderate‐certainty evidence) (<a href="./references#CD001269-fig-0005" title="">Analysis 1.2</a>). There was wide variation in the control group risks, with risk differences in low‐, moderate‐, and high‐risk groups of 0.6%, 3.4%, and 14.6%. Based on the median (i.e. moderate risk) control group risk of 21.5%, 29 healthy adults need to be vaccinated to prevent one adult experiencing an ILI. For low‐ and high‐risk control group the corresponding NNVs were 167 and 7, respectively. Sensitivity analysis by risk of bias did not change the size or direction of effect (<a href="#CD001269-tbl-0005">Table 4</a>). </p> <p>Results across the subgroups by matching criteria were very similar (I<sup>2</sup> = 0%). </p> <p>Based on the results from a single study (<a href="./references#CD001269-bbs2-0005" title="Buxton BridgesC , ThompsonVV , MeltzerMI , ReeveGR , TalamontiVJ , CoxNJ . Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA2000;284(13):1655‐63. ">aa Bridges 2000b</a>), physician visits appear 42% less frequent (95% CI 9% to 63%) in participants immunised with vaccines prepared with strains matching circulating viruses (Analysis 1.3.1), whereas there were no significant results when the degree of matching was unknown or absent (RR 1.28, 95% CI 0.90 to 1.83; Analysis 1.3.2). The overall effect was also not significant (RR 0.87, 95% CI 0.40 to 1.89) (<a href="./references#CD001269-fig-0006" title="">Analysis 1.3</a>). Even though the two data sets of <a href="./references#CD001269-bbs2-0005" title="Buxton BridgesC , ThompsonVV , MeltzerMI , ReeveGR , TalamontiVJ , CoxNJ . Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA2000;284(13):1655‐63. ">aa Bridges 2000b</a> showed very high heterogeneity (I<sup>2</sup> = 87%), no difference arose when comparing the results from the fixed‐effect with the random‐effects model. </p> <p>We observed a similar conflicting result when analysing the effect of inactivated vaccine administration on days of illness (<a href="./references#CD001269-fig-0007" title="">Analysis 1.4</a>), when the estimate (mean difference (MD)) obtained in good‐match conditions was compared with unknown or absent degree of matching. As a consequence of the high overall heterogeneity (I<sup>2</sup> = 87%), the result obtained from the fixed‐effect model analysis (MD ‐0.31, 95% CI ‐0.54 to ‐0.07) differed from the result of the application of a random‐effects model (MD ‐0.21, 95% CI ‐0.98 to 0.56). </p> <p>There seemed to be no effect on the time an antibiotic or drug was prescribed (<a href="./references#CD001269-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD001269-fig-0009" title="">Analysis 1.6</a>). </p> <p>Four trials evaluated time off work, estimating that vaccination may save around 0.04 working days per person over a single influenza season. This result was affected by high levels of heterogeneity (I<sup>2</sup> = 82%) but did not change depending on whether a fixed‐effect (MD ‐0.04, 95% CI ‐0.06 to ‐0.01) or random‐effects model (MD ‐0.04, 95% CI ‐0.14 to 0.06) (<a href="./references#CD001269-fig-0010" title="">Analysis 1.7</a>) was used. We rated the evidence as of low certainty. </p> <p>Vaccination may have a small effect on hospitalisation (<a href="./references#CD001269-fig-0011" title="">Analysis 1.8</a>), but the CI was wide and does not rule out a large reduction in hospitalisation (RR 0.96, 95% CI 0.85 to 1.08; low‐certainty evidence). We found no evidence for cases of pneumonia. </p> <section id="CD001269-sec-0109"> <h5 class="title">Harms</h5> <p>Live parenteral influenza vaccines increase fever from 1.5% to 2.33% (RR 1.55, 95% CI 1.26 to 1.91; 23,850 participants; 13 studies; high‐certainty evidence) (Analysis 1.11.2). The rate of nausea or vomiting was low in the trials (4% in unvaccinated population versus 7% with vaccines), although we rated this evidence as low certainty due to wide CIs and possible impact of bias (see <a href="#CD001269-tbl-0005">Table 4</a>) (RR 1.80, 95% CI 0.65 to 5.04; 6315 participants; 4 trials) (Analysis 1.11.5). </p> <p>Local tenderness and soreness were more than three times as common among parenteral vaccine recipients than among those in the placebo group (RR 3.13, 95% CI 2.44 to 4.02) (Analysis 1.10.1). There were also increases in erythema (RR 2.59, 95% CI 1.77 to 3.78; Analysis 1.10.2) and induration (RR 4.28, 95% CI 1.25 to 14.67) but not in arm stiffness. The combined local effects endpoint was significantly higher for those receiving the vaccine (RR 2.44, 95% CI 1.82 to 3.28; Analysis 1.10.5). </p> <p>Myalgia was significantly associated with vaccination (RR 1.74, 95% CI 1.41 to 2.14) (Analysis 1.11.1), fatigue or indisposition (RR 1.19, 95% CI 1.05 to 1.36) (Analysis 1.11.4), and malaise (RR 1.51, 95% CI 1.18 to 1.92) (Analysis 1.11.6). The combined endpoint was not increased (RR 1.16, 95% CI 0.87 to 1.53; Analysis 1.11.7). </p> </section> </section> <section id="CD001269-sec-0110"> <h4 class="title">Live aerosol influenza vaccine versus placebo or 'do nothing' (Comparison 02)</h4> <p>Live aerosol vaccines have an overall efficacy of 53% (95% CI 38% to 65%), and the NNV is 39 (95% CI 32 to 54). Neither content nor matching appeared to affect their performance significantly. The vaccines have an effectiveness against ILI of 10% (95% CI 4% to 16%; NNV 46, 95% CI 29 to 115), and content and matching appeared not to affect their performance significantly (<a href="./references#CD001269-fig-0016" title="">Analysis 2.2</a>). </p> <p>No evidence was available on complications (e.g. bronchitis, otitis media, pneumonia).</p> <p>The effectiveness of the aerosol vaccines against ILI (with no clear definition) was significant only for vaccines with absent or unknown matching (37%, 95% CI 20% to 51%), and the NNV was 69 (95% CI 23 to 46) (<a href="./references#CD001269-fig-0017" title="">Analysis 2.3</a>). </p> <p>The conclusions of this comparison were unaffected by analysis using either the fixed‐effect or random‐effects models. </p> <section id="CD001269-sec-0111"> <h5 class="title">Harms</h5> <p>Significantly more recipients experienced local symptoms after vaccine administration than after placebo administration (<a href="./references#CD001269-fig-0018" title="">Analysis 2.4</a>). </p> <p> <ul id="CD001269-list-0030"> <li> <p>Upper respiratory infection (RR 1.66, 95% CI 1.22 to 2.27).</p> </li> <li> <p>Cough (RR 1.51, 95% CI 1.08 to 2.10).</p> </li> <li> <p>Coryza (RR 1.56, 95% CI 1.26 to 1.94).</p> </li> <li> <p>Sore throat (RR 1.66, 95% CI 1.49 to 1.86).</p> </li> <li> <p>Combined endpoint (any or highest symptom) (RR 1.56, 95% CI 1.31 to 1.87).</p> </li> </ul> </p> <p>There was no significant increase in systemic harms (combined endpoint: any or highest symptom RR 1.40, 95% CI 0.82 to 2.38), although rates of myalgia (RR 2.47, 95% CI 1.26 to 4.85) and headache (RR 1.54, 95% CI 1.09 to 2.18) were higher in the vaccine group than in the placebo group (<a href="./references#CD001269-fig-0019" title="">Analysis 2.5</a>). </p> </section> </section> <section id="CD001269-sec-0112"> <h4 class="title">Inactivated aerosol influenza vaccine versus placebo or 'do nothing' (Comparison 03)</h4> <p>We could include no RCTs assessing the effectiveness of inactivated aerosol vaccines in preventing ILI; the only available evidence comes from studies carried out during the 1968 to 1969 pandemic (Analyses 12 to 16). </p> <p>The efficacy of inactivated aerosol vaccine in preventing laboratory‐confirmed influenza (Analysis 3.1.1) was assessed in one RCT (<a href="./references#CD001269-bbs2-0020" title="LangleyJM , AokiF , WardBJ , McGeerA , AngelJB , StiverG , et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine2011;29(10):1921‐8. ">aa Langley 2011</a>), whose results do not show a statistically significant protective effect (RR 0.38, 95% CI 0.14 to 1.02). </p> <section id="CD001269-sec-0113"> <h5 class="title">Harms</h5> <p>None of the trials on inactivated aerosol vaccines reported significant harms.</p> </section> </section> <section id="CD001269-sec-0114"> <h4 class="title">Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy (Comparison 04) </h4> <p>In this analysis, we considered the results of one RCT (at low risk of bias) and one CCT (at high risk of bias) assessing the effect of vaccination during pregnancy on the prevention of influenza and ILI in both mother and newborns. </p> <p>Vaccination with trivalent inactivated vaccine containing pH1N1 was weakly protective against influenza (RCT data only) in mothers within 24 weeks after delivery (RR 0.50, 95% CI 0.29 to 0.86; vaccine efficacy (or effectiveness) (VE) 50%, 95% CI 14% to 71%; NNV 55, 95% CI 39 to 198; <a href="./references#CD001269-fig-0023" title="">Analysis 4.1</a>), as well as among children born from a vaccinated mother until their first 24 weeks of life (VE 49%, 95% CI 12% to 70%; NNV 56, 95% CI 39 to 230; <a href="./references#CD001269-fig-0025" title="">Analysis 4.3</a>). Vaccination with monovalent pandemic or trivalent inactivated vaccine containing pH1N1 did not confer significant protection against ILI, either in mothers (RR 0.96, 95% CI 0.79 to 1.16; <a href="./references#CD001269-fig-0024" title="">Analysis 4.2</a>) or in newborns (RR 1.02, 95% CI 0.94 to 1.09; <a href="./references#CD001269-fig-0026" title="">Analysis 4.4</a>). </p> </section> <section id="CD001269-sec-0115"> <h4 class="title">Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies (Comparison 05) </h4> <p>Based on unadjusted data from a cohort study (high risk of bias), 2009/2010 H1N1 monovalent pandemic vaccines (Analysis 5.1.1) provide a significant protective effect against ILI in pregnant women (RR 0.11, 95% CI 0.06 to 0.21; VE 89%, 95% CI 79% to 94%; NNV 54, 95% CI 51 to 61). Seasonal inactivated vaccine is not effective against ILI (RR 0.54, 95% CI 0.24 to 1.18; Analysis 5.1.2). Sensitivity analysis performed using the fixed‐effect model showed statistical significance, even for a modest protective effect (RR 0.76, 95% CI 0.64 to 0.89; NNV 94, 95% CI 63 to 205; VE 24%, 95% CI 11% to 36%). </p> <p>The effectiveness of vaccination with seasonal inactivated vaccine during pregnancy for preventing ILI in newborns was not statistically significant, as the results are based on two cohort studies using either hazard ratio (HR) or RR adjusted estimates (Analysis 5.2.1 and Analysis 5.3.1, respectively). Efficacy against confirmed influenza (Analysis 5.3.2) is modest but has statistical significance (adjusted RR 0.59, 95% CI 0.37 to 0.94; NNV 27, 95% CI 18 to 185; VE 41%, 95% CI 6% to 63%). </p> <p>Vaccination with the 2009/2010 H1N1 monovalent pandemic vaccine during pregnancy may not be associated with a higher risk of abortion (Analysis 5.4.1 and Analysis 5.4.2), congenital malformation (Analysis 5.4.3), or neonatal death (Analysis 5.4.9). From a meta‐analysis of seven cohort studies, preterm deliveries (before 37 weeks of gestation) occurred with slightly less frequency among women who were immunised with monovalent pandemic H1N1 vaccine during pregnancy compared to unvaccinated women (Analysis 5.4.5, adjusted OR 0.84, 95% CI 0.76 to 0.93). This result was not confirmed by two other cohort studies, which found no significant association (Analysis 5.4.6, adjusted HR 1.11, 95% CI 0.46 to 2.68) or by two other cohort studies that separately analysed vaccine administration during the first trimester of gestation with that during the second or third trimester (Analysis 5.4.6; Analysis 5.4.7; Analysis 5.4.8). </p> <p>Cases of neonatal death and abortion were observed less frequently among women immunised with seasonal influenza vaccine (Analysis 5.5.1 and Analysis 5.5.4, both unadjusted estimates). We found no statistically relevant association between seasonal influenza vaccine exposure during pregnancy and prematurity or congenital malformations (Analysis 5.5.2; Analysis 5.5.3; Analysis 5.5.4). Two other cohort studies did not find any statistically significant association between exposure to seasonal trivalent inactivated vaccine containing pH1N1 and prematurity, whatever the trimester of gestation (<a href="./references#CD001269-fig-0032" title="">Analysis 5.6</a>). This finding was confirmed by one other retrospective cohort study, which was not included in the analysis (<a href="./references#CD001269-bbs2-0115" title="CantuJ , BiggioJ , JaukV , WettaL , AndrewsW , TitaA . Selective uptake of influenza vaccine and pregnancy outcomes. Journal of Maternal‐Fetal and Neonatal Medicine2013;26(12):1207‐11. ">pcb Cantu 2013</a>, adjusted RR 1.2, 95% CI 0.9 to 1.6). </p> <p>The results of <a href="./references#CD001269-bbs2-0118" title="DeinardAS , OgburnPJr . A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. American Journal of Obstetrics and Gynecology1981;140(3):240‐5. ">pcb Deinard 1981</a> are based on the follow‐up results of 189 pregnant women immunised with monovalent pandemic A/New Jersey/8/76 (either in split‐ or whole‐virus formulation) and 517 pregnant women who did not receive vaccination. The time of observation was extended up to the first eight weeks of life of the newborns. No statistically different incidence of maternal pregnancy outcomes or infant deaths was observed between vaccinated and unvaccinated groups. Statistical analysis (Chi<sup>2</sup> test) showed no relation between immunisation history and presence of anomalities at the eighth week of life. We did not include this cohort study in the analysis, as the vaccine studied is no longer in use. </p> </section> <section id="CD001269-sec-0116"> <h4 class="title">Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies (Comparison 06) </h4> <p>This analysis only included studies assessing the effect of vaccination against influenza during pregnancy. The incidence of ILI in pregnant women who were immunised with inactivated seasonal vaccine during pregnancy was not statistically different when compared with that observed among unvaccinated pregnant women (Analysis 6.1.1). However, the results of the analysis became statistically significant in sensitivity analysis using the fixed‐effect model, leading us to conclude that the results of this comparison were affected by the model used to perform the analysis. </p> <p>One further case‐control study did not find a statistically significant association between exposure to seasonal inactivated vaccine in pregnancy and abortion cases (Analysis 6.2.1). </p> <p>One retrospective cohort study attempted to assess the effect of live attenuated vaccine during pregnancy based on data from a health insurance database during six subsequent influenza seasons (<a href="./references#CD001269-bbs2-0136" title="TobackSL , BeigiR , TennisP , SifakisF , CalingaertB , AmbroseCS . Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza and Other Respiratory Viruses2012;6(1):44‐51. ">pcb Toback 2012</a>). A total of 834,999 pregnant women were identified, of whom 138 received live attenuated vaccine at any time during pregnancy. Claims for hospitalisation or visits to the emergency department within 42 days after immunisation were searched for, but all observed events were considered to be related to a normal physiological pregnancy and not to immunisation. The system used (claim data) would be unable to detect birth outcomes. </p> </section> <section id="CD001269-sec-0117"> <h4 class="title">Serious adverse events: Guillain‐Barré syndrome ‐ cohort studies (Comparison 07)</h4> <p>Two cohort studies performed during two subsequent epidemic seasons investigated the possible association between exposure to seasonal inactivated vaccine in healthy adults and Guillain‐Barré syndrome onset within six weeks following immunisation. No significant association was found (Analysis 7.1.1). Administration of seasonal inactivated vaccine during pregnancy was not associated with Guillain‐Barré syndrome onset within six weeks from immunisation (Analysis 7.1.2). </p> <p>The cohort of <a href="./references#CD001269-bbs2-0101" title="SchonbergerLB , BregmanDJ , Sullivan‐BolyaiJZ , KeenlysideRA , ZieglerDW , RetailliauHF , et al. Guillain‐Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976 ‐ 1977. American Journal of Epidemiology1979;110(2):105‐23. ">cb Shonberger 1979</a> was the first study that compared Guillain‐Barré syndrome cases by vaccination status and the national incidence in vaccinated and unvaccinated national cohorts after the suspension of the National Influenza Immunization Program in the winter of 1976 to 1977. At that time the monovalent inactivated swine vaccine A/New Jersey/8/76 had been administered. The attributable risk from vaccination was just below one case of Guillain‐Barré syndrome in every 100,000 vaccinations. We did not include this cohort study in the analysis as the vaccine studied is no longer in use. </p> </section> <section id="CD001269-sec-0118"> <h4 class="title">Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies (Comparison 08) </h4> <p>In an analysis performed using the mean of unadjusted data relative to six data sets, exposure to monovalent H1N1 pandemic inactivated vaccine resulted in an apparent statistically significant association with Guillain‐Barré syndrome onset when administration took place within six weeks before symptoms occurred (odds ratio (OR) 2.22, 95% CI 1.14 to 4.31; Analysis 8.1.1). It should thus be taken into account that only one out of the six data sets showed a statistically significant association between vaccine exposure and Guillain‐Barré syndrome onset (<a href="./references#CD001269-bbs2-0079" title="DielemanJ , RomioS , JohansenK , WeibelD , BonhoefferJ , SturkenboomM , et al. Guillain‐Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case‐control study in Europe. BMJ2012;343:d3908. ">bb Dieleman 2011e</a>). When we performed a sensitivity analysis excluding this data set from the pooled estimate, the result was no longer significant. When the analysis was performed for vaccine exposure that occurred at any time before disease onset, there was no significant association (Analysis 8.1.2). </p> <p>The analyses performed by pooling authors' estimates adjusted for several confounders (i.e. receipt of other vaccines, family history of autoimmune diseases, physician consultation during the previous year, and use of antibiotic, antiviral, or antipyretic agents) did not show a statistical association for exposure within six weeks (Analysis 8.2.1) before disease onset or for exposure at any time (Analysis 8.2.2). </p> <p>Data from one other case‐control study confirmed that immunisation with seasonal inactivated vaccine is not significantly associated with the onset of Guillain‐Barré syndrome within six weeks after inoculation (<a href="./references#CD001269-fig-0038" title="">Analysis 8.3</a>) (<a href="./references#CD001269-bbs2-0080" title="GaleottiF , MassariM , D'AlessandroR , BeghiE , ChiòA , LogroscinoG , et al. Risk of Guillain‐Barré syndrome after 2010‐2011 influenza vaccination. European Journal of Epidemiology2013;28(5):433‐44. ">bb Galeotti 2013</a>). </p> </section> <section id="CD001269-sec-0119"> <h4 class="title">Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies (Comparison 09) </h4> <p>In one cohort study the authors attempted to assess whether there was an association between exposure to inactivated trivalent seasonal influenza vaccine during pregnancy and several pathologies (e.g. Guillain‐Barré syndrome, demyelinating diseases, immune thrombocytopenic purpura) within six weeks after immunisation. Unadjusted estimates were calculated for an association with demyelinating diseases by using the number of cases observed among exposed and unexposed hemi‐cohorts, and indicated that there was no association (Analysis 9.1.2). </p> <p>One cohort study assessed the safety of the H1N1 vaccine. No statistical association was found between vaccination with H1N1 monovalent pandemic vaccine and demyelinating diseases. </p> </section> <section id="CD001269-sec-0120"> <h4 class="title">Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies (Comparison 10) </h4> <p>An association between exposure to seasonal inactivated vaccine and demyelinating diseases (including both multiple sclerosis and optic neuritis case definitions) in a healthy adult population was not statistically significant when we pooled unadjusted data from four case‐control studies (OR 0.96, 95% CI 0.79 to 1.17) (<a href="./references#CD001269-fig-0041" title="">Analysis 10.1</a>). Also, when we analysed adjusted data for each of the case definitions separately, the estimates remained non‐statistically significant for multiple sclerosis (<a href="./references#CD001269-fig-0042" title="">Analysis 10.2</a>) and for optic neuritis (<a href="./references#CD001269-fig-0043" title="">Analysis 10.3</a>). </p> </section> <section id="CD001269-sec-0121"> <h4 class="title">Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies (Comparison 11) </h4> <p>One cohort study aimed to assess whether there was an association between exposure to inactivated trivalent seasonal influenza vaccine during pregnancy and several pathologies (e.g. Guillain‐Barré syndrome, demyelinating diseases, immune thrombocytopenic purpura) within six weeks after immunisation. Neither the unadjusted (Analysis 11.2.2) nor adjusted estimates (Analysis 11.1.2) for an association with immune thrombocytopenic purpura were statistically significant. </p> </section> <section id="CD001269-sec-0122"> <h4 class="title">Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies (Comparison 12) </h4> <p>Data analysis of two case‐control studies did not show a statistically significant association between immune thrombocytopenic purpura and seasonal influenza vaccine in any of the time frames considered (i.e. less than two months, six or 12 months between immunisation and disease onset), or when the data were pooled together (<a href="./references#CD001269-fig-0047" title="">Analysis 12.2</a>) (<a href="./references#CD001269-bbs2-0081" title="GarbeE , AndersohnF , BronderE , KlimpelA , ThomaeM , KurtalH . Association between drug use and acute immune thrombocytopenia in adults: results from the Berlin case‐control surveillance study. Pharmacoepidemiology and Drug Safety2011;20:S147. GarbeE , AndersohnF , BronderE , SalamaA , KlimpelA , ThomaeM , et al. Drug‐induced immune thrombocytopaenia: results from the Berlin Case‐Control Surveillance Study. European Journal of Clinical Pharmacology2012;68(5):821‐32. ">bb Garbe 2012</a>; <a href="./references#CD001269-bbs2-0083" title="Grimaldi‐BensoudaL , MichelM , AubrunE , LeightonP , ViallardJF , AdoueD , et al. A case‐control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood2012;120(25):4938‐44. Grimaldi‐BensoudaL , MichelM , ViallardJ‐F , AdoueD , Magy‐BertrandN , KhellafM , et al. A multicenter case‐control prospective study to assess the risk of immune thrombocytopenia (ITP) associated with vaccines in adults using the PGRx‐ITP registry. Blood2011;118(21):1169. ">bb Grimaldi‐Bensouda 2012</a>). We drew the same conclusions when analysis was performed using estimates adjusted for confounders (<a href="./references#CD001269-fig-0046" title="">Analysis 12.1</a>), and a sensitivity analysis carried out using either a random‐effects or fixed‐effect model did not change our conclusions, providing further confirmation of them. It should be observed that no data sets included in this comparison, with the exception of <a href="./references#CD001269-bbs2-0081" title="GarbeE , AndersohnF , BronderE , KlimpelA , ThomaeM , KurtalH . Association between drug use and acute immune thrombocytopenia in adults: results from the Berlin case‐control surveillance study. Pharmacoepidemiology and Drug Safety2011;20:S147. GarbeE , AndersohnF , BronderE , SalamaA , KlimpelA , ThomaeM , et al. Drug‐induced immune thrombocytopaenia: results from the Berlin Case‐Control Surveillance Study. European Journal of Clinical Pharmacology2012;68(5):821‐32. ">bb Garbe 2012</a>, showed a statistical association between disease and influenza vaccination. It is possible that the ages of the participants (cases and controls) were different in these two studies, and that some elderly participants may have been included. Unlike <a href="./references#CD001269-bbs2-0083" title="Grimaldi‐BensoudaL , MichelM , AubrunE , LeightonP , ViallardJF , AdoueD , et al. A case‐control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood2012;120(25):4938‐44. Grimaldi‐BensoudaL , MichelM , ViallardJ‐F , AdoueD , Magy‐BertrandN , KhellafM , et al. A multicenter case‐control prospective study to assess the risk of immune thrombocytopenia (ITP) associated with vaccines in adults using the PGRx‐ITP registry. Blood2011;118(21):1169. ">bb Grimaldi‐Bensouda 2012</a>, the case‐control study <a href="./references#CD001269-bbs2-0081" title="GarbeE , AndersohnF , BronderE , KlimpelA , ThomaeM , KurtalH . Association between drug use and acute immune thrombocytopenia in adults: results from the Berlin case‐control surveillance study. Pharmacoepidemiology and Drug Safety2011;20:S147. GarbeE , AndersohnF , BronderE , SalamaA , KlimpelA , ThomaeM , et al. Drug‐induced immune thrombocytopaenia: results from the Berlin Case‐Control Surveillance Study. European Journal of Clinical Pharmacology2012;68(5):821‐32. ">bb Garbe 2012</a> considered as exposed those cases that were immunised up until 28 days before immune thrombocytopenic purpura onset. </p> <section id="CD001269-sec-0123"> <h5 class="title">Serious and rare harms</h5> <section id="CD001269-sec-0124"> <h6 class="title">Oculo‐respiratory syndrome</h6> <p>On the basis of one randomised trial in 651 healthy adults aged around 45, trivalent split inactivated vaccine caused mild oculo‐respiratory syndrome in people with no previous history of oculo‐respiratory syndrome (<a href="./references#CD001269-bbs2-0071" title="ScheifeleDW , DuvalB , RussellML , WarringtonR , DeSerresG , SkowronskiDM , et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clinical Infectious Diseases2003;36(7):850‐7. ">ab Scheifele 2003</a>). Oculo‐respiratory syndrome was defined as bilateral conjunctivitis, facial swelling (lip, lid, or mouth), difficulty in breathing and chest discomfort (including cough, wheeze, dysphagia, or sore throat). Oculo‐respiratory syndrome (attributable risk 2.9%, 95% CI 0.6 to 5.2), hoarseness (1.3%, 95% CI 0.3 to 1.3), and coughing (1.2%, 95% CI 0.2 to 1.6) occurred within six days of vaccination. The association did not appear to be specific to any type of trivalent inactivated vaccine. One register‐based case‐control study carried out in Quebec showed an increased risk (adjusted OR 2.71, 95% CI 1.80 to 4.08) of oculo‐respiratory syndrome during the first four weeks of the 2009 pandemic vaccination campaign (monovalent, AS03‐adjuvanted pH1N1 vaccine) (<a href="./references#CD001269-bbs2-0090" title="RouleauI , DeSerresG , SkowronskiDM , DroletJP , LemireC , TothE , et al. Risk factors associated with anaphylaxis and other allergic‐like events following receipt of 2009 monovalent AS03‐adjuvanted pandemic influenza vaccine in Quebec, Canada. Vaccine2014;32(28):3480‐7. ">bb Rouleau 2014</a>). </p> </section> <section id="CD001269-sec-0125"> <h6 class="title">Bell's palsy</h6> <p>One case‐control study and case series based in the German‐speaking regions of Switzerland assessed the association between an intranasal inactivated virosomal influenza vaccine and Bell's palsy (<a href="./references#CD001269-bbs2-0087" title="MutschM , ZhouW , RhodesP , BoppM , ChenRT , LinderT , et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New England Journal of Medicine2004;350(9):896‐903. ">bb Mutsch 2004</a>). Two hundred and fifty cases that could be evaluated (from an original 773 cases identified) were matched to 722 controls. All were aged around 50. The study reported a massive increase in risk (adjusted OR 84, 95% CI 20.1 to 351.9) within 1 to 91 days from vaccination. Despite the many limitations of this study (case attrition: 187 cases could not be identified; ascertainment bias: physicians picked controls for their own cases; confounding by indication: different vaccine exposure rate between controls and the reference population), it is unlikely that such a large OR could have been affected significantly by systematic error. The authors called for larger pre‐licence harms trials, given the rarity of Bell's palsy. On the basis of this study the vaccine was withdrawn from sale. </p> </section> <section id="CD001269-sec-0126"> <h6 class="title">Rheumatoid arthritis</h6> <p>One case‐control study used the register of the Northern California Kaiser Permanente Health Plan (NCKPHP) in order to identify cases of rheumatoid arthritis diagnosed during a three‐year period (1 January 1997 to 31 December 1999) among members of NCKPHP for at least two years (i.e. since 1 January 1995) and aged between 15 and 59 (<a href="./references#CD001269-bbs2-0089" title="RayP , BlackS , ShinefieldH , DillonA , CarpenterD , LewisE , et al. Vaccine Safety Datalink Team. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15‐59 years of age. Vaccine2011;29(38):6592‐7. ">bb Ray 2011</a>). After reviewing clinical cards, 415 cases of definite or probable rheumatoid arthritis were included with 1245 randomly selected controls matched for age within one year and for a categorical utilisation variable based on the number of clinic visits during the year prior to the rheumatoid arthritis symptom onset date (none, one to two, three to five, six to nine, or 10+ visits). The Kaiser Immunisation Tracking System and chart review were used to determine vaccination status of cases and controls. Different time intervals between immunisation and rheumatoid arthritis onset were considered for analysis: 90, 180, 365, and 730 days. No significant association between vaccination and rheumatoid arthritis could be determined for any time interval, even after adjustment for confounders (sex, race, and exact number of utilisation visits). The authors of this study performed a data analysis by using a person‐time cohort design, in which vaccinated cases contributed to the unexposed follow‐up time until they were immunised and to the exposed follow‐up time thereafter. Unlike case‐control analysis, person‐time cohort analysis was performed by excluding cases who showed symptoms in 1996. Even if a significant association for exposure to vaccine occurred within 180 and 365 days before disease onset (OR adjusted for race, sex, and number of clinic visits 1.36, 95% CI 1.03 to 1.80 and 1.34, 95% CI 1.06 to 1.69, respectively), the authors note that it is very difficult to estimate with sufficient precision the true onset date of rheumatoid arthritis, as the first symptoms could already be present for some time before people present for medical care. This is the most important limitation of this study and could have significantly affected the estimates. </p> </section> <section id="CD001269-sec-0127"> <h6 class="title">Neurological and autoimmune disorders</h6> <p>The study of <a href="./references#CD001269-bbs2-0093" title="BardageC , PerssonI , OrtqvistA , BergmanU , LudvigssonJF , GranathF . Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ2011;343:d5956. ">cb Bardage 2011</a> was a large, prospective cohort study carried out in a Stockholm population (n = 1,945,024) during the vaccination campaign with monovalent A (H1N1) pandemic vaccine Pandemrix (GlaxoSmithKline, containing adjuvants AS03 and squalene) to evaluate the presence of an association between Pandemrix and neurological and/or autoimmune diseases (Guillain‐Barré syndrome, multiple sclerosis, Bell's palsy, narcolepsy, polyneuropathy, an/hypoaesthesia, paraesthesia, rheumatological disease and inflammatory bowel disease). During the first 45 days, participants with high‐risk conditions were preferentially vaccinated; vaccination was then offered to the remainder of the population in a second phase of the campaign (see Characteristics of included studies’ table for more details). </p> <p>The analysis of the HR adjusted for age, sex, socioeconomic status, and healthcare consumption (number of hospital admissions and visits to specialist care one year before the pandemic period) showed that in participants immunised during the early phase of the campaign, there was a significantly increased risk of Bell's palsy (HR 1.34, 95% CI 1.11 to 1.64), paraesthesia (HR 1.25, 95% CI 1.10 to 1.41), and inflammatory bowel disease (HR 1.25, 95% CI 1.04 to 1.50). For the participants vaccinated in the late phase of the campaign (&gt; 45 days), HR estimates showed there was no statistically different incidence in the investigated diseases between vaccinated and unvaccinated participants. </p> <p>A further stratification was performed considering the time since first vaccination (six weeks or less and more than six weeks), which showed that in participants immunised during the first phase of the campaign, an increased incidence of Bell's palsy and paraesthesia was most pronounced, as well as within six weeks of vaccination (HR 1.74, 95% CI 1.16 to 2.59 for Bell's palsy and HR 1.60, 95% CI 1.25 to 2.05 for paraesthesia) and thereafter (HR 1.26, 95% CI 1.01 to 1.57 for Bell's palsy and HR 1.17, 95% CI 1.02 to 1.34 for paraesthesia). An increased risk of inflammatory bowel disease among those vaccinated in the early phase was only observed more than six weeks after vaccination (HR 1.29, 95% CI 1.06 to 1.58). Formal tests to determine whether risks differed further between those within and more than six weeks from vaccination were only statistically significant for paraesthesia (P = 0.005). In participants immunised during the second phase of the campaign, polyneuropathy was significantly more common within six weeks of immunisation (HR 1.79, 95% CI 1.16 to 2.77). </p> <p>The study by <a href="./references#CD001269-bbs2-0099" title="PerssonI , GranathF , AsklingJ , LudvigssonJF , OlssonT , FelteliusN . Risks of neurological and immune‐related diseases, including narcolepsy, after vaccination with Pandemrix: a population‐ and registry‐based cohort study with over 2 years of follow‐up. Journal of Internal Medicine2014;275(2):172‐90. ">cb Persson 2014</a> consisted of an extension of the Bardage study to more Swedish regions, namely the healthcare regions of Skåne and Västra Götaland and the counties of Kalmar, Östergötland, Värmland, and Norrbotten. The study included over 5.8 million participants, corresponding to about 61% of the whole Swedish population in 2009. In all, 207 cases of narcolepsy were confirmed, with the exclusion of eight cases with prodromal conditions during the last five years. The overall risk of narcolepsy after immunisation with Pandemrix assessed by Cox regression after adjusting for age, gender, county, education, income, number of hospital admissions and ambulatory care visits, pregnancy status, and presence of other diagnoses was not statistically relevant in the population aged above 20 years (HR 1.35, 95% CI 0.93 to 1.95). A significant association was instead found in those aged below 20 (HR 2.92, 95% CI 1.78 to 4.79), in whom most cases of narcolepsy had occurred (n = 126). </p> <p>A population‐based cohort study carried out in Ireland identified only three cases of narcolepsy in the whole Irish adult population aged above 20 years during the pandemic season 2009 to 2010; two of them received Pandremix and one did not (<a href="./references#CD001269-bbs2-0098" title="O'FlanaganD , BarretAS , FoleyM , CotterS , BonnerC , CroweC , et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009‐December 2010. Eurosurveillance2014;19(17):15‐25. ">cb O'Flanagan 2014</a>). The risk estimate was extremely imprecise and did not allow us to draw any conclusions (RR 20.4, 95% CI 1.8 to 225). One case‐control study (<a href="./references#CD001269-bbs2-0073" title="DauvilliersY , ArnulfI , LecendreuxM , Monaca CharleyC , FrancoP , DrouotX , et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain2013;139(Pt 8):2486‐96. ">bb Dauvilliers 2013</a>), performed across the institutions of 14 French expert orphan disease narcolepsy centres, identified 25 narcolepsy cases and 73 matched controls (age, sex, and geographical location) in the study population aged at least 18 years. An association between exposure to H1N1 vaccination and narcolepsy‐catalepsy (crude OR 4.7, 95% CI 2.1 to 13.9) was found and was also confirmed after the performance of a sensitivity analysis and adjusting for smoking habits and family history of excessive daytime sleepiness (OR 4.1, 95% CI 1.4 to 12.2). </p> </section> <section id="CD001269-sec-0128"> <h6 class="title">Cutaneous melanoma</h6> <p>A case‐control study assessed the association between influenza vaccines and cutaneous melanoma in 99 cases and 104 controls (<a href="./references#CD001269-bbs2-0086" title="MastrangeloG , RossiCR , PfahlbergA , MarziaV , BarbaA , BaldoM , et al. Is there a relationship between influenza vaccinations and risk of melanoma? A population‐based case‐control study. European Journal of Epidemiology2000;16(9):777‐82. ">bb Mastrangelo 2000</a>). The authors reported a protective effect of repeated influenza vaccination on risk of cutaneous melanoma (OR 0.43, 95% CI 0.19 to 1.00). The study was at high risk of bias due to the selective nature of cases (all patients in the authors' hospital), attrition bias (four cases and four controls eliminated due to "failure to collaborate"), recall bias (up to five years' exposure data were based on patients' recollection), and ascertainment bias (non‐blinded exposure survey). </p> </section> <section id="CD001269-sec-0129"> <h6 class="title">Primary cardiac arrest</h6> <p>A case‐control study assessed the association between influenza vaccination the previous year and the risk of primary cardiac arrest (i.e. occurring in people with no previous history of cardiac disease) in 360 cases and 418 controls (<a href="./references#CD001269-bbs2-0091" title="SiscovickDS , RaghunathanTE , LinD , WeinmannS , ArbogastP , LemaitreRN , et al. Influenza vaccination and the risk of primary cardiac arrest. American Journal of Epidemiology2000;152(7):674‐7. ">bb Siscovick 2000</a>). The authors concluded that vaccination is protective against primary cardiac arrest (OR 0.51, 95% CI 0.33 to 0.79). The difficulty of case ascertainment (77% of potential cases had no medical examiner report and/or autopsy) and recall bias (spouses provided exposure data for 304 cases, while 56 survivor cases provided data jointly with their spouses) make the conclusions of this study unreliable. It is impossible to judge the reliability of this study because of a lack of detail on the circulation of influenza in the study areas in the 12 months preceding cardiac arrest (the causal hypothesis is based on the effects of influenza infection on the oxygen supply to the myocardium through lung infection and inflammation). </p> </section> <section id="CD001269-sec-0130"> <h6 class="title">Acute myocardial infarction</h6> <p>One case‐control study performed in Australia assessed whether exposure to influenza vaccine provides protection against acute myocardial infarction in an adult population aged over 40 (<a href="./references#CD001269-bbs2-0085" title="MacIntyreCR , HeywoodAE , KovoorP , RiddaI , SealeH , TanT , et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. Heart2013;99(24):1843‐8. ">bb MacIntyre 2013</a>). Cases of acute myocardial infarction admitted to the cardiology unit of a tertiary hospital in Sydney during three consecutive epidemic seasons (2008, 2009, and 2010) were compared to unmatched controls attending the orthopaedic or ophthalmic outpatient clinics during the same time period with respect to their exposure to influenza vaccine (176 cases and 72 controls aged below 64 were included). From multivariate analysis, after adjusting for several confounders, influenza vaccination did not confer significant protection against acute myocardial infarction in an adult population aged between 40 and 64 years (OR 0.55, 95% CI 0.27 to 1.15). </p> </section> <section id="CD001269-sec-0131"> <h6 class="title">Pulmonary function</h6> <p>A double‐blind, placebo‐controlled randomised trial in 72 healthy volunteers aged around 26 assessed the effects of different types of live attenuated cold recombinant influenza vaccination on pulmonary function (data on 17 asthmatics were not extracted) (<a href="./references#CD001269-bbs2-0052" title="AtmarRL , BloomK , KeitelW , CouchRB , GreenbergSB . Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine1990;8(3):217‐24. ">ab Atmar 1990</a>). The authors reported several non‐significant drops in lung function up to seven days postinoculation and a higher incidence of ILI (17/46 versus 4/26) in the vaccinated arms. </p> </section> <section id="CD001269-sec-0132"> <h6 class="title">Other serious adverse events</h6> <p>The study of <a href="./references#CD001269-bbs2-0094" title="BaxterR , TobackSL , SifakisF , HansenJ , BartlettJ , AukesL , et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18‐49 years of age. Vaccine2012;30(20):3053‐60. ">cb Baxter 2012</a> is a large, retrospective cohort performed among members of Kaiser Permanente Health Plans of Northern California, Hawaii, and Colorado aged between 18 and 59 years, who were immunised with live attenuated, inactivated influenza vaccine or who did not receive vaccination. The study retrospectively investigated the occurrence of adverse events (see Characteristics of included studies’ table for more details) during five subsequent epidemics, but did not identify any unexpected serious risks when the live attenuated vaccine was used in approved populations. </p> </section> </section> </section> <section id="CD001269-sec-0133"> <h4 class="title">Vaccines for the 1968 to 1969 (H3N2) influenza pandemic (Comparisons 13 to 17)</h4> <p>Five studies yielded 12 data sets (<a href="./references#CD001269-bbs2-0006" title="EddyTS , DaviesNA . The effect of vaccine on a closed epidemic of Hong Kong influenza. South African Medical Journal1970;44(8):214‐6. ">aa Eddy 1970</a>; <a href="./references#CD001269-bbs2-0026" title="MogabgabWJ , LeidermanE . Immunogenicity of 1967 polyvalent and 1968 Hong Kong influenza vaccines. JAMA1970;211(10):1672‐6. ">aa Mogabgab 1970a</a>; <a href="./references#CD001269-bbs2-0027" title="MogabgabWJ , LeidermanE . Immunogenicity of 1967 polyvalent and 1968 Hong Kong influenza vaccines. JAMA1970;211(10):1672‐6. ">aa Mogabgab 1970b</a>; <a href="./references#CD001269-bbs2-0038" title="SumarokowAA , PopovVF , NefedovaLA , SalminLV , LazorenkoNF . A study of live influenza vaccines in a controlled trial. Zhumal Mikrobiologii Epidemiologii Immunobiologii1971;48(2):46‐52. ">aa Sumarokow 1971</a>; <a href="./references#CD001269-bbs2-0041" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969a</a>; <a href="./references#CD001269-bbs2-0042" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969b</a>; <a href="./references#CD001269-bbs2-0043" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969c</a>; <a href="./references#CD001269-bbs2-0044" title="WaldmanRH , BondJO , LevittLP , HartwigEC , PratherEC , BarattaRL , et al. An evaluation of influenza immunization. Bulletin of the World Health Organization1969;41(3):543‐8. ">aa Waldman 1969d</a>; <a href="./references#CD001269-bbs2-0045" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972a</a>; <a href="./references#CD001269-bbs2-0046" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972b</a>; <a href="./references#CD001269-bbs2-0047" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972c</a>; <a href="./references#CD001269-bbs2-0048" title="WaldmanRH , CogginsWJ . Influenza immunization: field trial on a university campus. Journal of Infectious Diseases1972;126(3):242‐8. ">aa Waldman 1972d</a>). As one would expect, vaccine performance was poor when the content did not match the pandemic strain (<a href="./references#CD001269-fig-0048" title="">Analysis 13.1</a>; <a href="./references#CD001269-fig-0049" title="">Analysis 13.2</a>). However, one‐ or two‐dose monovalent whole‐virion (i.e. containing dead complete viruses) vaccines achieved a VE of 65% (95% CI 52% to 75%) protection against ILI (NNV 16, 95% CI 14 to 20), a VE of 93% (95% CI 69% to 98%) with NNV 35 (95% CI 33 to 47) protection against influenza, and a VE of 65% (95% CI 6% to 87%) with NNV 94 (95% CI 70 to 1022) against hospitalisation (<a href="./references#CD001269-fig-0052" title="">Analysis 14.1</a>; <a href="./references#CD001269-fig-0053" title="">Analysis 14.2</a>; <a href="./references#CD001269-fig-0054" title="">Analysis 14.3</a>). </p> <p>Approximately half a working day and half a day of illness were saved (<a href="./references#CD001269-fig-0056" title="">Analysis 14.5</a>; <a href="./references#CD001269-fig-0057" title="">Analysis 14.6</a>), but no effect was observed on pneumonia (<a href="./references#CD001269-fig-0055" title="">Analysis 14.4</a>). All comparisons except for ILI were based on a single study (<a href="./references#CD001269-fig-0055" title="">Analysis 14.4</a>). The large effect on ILI is coherent with the high proportion of these illnesses caused by influenza viruses in a pandemic (i.e. the gap between the efficacy and effectiveness of the vaccines is narrow). Aerosol polyvalent or monovalent vaccines had a modest effect. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001269-sec-0134" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001269-sec-0134">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001269-sec-0273">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001269-sec-0134"></div> <section id="CD001269-sec-0135"> <h3 class="title" id="CD001269-sec-0135">Summary of main results</h3> <p>In healthy adults live parenteral vaccines probably reduce influenza from 2.3% to 1%, based on a vaccine efficacy of 59% (moderate‐certainty evidence). This corresponds with an NNV of 71. Live parenteral vaccine effectiveness against ILI was lower (16%), with a NNV of 29 based on an assumed control group risk of 21.5%. We found greater variation in control group risks of ILI compared with influenza (<a href="./full#CD001269-tbl-0001">summary of findings Table for the main comparison</a>). Low and high control group risks (4% and 91%) corresponded to NNVs 167 and 7, respectively. The overall efficacy of inactivated vaccines in preventing influenza is 59% (95% CI 51% to 66%) with a NNV of 77. When vaccine content matches the circulating strain the efficacy is 59% (95% CI 53% to 64%). Based on results of a single study (<a href="./references#CD001269-bbs2-0005" title="Buxton BridgesC , ThompsonVV , MeltzerMI , ReeveGR , TalamontiVJ , CoxNJ . Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA2000;284(13):1655‐63. ">aa Bridges 2000b</a>), physician visits appear to be 42% less frequent in participants immunised with vaccines prepared with strains matching circulating viruses, whereas no significant differences were found when the degree of matching was unknown or absent (RR 1.28, 95% CI 0.90 to 1.83). The overall effect was again not significant (RR 0.87, 95% CI 0.40 to 1.89). There seems to be no effect on the time an antibiotic or a drug is prescribed. Four trials evaluated time off work, estimating that vaccination saves on average around 0.04 working days. This result was affected by high levels of heterogeneity and changes depending on whether a fixed‐effect (MD ‐0.04, 95% CI ‐0.06 to ‐0.01) or random‐effects model (MD ‐0.04, 95% CI ‐0.14 to 0.06) was used. </p> <p>Live aerosol vaccines have an overall effectiveness against ILI of 10% (95% CI 4% to 16%) and a NNV of 46. Content and matching appear not to affect their performance significantly. The overall efficacy against influenza is 53% (95% CI 38% to 65%) and the NNV is 39. Again, neither content nor matching appear to affect their performance significantly. Many more recipients administered vaccine experienced local symptoms than did those administered placebo. </p> <p>One RCT assessed the efficacy of inactivated aerosol vaccine in preventing influenza (Analysis 3.1.1) (<a href="./references#CD001269-bbs2-0020" title="LangleyJM , AokiF , WardBJ , McGeerA , AngelJB , StiverG , et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine2011;29(10):1921‐8. ">aa Langley 2011</a>). The results did not show a statistically significant protective effect (RR 0.38, 95% CI 0.14 to 1.02). </p> <p>One RCT investigated the effects of influenza vaccine administration in pregnant women and their newborns (<a href="./references#CD001269-bbs2-0103" title="MadhiSA , CutlandCL , KuwandaL , WeinbergA , HugoA , JonesS , et al. Influenza vaccination of pregnant women and protection of their infants. New England Journal of Medicine2014;371(10):918‐31. ">paa Madhi 2014</a>). A trivalent inactivated vaccine containing pH1N1 was weakly protective against confirmed influenza in both mothers (RR 0.50, 95% CI 0.29 to 0.86; VE 50%, 95% CI 14% to 71%; NNV 55, 95% CI 39 to 198; Analysis 4.1.1) and children (RR 0.51, 95% CI 0.30 to 0.88; VE 49%, 95% CI 12% to 70%; NNV 56; Analysis 4.3.1). Protection against ILI was not statistically significant. The rest of the evidence on vaccination during pregnancy was based on observational studies (case‐control and cohort studies); the effectiveness of vaccination with seasonal inactivated parenteral vaccine during pregnancy for preventing ILI in newborns was not statistically significant. The evidence comes from two cohort studies using either HR or RR adjusted estimates. Pooled data from three cohort studies (two of them at high risk of bias) show a modest effect of vaccination against ILI in pregnant women when the fixed‐effect model is applied to the analysis (NNV 92, 95% CI 63 to 201). One cohort study showed a modest protective effect against influenza in newborns of vaccinated mothers (NNV 27, 95% CI 18 to 185). </p> <p>Pooled analysis of three RCTs and one CCT showed that immunisation with at least one dose of the 1968 to 1969 pandemic monovalent inactivated whole‐virion vaccines achieved a VE of 65% (95% CI 52% to 75%) against ILI (NNV 16, 95% CI 14 to 20). One RCT showed that the efficacy of the 1968 to 1969 pandemic monovalent inactivated whole‐virion vaccines in preventing influenza was 93% (95% CI 69% to 98%; NNV 35). One other RCT showed an efficacy of 65% (95% CI 6% to 87%); NNV 94 (95% CI 70 to 1022) in preventing hospitalisation. One CCT provided evidence on the effect of immunisation with the 1968 to 1969 pandemic monovalent inactivated whole‐virion vaccines on working days lost and days of illness: approximately half a working day and half a day of illness were saved (MD ‐0.45, 95% CI ‐0.60 to ‐0.30). The effect of this vaccine on prevention of pneumonia was not statistically significant (RR 0.59, 95% CI 0.05 to 6.51). </p> <p>Based on evidence from observational studies, administration of either seasonal inactivated vaccine or monovalent H1N1 pandemic vaccine during pregnancy is not associated with an increased risk of abortion, congenital malformation, prematurity, or neonatal death, but CIs are wide. </p> <p>We found no evidence of an association between seasonal inactivated vaccines and Guillain‐Barré syndrome or H1N1 pandemic vaccine and Guillain‐Barré syndrome. </p> <p>There was no evidence of an association between exposure to seasonal inactivated influenza vaccine and other serious adverse events (multiple sclerosis, optic neuritis, and immune thrombocytopenic purpura). </p> </section> <section id="CD001269-sec-0136"> <h3 class="title" id="CD001269-sec-0136">Overall completeness and applicability of evidence</h3> <p>A number of issues should be taken into consideration when interpreting the results of this review. </p> <p> <ol id="CD001269-list-0031"> <li> <p>Methods of vaccine standardisation have changed significantly.</p> </li> <li> <p>Recent vaccines present significant differences in purity when compared with older ones. </p> </li> <li> <p>Different doses and schedules were pooled in the analysis.</p> </li> </ol> </p> <p>Taken alone, this review shows that according to randomised evidence, inactivated vaccines have a small effect in preventing the symptoms of influenza and getting people back to work more quickly. Looking at the NNVs for influenza and ILI for inactivated parenteral vaccine, it seems that effectiveness against ILI is higher than efficacy against laboratory‐confirmed influenza (NNV‐ILI 29; NNV‐influenza 71). These paradoxical results show an apparently higher non‐specific effectiveness and a lower specific efficacy. This reflects different rates of ILI and confirmed influenza among the study populations in the respective outcomes. The percentage of unvaccinated participants who developed ILI symptoms was 21.5%, whilst 2.3% participants in the unvaccinated arms of the trials developed laboratory‐confirmed influenza. </p> </section> <section id="CD001269-sec-0137"> <h3 class="title" id="CD001269-sec-0137">Quality of the evidence</h3> <p>We rated the quality of the evidence for ILI and influenza as moderate; hospitalisation, time off work, and increased risk of nausea or vomiting as low; and fever as high (<a href="./full#CD001269-tbl-0001">summary of findings Table for the main comparison</a>). The impact of bias varied across the outcomes, leading us to downgrade the quality of evidence for hospitalisation, time off work, and nausea. For other outcomes, analyses drew more heavily on studies at low risk of bias or where the likely impact of bias across the studies was small. Variation in the definition of ILI led us to present stratified risk and to downgrade for inconsistency given some discordance in the direction of effect and high statistical heterogeneity. Our decision to downgrade the quality of the evidence for influenza due to indirectness reflects our uncertainty in the methods to ascertain the outcome in older studies and the impact this has on the applicability of the evidence to current settings. The data for hospitalisation was dominated by the <a href="./references#CD001269-bbs2-0021" title="LeibovitzA , CoultripRL , KilbourneED , LegtersLJ , SmithCD , ChinJ , et al. Correlated studies of a recombinant influenza‐virus vaccine. IV. Protection against naturally occurring influenza in military trainees. Journal of Infectious Diseases1971;124(5):481‐7. ">aa Leibovitz 1971</a> study in <a href="./references#CD001269-fig-0011" title="">Analysis 1.8</a>. Whilst the overall direction of effect indicated a small reduction in absolute terms with the vaccine, we are unable to rule out there being no effect of the intervention. The CI for the effect on nausea/vomiting was wide, although this may reflect the incorporation of variation in the study results, rather than low power. </p> </section> <section id="CD001269-sec-0138"> <h3 class="title" id="CD001269-sec-0138">Potential biases in the review process</h3> <p>The conclusions of this review regarding the safety profile of inactivated vaccines are uncertain, which is a reflection of the size of the evidence base. </p> <p>An earlier review of 274 influenza vaccine studies in all age groups (which included most of the studies in this review) showed an inverse relationship between risk of bias and the direction of study conclusions. Conclusions favourable to the use of influenza vaccines were associated with a higher risk of bias. The authors of studies in this review made claims and drew conclusions that were unsupported by the data they presented. In addition, industry‐funded studies are more likely to have favourable conclusions, to be published in significantly higher‐impact factor journals, and to have higher citation rates than non‐industry‐funded studies. This difference is not explained by either their size or methodological quality (<a href="./references#CD001269-bbs2-0337" title="JeffersonT , DiPietrantonjC , DebaliniMG , RivettiA , DemicheliV . Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ2009;338:b354. [DOI: 10.1136/bmj.b354] ">Jefferson 2009b</a>). Any interpretation of the body of evidence in this review should be made with these findings in mind. </p> <p>Additional care should be taken when interpreting the results of observational studies in pregnancy, as the possible presence and effects of immortal time bias were not analysed in previous versions of this review. Immortal time bias occurs when a time‐dependent exposure (in this case vaccination) is not included appropriately in an analysis of a survival outcome. The term 'immortal time bias' is used because in observational studies patients must survive sufficiently long to receive treatment; hence, they are immortal by definition before exposure. This type of bias, sometimes referred to as time‐dependent bias, is not generally a problem in randomised studies, as treatment (including placebo) is usually given at the beginning of the study. Conversely, in observational studies, exposure to the vaccine has usually taken place before study commencement, with a resulting exposure misclassification. Such bias can affect study conclusions (<a href="./references#CD001269-bbs2-0339" title="JonesM , FowlerR . Immortal time bias in observational studies of time to event outcomes. Journal of Critical Care2016;36:195‐9. ">Jones 2016</a>). </p> </section> <section id="CD001269-sec-0139"> <h3 class="title" id="CD001269-sec-0139">Agreements and disagreements with other studies or reviews</h3> <section id="CD001269-sec-0140"> <h4 class="title">Systematic reviews estimating the efficacy of influenza vaccination</h4> <p><a href="./references#CD001269-bbs2-0329" title="DiazGranadosCA , DenisM , PlotkinS . Seasonal influenza vaccine efficacy and its determinants in children and non‐elderly adults: a systematic review with meta‐analyses of controlled trials. Vaccine2012;31(1):49‐57. ">DiazGranados 2012</a> performed a meta‐analysis that included RCTs on seasonal inactivated or live attenuated influenza vaccines with influenza (with either polymerase chain reaction (PCR) or serological confirmation of infection) as the efficacy outcome. The meta‐analysis included 30 studies in children and adults. The authors provided efficacy estimates (RR with 95% CI) stratified by the degree of matching between the vaccine and circulating strains (good, poor, no matching, matching) and by strain type (A H1N1, A H3N2, B). <a href="./references#CD001269-bbs2-0329" title="DiazGranadosCA , DenisM , PlotkinS . Seasonal influenza vaccine efficacy and its determinants in children and non‐elderly adults: a systematic review with meta‐analyses of controlled trials. Vaccine2012;31(1):49‐57. ">DiazGranados 2012</a> estimated that in an adult population the efficacy of inactivated vaccine against laboratory‐confirmed influenza is 59% (95% CI 50% to 66%). The efficacy estimate for live attenuated vaccine is 39% (95% CI 16% to 55%). </p> <p>The systematic review by <a href="./references#CD001269-bbs2-0344" title="OsterholmMT , KelleyNS , SommerA , BelongiaEA . Efficacy and effectiveness of influenza vaccines: a systematic review and meta‐analysis. Lancet Infectious Diseases2012;12:36‐44. ">Osterholm 2012</a> included evidence of the efficacy of both live attenuated and inactivated vaccines in preventing laboratory‐confirmed influenza infection assessed exclusively by either PCR or a positive culture. Considering studies carried out in adults only, the pooled estimate of efficacy from six studies (eight data sets) was 59% (95% CI 51% to 67%). Even though three RCTs estimating the efficacy of live attenuated vaccines were included, the authors did not perform an analysis because none of the single estimates was statistically significant. Observational studies were also included and discussed. </p> </section> <section id="CD001269-sec-0141"> <h4 class="title">Systematic reviews assessing the efficacy/effectiveness and/or safety issues of influenza vaccines when administered during pregnancy </h4> <p>The review by <a href="./references#CD001269-bbs2-0346" title="SkowronskiDM , DeSerresG . Is routine immunisation warranted in early pregnancy?. Vaccine2009;27:4754‐70. ">Skowronski 2009</a> is the first comprehensive publication in which evidence for the effectiveness and safety aspects of vaccination during pregnancy has been exhaustively discussed. In the first part of the paper, the authors consider the burden of disease during pregnancy, the risk of death, and the influenza‐related risk for the foetus and summarise how the US Advisory Committee on Immunization Practice (ACIP) recommendations have changed over the last four decades. The available evidence on protection (in mother and newborns) and vaccination safety issues are descriptively illustrated, discussed, and compared with the statements in the current vaccination policies reported. In the authors' opinion, immunisation against influenza at any stage of pregnancy may be warranted during pandemics or for women with comorbidity. Seasonal immunisation with trivalent inactivated vaccine may be warranted in pregnancy, without potential complications during the second half of the pregnancy. Finally, the available evidence is insufficient to recommend standard routine vaccination in the early stages of pregnancy. </p> </section> <section id="CD001269-sec-0142"> <h4 class="title">Systematic reviews of evidence of severe harms</h4> <p><a href="./references#CD001269-bbs2-0332" title="FarezMF , CorrealeJ . Immunizations and risk of multiple sclerosis: systematic review and meta‐analysis. Journal of Neurology2011;258(7):1197‐206. ">Farez 2011</a> evaluated the risk of developing multiple sclerosis or experiencing relapsing multiple sclerosis following immunisation with several vaccinations, including influenza. Meta‐analysis performed by pooling the results of four case‐control studies would exclude an increased risk of developing multiple sclerosis following influenza vaccine administration (OR 0.97, 95% CI 0.77 to 1.23) (<a href="./references#CD001269-bbs2-0074" title="DeStefanoF , VerstraetenT , JacksonLA , OkoroCA , BensonP , BlackSB , et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Archives of Neurology2003;60(4):504‐9. ">bb DeStefano 2003</a>; <a href="./references#CD001269-bbs2-0084" title="HernanMA , JickSS , OlekMJ , JickH . Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology2004;63(5):838‐42. ">bb Hernan 2004</a>; <a href="./references#CD001269-bbs2-0088" title="PayneDC , RoseCEJr , KerrisonJ , AranasA , DuderstadtS , McNeilMM . Anthrax vaccination and risk of optic neuritis in the United States military, 1998‐2003. Archives of Neurology2006;63(6):871‐5. ">bb Payne 2006</a>; <a href="./references#CD001269-bbs2-0092" title="ZorzonM , ZivadinovR , NasuelliD , DolfiniP , BoscoA , BratinaA , et al. Risk factors of multiple sclerosis: a case‐control study. Neurological Sciences2003;24(4):242‐7. ">bb Zorzon 2003</a>). </p> </section> <section id="CD001269-sec-0143"> <h4 class="title">Other issues</h4> <p><a href="./references#CD001269-bbs2-0348" title="TobackSL , LevinMJ , BlockSL , BelsheRB , AmbroseCS , FalloonJ . Quadrivalent Ann Arbor strain live‐attenuated influenza vaccine. Expert Reviews Vaccines2012;11(11):1293‐303. ">Toback 2012</a> provided evidence supporting the introduction of a new quadrivalent live attenuated influenza vaccine (Q‐LAIV, already licensed in the USA, where it will was available for the 2013 to 2014 season) containing two different B strains of different lineage (B/Yamagata/16/88 and B/Victoria/2/87). This evidence comes from two RCTs comparing immunogenicity and local and systemic reactions after administration of either Q‐LAIV, trivalent inactivated, or trivalent live attenuated vaccines. One RCT was performed in adults, the other in a paediatric population. The presence of two B strains would not significantly affect the antibody response against each B strain. Local and systemic adverse events induced by Q‐LAIV administration did not differ significantly from those recorded after administration of other vaccines already in use. </p> <p>In summary, the conclusions of the cited reviews are broadly comparable with ours, but the results are reported using relative effects‐based estimates. In addition, none of the reviews have identified effects of the vaccines on important outcomes such as complications, hospitalisations, and deaths. These findings are also similar to ours. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001269-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001269-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001269-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001269-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 1 Influenza." data-id="CD001269-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 1 Influenza. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 2 Influenza‐like illness." data-id="CD001269-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 2 Influenza‐like illness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 3 Physician visits." data-id="CD001269-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 3 Physician visits. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 4 Days ill." data-id="CD001269-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 4 Days ill. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 5 Times any drugs were prescribed." data-id="CD001269-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 5 Times any drugs were prescribed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 6 Times antibiotic was prescribed." data-id="CD001269-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 6 Times antibiotic was prescribed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 7 Working days lost." data-id="CD001269-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 7 Working days lost. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 8 Hospitalisations." data-id="CD001269-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 8 Hospitalisations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 9 Clinical cases (clinically defined without clear definition)." data-id="CD001269-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 9 Clinical cases (clinically defined without clear definition). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 10 Local harms." data-id="CD001269-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 10 Local harms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 11 Systemic harms." data-id="CD001269-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Inactivated parenteral influenza vaccine versus placebo or 'do nothing', Outcome 11 Systemic harms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 1 Influenza." data-id="CD001269-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 1 Influenza. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 2 Influenza‐like illness." data-id="CD001269-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 2 Influenza‐like illness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 3 Influenza cases (clinically defined without clear definition)." data-id="CD001269-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 3 Influenza cases (clinically defined without clear definition). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 4 Local harms." data-id="CD001269-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 4 Local harms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 5 Systemic harms." data-id="CD001269-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Live aerosol influenza vaccine versus placebo or 'do nothing', Outcome 5 Systemic harms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Inactivated aerosol influenza vaccine versus placebo or 'do nothing', Outcome 1 Influenza." data-id="CD001269-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Inactivated aerosol influenza vaccine versus placebo or 'do nothing', Outcome 1 Influenza. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Inactivated aerosol influenza vaccine versus placebo or 'do nothing', Outcome 2 Local harms." data-id="CD001269-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Inactivated aerosol influenza vaccine versus placebo or 'do nothing', Outcome 2 Local harms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Inactivated aerosol influenza vaccine versus placebo or 'do nothing', Outcome 3 Systemic harms." data-id="CD001269-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Inactivated aerosol influenza vaccine versus placebo or 'do nothing', Outcome 3 Systemic harms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 1 Influenza in mothers." data-id="CD001269-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 1 Influenza in mothers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 2 Influenza‐like illness in mothers." data-id="CD001269-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 2 Influenza‐like illness in mothers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 3 Influenza in newborn." data-id="CD001269-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 3 Influenza in newborn. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 4 Influenza‐like illness in newborn." data-id="CD001269-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy, Outcome 4 Influenza‐like illness in newborn. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 1 Seasonal inactivated vaccine effectiveness in mothers ‐ pregnant women." data-id="CD001269-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 1 Seasonal inactivated vaccine effectiveness in mothers ‐ pregnant women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 2 Seasonal inactivated vaccine effectiveness in newborns ‐ pregnant women." data-id="CD001269-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 2 Seasonal inactivated vaccine effectiveness in newborns ‐ pregnant women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 3 Seasonal inactivated vaccine effectiveness in newborns ‐ pregnant women." data-id="CD001269-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 3 Seasonal inactivated vaccine effectiveness in newborns ‐ pregnant women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 4 H1N1 vaccine ‐ safety ‐ pregnancy‐related outcomes ‐ pregnant women." data-id="CD001269-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 4 H1N1 vaccine ‐ safety ‐ pregnancy‐related outcomes ‐ pregnant women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 5 Seasonal vaccine ‐ safety ‐ pregnancy‐related outcomes ‐ pregnant women." data-id="CD001269-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 5 Seasonal vaccine ‐ safety ‐ pregnancy‐related outcomes ‐ pregnant women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 6 Seasonal vaccine containing H1N1." data-id="CD001269-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies, Outcome 6 Seasonal vaccine containing H1N1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies, Outcome 1 Effectiveness in newborns ‐ pregnant women (adjusted data)." data-id="CD001269-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies, Outcome 1 Effectiveness in newborns ‐ pregnant women (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies, Outcome 2 Seasonal vaccine safety ‐ pregnancy‐related outcomes (adjusted data)." data-id="CD001269-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies, Outcome 2 Seasonal vaccine safety ‐ pregnancy‐related outcomes (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Serious adverse events: Guillain‐Barré syndrome ‐ cohort studies, Outcome 1 Seasonal influenza vaccination and Guillain‐Barré syndrome." data-id="CD001269-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Serious adverse events: Guillain‐Barré syndrome ‐ cohort studies, Outcome 1 Seasonal influenza vaccination and Guillain‐Barré syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies, Outcome 1 2009 to 2010 A/H1N1 ‐ general population (unadjusted data)." data-id="CD001269-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies, Outcome 1 2009 to 2010 A/H1N1 ‐ general population (unadjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies, Outcome 2 2009 to 2010 A/H1N1 ‐ general population (adjusted data)." data-id="CD001269-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies, Outcome 2 2009 to 2010 A/H1N1 ‐ general population (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies, Outcome 3 Seasonal influenza vaccination general population (adjusted data)." data-id="CD001269-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies, Outcome 3 Seasonal influenza vaccination general population (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies, Outcome 1 Influenza vaccination (seasonal) ‐ demyelinating diseases (unadjusted data)." data-id="CD001269-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies, Outcome 1 Influenza vaccination (seasonal) ‐ demyelinating diseases (unadjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies, Outcome 2 Influenza vaccination (H1N1) ‐ demyelinating diseases (unadjusted)." data-id="CD001269-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies, Outcome 2 Influenza vaccination (H1N1) ‐ demyelinating diseases (unadjusted). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies, Outcome 1 Influenza vaccination (seasonal) ‐ general population ‐ demyelinating diseases (unadjusted data)." data-id="CD001269-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies, Outcome 1 Influenza vaccination (seasonal) ‐ general population ‐ demyelinating diseases (unadjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies, Outcome 2 Influenza vaccination (seasonal) ‐ general population ‐ multiple sclerosis (adjusted data)." data-id="CD001269-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies, Outcome 2 Influenza vaccination (seasonal) ‐ general population ‐ multiple sclerosis (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies, Outcome 3 Influenza vaccination (seasonal) ‐ general population ‐ optic neuritis (adjusted data)." data-id="CD001269-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies, Outcome 3 Influenza vaccination (seasonal) ‐ general population ‐ optic neuritis (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies, Outcome 1 Seasonal influenza vaccine ‐ HR (adjusted data)." data-id="CD001269-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies, Outcome 1 Seasonal influenza vaccine ‐ HR (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies, Outcome 2 Seasonal influenza vaccine (unadjusted data)." data-id="CD001269-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies, Outcome 2 Seasonal influenza vaccine (unadjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies, Outcome 1 Seasonal influenza vaccine ‐ general population (adjusted data)." data-id="CD001269-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies, Outcome 1 Seasonal influenza vaccine ‐ general population (adjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies, Outcome 2 Seasonal influenza vaccine ‐ general population (unadjusted data)." data-id="CD001269-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies, Outcome 2 Seasonal influenza vaccine ‐ general population (unadjusted data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 1 Influenza‐like illness." data-id="CD001269-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 1 Influenza‐like illness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 2 Influenza." data-id="CD001269-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 2 Influenza. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 3 Hospitalisations." data-id="CD001269-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 3 Hospitalisations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 4 Pneumonia." data-id="CD001269-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo, Outcome 4 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 1 Influenza‐like illness." data-id="CD001269-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 1 Influenza‐like illness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 2 Influenza." data-id="CD001269-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 2 Influenza. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 3 Hospitalisations." data-id="CD001269-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 3 Hospitalisations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 4 Pneumonia." data-id="CD001269-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 4 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-014-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-014-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 5 Working days lost." data-id="CD001269-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 5 Working days lost. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-014-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-014-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 6 Days ill." data-id="CD001269-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14 1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo, Outcome 6 Days ill. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-014-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 1968 to 1969 pandemic: inactivated polyvalent aerosol influenza vaccine versus placebo, Outcome 1 Influenza‐like illness." data-id="CD001269-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 1968 to 1969 pandemic: inactivated polyvalent aerosol influenza vaccine versus placebo, Outcome 1 Influenza‐like illness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 1968 to 1969 pandemic: inactivated monovalent aerosol influenza vaccine versus placebo, Outcome 1 Influenza‐like illness." data-id="CD001269-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 1968 to 1969 pandemic: inactivated monovalent aerosol influenza vaccine versus placebo, Outcome 1 Influenza‐like illness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 1968 to 1969 pandemic: live aerosol influenza vaccine versus placebo, Outcome 1 Influenza cases (clinically defined without clear definition)." data-id="CD001269-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 1968 to 1969 pandemic: live aerosol influenza vaccine versus placebo, Outcome 1 Influenza cases (clinically defined without clear definition). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001269-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/urn:x-wiley:14651858:media:CD001269:CD001269-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_t/tCD001269-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 1968 to 1969 pandemic: live aerosol influenza vaccine versus placebo, Outcome 2 Complications (bronchitis, otitis, pneumonia)." data-id="CD001269-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 1968 to 1969 pandemic: live aerosol influenza vaccine versus placebo, Outcome 2 Complications (bronchitis, otitis, pneumonia). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/media/CDSR/CD001269/image_n/nCD001269-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001269-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Inactivated parenteral influenza vaccine compared to placebo or 'do nothing' for preventing influenza in healthy adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Inactivated parenteral influenza vaccine compared to placebo or 'do nothing' for preventing influenza in healthy adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> healthy adults<br/> <b>Setting:</b> community‐based studies in North America, South America, and Europe (1969 to 2009)<br/> <b>Intervention:</b> inactivated parenteral influenza vaccine<br/> <b>Comparison:</b> placebo or 'do nothing' </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or 'do nothing'</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactivated parenteral influenza vaccine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Influenza</b><br/> assessed by laboratory confirmation </p> <p>Timing of assessment: most studies tested vaccines over a single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/> (0.36 to 0.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71,221<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (8 to 11) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Influenza‐like illness</b><br/> assessed by subjective report </p> <p>Timing of assessment: most studies tested vaccines over a single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.84<br/> (0.75 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>25,795<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/> (30 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000<br/> (161 to 205) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>910 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>764 per 1000<br/> (683 to 864) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hospitalisations</b> </p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.85 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,924<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>147 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/> (125 to 158) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time off work</b> </p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3726</p> <p>(4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average number of days lost per person ranged from 0.2 to 2 days over the season.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Average reduction in working days lost following vaccination was 0.04 days fewer (0.14 fewer to 0.06 days more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fever</b> </p> <p>assessed by subjective report</p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.55<br/> (1.26 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23,850<br/> (13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (19 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Nausea or vomiting</b><br/> assessed by subjective report </p> <p>Timing of assessment: single influenza season</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.80<br/> (0.65 to 5.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6315<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (24 to 185) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk calculated as the sum of events over total sample size from the control groups. For the outcome of influenza‐like illness, control group risk was stratified as low, moderate (or median), and high due to variation in risk groups across the studies. For the remaining outcomes, the control group risk was taken as aggregate.<br/> <sup>2</sup>Sensitivity analysis by excluding studies with two or more domains at unclear risk of bias did not meaningfully alter the direction, size, or precision of effect. We are confident that bias is unlikely to exaggerate the intervention effect because the absolute reduction in influenza and relative reduction in the risk of influenza‐like illness are small with vaccination.<br/> <sup>3</sup>Downgraded one level due to serious indirectness. Uncertainty over definition, surveillance and testing of influenza in older trials.<br/> <sup>4</sup>Downgraded one level for serious inconsistency. There is discordance between the direction and size of effects across the studies. Different definitions of influenza‐like illness across the studies could explain why there is variation in the event rates across the control arms.<br/> <sup>5</sup>Downgraded one level due to serious risk of bias. Meta‐analysis heavily influenced by a large study with high risk of bias across several domains.<br/> <sup>6</sup>Downgraded one level due to serious imprecision. Confidence interval includes meaningful reduction and increase in effect.<br/> <sup>7</sup>Downgraded one level due to serious risk of bias. Effect is influenced by studies judged to be at unclear risk of bias.<br/> <sup>8</sup>Downgraded one level due to serious inconsistency. Direction and magnitude of effect differed across the studies (I<sup>2</sup> = 82%). Wide confidence interval reflects the range of study effect sizes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Inactivated parenteral influenza vaccine compared to placebo or 'do nothing' for preventing influenza in healthy adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001269-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies included in the various versions of this review and their impact on our conclusions</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Review version (searches date)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included trials (RCTs/CCTs)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of included observational studies</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Estimates of effect (RCTs/CCTs only)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions (1‐2 lines from abstract)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 1</p> <p><a href="./references#CD001269-bbs2-0353" title="DemicheliV , RivettiD , DeeksJJ , JeffersonTO . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD001269] ">Demicheli 1999</a> </p> <p>(6 July 1999)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical influenza</b> </p> <p>TIV = 24% (95% CI 15% to 32%)</p> <p>LAIV = 13% (95% CI 5% to 20%)</p> <p>IAV = 40% (95% CI 13% to 59%)</p> <p><b>Laboratory‐confirmed influenza</b> </p> <p>TIV = 68% (95% CI 49% to 79%)</p> <p>LAIV = 48% (95% CI 24% to 64%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines are effective in reducing serologically confirmed cases of influenza A. However, they are not as effective in reducing cases of clinical influenza. The use of WHO recommended vaccines appears to enhance their effectiveness in practice. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 2<br/> <a href="./references#CD001269-bbs2-0355" title="DemicheliV , RivettiD , DeeksJJ , JeffersonTO . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD001269.pub2] ">Demicheli 2004</a> </p> <p>(24 May 2004)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical influenza</b> </p> <p>TIV = 25% (95% CI 13% to 35%)</p> <p>LAIV = 15% (95% CI 8% to 21%)</p> <p>IAV = 40% (95% CI 13% to 59%)</p> <p><b>Laboratory‐confirmed influenza</b> </p> <p>TIV = 70% (95% CI 56% to 80%)</p> <p>LAIV = 48% (95% CI 24% to 64%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines are effective in reducing serologically confirmed cases of influenza. However, they are not as effective in reducing cases of clinical influenza and number of working days lost. Universal immunisation of healthy adults is not supported by the results of this review. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 3<br/> <a href="./references#CD001269-bbs2-0356" title="JeffersonTO , RivettiD , DiPietrantonjC , RivettiA , DemicheliV . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD001269.pub3] ">Jefferson 2007</a> </p> <p>(16 February 2007)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(for harms only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ILI</b> </p> <p>TIV = 30% (95% CI 17% to 41%)</p> <p>LAIV = n.s.</p> <p>IAV = n.s.</p> <p><b>Influenza</b> </p> <p>TIV = 80% (95% CI 56% to 81%)</p> <p>LAIV = 56% (95% CI 19% to 76%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines are effective in reducing cases of influenza, especially when the content accurately predicts circulating types and circulation is high. However, they are less effective in reducing cases of influenza‐like illness and have a modest impact on working days lost. There is insufficient evidence to assess their impact on complications. Whole‐virion monovalent vaccines may perform best in a pandemic. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 4<br/> <a href="./references#CD001269-bbs2-0357" title="JeffersonTO , DiPietrantonjC , RivettiA , BawazeerGA , Al‐AnsaryLA , FeroniE . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD001269.pub4] ">Jefferson 2010</a> </p> <p>(15 June 2010)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(for harms only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ILI</b> </p> <p>TIV = 30% (95% CI 17% to 41%)</p> <p>LAIV = n.s.</p> <p>IAV = n.s.</p> <p><b>Influenza</b> </p> <p>TIV = 73% (95% CI 54% to 84%)</p> <p>LAIV = 56% (95% CI 19% to 76%)</p> <p>IAV = no evidence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines have a modest effect in reducing influenza symptoms and working days lost. There is no evidence that they affect complications, such as pneumonia, or transmission. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Version 5<br/> <a href="./references#CD001269-bbs2-0358" title="JeffersonT , DiPietrantonjC , RivettiA , BawazeerGA , Al‐AnsaryLA , FerroniE . Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD001269.pub5] ">Jefferson 2014</a> </p> <p>(4 March 2014)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ILI</b> </p> <p>TIV = 17% (95% CI 11% to 23%)</p> <p>LAIV = n.s.</p> <p>IAV = n.s.</p> <p><b>Influenza</b> </p> <p>TIV = 63% (95% CI 55% to 69%)</p> <p>LAIV = 45% (95% CI 18% to 63%)</p> <p>IAV = n.s.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza vaccines have a very modest effect in reducing influenza symptoms and working days lost in the general population, including pregnant women. No evidence of association between influenza vaccination and serious adverse events was found in the comparative studies considered in the review. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/> CI: confidence interval<br/> IAV: inactivated aerosol vaccines<br/> ILI: influenza‐like illness<br/> LAIV: live attenuated vaccines<br/> n.s.: not statistically significant<br/> RCT: randomised controlled trial<br/> TIV: trivalent inactivated vaccines<br/> WHO: World Health Organization<br/> <br/> <b>Versions 1 and 2</b> </p> <p>Effect estimates are from Comparison 02 (At least one vaccine recommended for that year versus placebo or other vaccine). </p> <p>A clinically defined case was assumed as any case definition based on symptoms without further specification. </p> <p>A clinically defined case (specific definition) was defined as:</p> <p> <ul id="CD001269-list-0003"> <li> <p>'flu‐like illness' according to a predefined list of symptoms (including the Centers for Disease Control and Prevention case definition for surveillance); </p> </li> <li> <p>'upper respiratory illness' according to a predefined list of symptoms.</p> </li> </ul> </p> <p>When more than one definition was given for the same trial, data related to the more specific definition were included. </p> <p>In Analysis 2.1 from versions 1 and 2, studies with both definitions are included.</p> <p>Evidence about effectiveness of aerosol inactivated vaccine comes only from studies carried out during the 1968‐69 pandemic. From version 3 onwards, specific comparisons have been added. </p> <p><b>Versions 3, 4, 5</b> </p> <p>Recommended vaccine matching circulating strains.</p> <p><b>Version 5</b> </p> <p>Out of the 42 included observational studies, 8 assessed efficacy or effectiveness of vaccine, or both, when administered during pregnancy (6 cohort and 2 case‐control studies). </p> <p><b>Version 6 (current)</b> </p> <p>In two new RCTs included in this version, vaccination was performed during pregnancy.</p> <p>Regarding efficacy/effectiveness of TIV administered in general population, estimates assessed by applying random‐effects model were 16% (95% CI 9% to 23%) against ILI and 62% (95% CI 52% to 69%) against influenza, respectively. </p> <p>In a previous interim unpublished update before the decision to stabilise the review was made, a further 16 observational studies were included: 3 case‐control and 2 cohort studies assessing the safety of influenza vaccine administration in general population, 10 cohort studies assessing the safety of influenza vaccine administration during pregnancy, and one cohort study assessing efficacy/effectiveness of the vaccine administration during pregnancy. In this 2016 updated review, we included a total of 160 studies (137 data sets), while we no longer updated searches for observational comparative studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies included in the various versions of this review and their impact on our conclusions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001269-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unclear risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case‐control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cohort</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RCT/CCT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/> RCT: randomised controlled trial </p> <p>This table displays the overall methodological quality assessment of the included studies described in the text and represented in extended form (with all items of the tools) in <a href="#CD001269-fig-0001">Figure 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001269-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Funding source of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Government, institutional, or public</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Industry</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mixed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case‐control</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cohort</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RCT/CCT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CCT: controlled clinical trial<br/> RCT: randomised controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Funding source of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001269-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for 'Summary of findings' table outcomes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome (analysis)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All studies (primary analysis)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies at low risk of bias (sensitivity analysis)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza (<a href="./references#CD001269-fig-0004" title="">Analysis 1.1</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.41 (0.36 to 0.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.34 (0.25 to 0.45)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Influenza‐like illness (<a href="./references#CD001269-fig-0005" title="">Analysis 1.2</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.84 (0.75 to 0.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.82 (0.69 to 0.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisations (<a href="./references#CD001269-fig-0011" title="">Analysis 1.8</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96 (0.85 to 1.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.89 (0.12 to 70.68)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever (<a href="./references#CD001269-fig-0014" title="">Analysis 1.11</a>.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.55 (1.26 to 1.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.59 (1 to 2.53)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting (<a href="./references#CD001269-fig-0014" title="">Analysis 1.11</a>.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.80 (0.65 to 5.04)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 7.05 (1.61 to 30.87)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>RR: risk ratio</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for 'Summary of findings' table outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/full#CD001269-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo or 'do nothing'</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.36, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.34, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.34, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Monovalent not WHO recommended ‐ vaccine matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.10, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Monovalent not WHO recommended ‐ vaccine matching ‐ high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.00, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Influenza‐like illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.75, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Monovalent not WHO recommended ‐ vaccine matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.28, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Monovalent not WHO recommended ‐ vaccine matching ‐ high dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.09, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physician visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.40, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.37, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.90, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Days ill <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.98, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐0.85, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 WHO recommended ‐ matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.16, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Times any drugs were prescribed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.03, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.04, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 WHO recommended ‐ matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Times antibiotic was prescribed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.03, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.03, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 WHO recommended ‐ matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.03, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Working days lost <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.19, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 WHO recommended ‐ matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hospitalisations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.12, 70.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Monovalent not WHO recommended ‐ vaccine matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Clinical cases (clinically defined without clear definition) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.72, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.69, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Local harms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Local ‐ tenderness/soreness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [2.44, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Local ‐ erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.77, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Local ‐ induration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.28 [1.25, 14.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Local ‐ arm stiffness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.54, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Local ‐ combined endpoint (any or highest symptom)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [1.82, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Systemic harms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Systemic ‐ myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.41, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Systemic ‐ fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.26, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Systemic ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.99, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Systemic ‐ fatigue or indisposition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.05, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Systemic ‐ nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.65, 5.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Systemic ‐ malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.18, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 Systemic ‐ combined endpoint (any or highest symptom)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.87, 1.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo or 'do nothing'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Live aerosol influenza vaccine versus placebo or 'do nothing'</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.35, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.37, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.27, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Non WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.08, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Influenza‐like illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.76, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Non WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Influenza cases (clinically defined without clear definition) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.71, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.49, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Non WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Local harms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Local ‐ upper respiratory infection symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.22, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Local ‐ cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.08, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Local ‐ coryza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.26, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Local ‐ sore throat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.49, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Local ‐ hoarseness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.51, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Local ‐ combined endpoint (any or highest symptom)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.31, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Systemic harms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Systemic ‐ myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [1.26, 4.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Systemic ‐ fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.54, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Systemic ‐ fatigue or indisposition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.93, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Systemic ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.09, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Systemic ‐ combined endpoint (any or highest symptom)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.82, 2.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Live aerosol influenza vaccine versus placebo or 'do nothing'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Inactivated aerosol influenza vaccine versus placebo or 'do nothing'</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 WHO recommended ‐ vaccine matching absent or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Local harms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.71, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Local ‐ sore throat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.54, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Local ‐ combined endpoint (any or highest symptom)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.71, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Systemic harms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.71, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Systemic ‐ myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.36, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Systemic ‐ fatigue or indisposition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.52, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Systemic ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.85, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Systemic ‐ fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.03, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Systemic ‐ combined endpoint (any or highest symptom)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.12, 1.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Inactivated aerosol influenza vaccine versus placebo or 'do nothing'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza in mothers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 TIV containing pH1N1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Influenza‐like illness in mothers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.20, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 TIV containing pH1N1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Monovalent pH1N1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Influenza in newborn <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 TIV containing pH1N1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Influenza‐like illness in newborn <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 TIV containing pH1N1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo or 'do nothing' administered during pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Seasonal inactivated vaccine effectiveness in mothers ‐ pregnant women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 H1N1 ‐ vaccine ‐ effectiveness ILI (unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.06, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Seasonal ‐ vaccine ‐ effectiveness ILI ‐ (unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seasonal inactivated vaccine effectiveness in newborns ‐ pregnant women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Seasonal vaccine effectiveness ILI (HR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Seasonal inactivated vaccine effectiveness in newborns ‐ pregnant women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Seasonal vaccine effectiveness ILI (RR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Seasonal vaccine efficacy influenza ‐ laboratory‐confirmed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 H1N1 vaccine ‐ safety ‐ pregnancy‐related outcomes ‐ pregnant women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Abortion (OR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.62, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Abortion (HR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.63, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Congenital malformation (OR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.99, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Prematurity (&lt; 37 weeks) (OR unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.67, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Prematurity (&lt; 37 weeks) (OR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Prematurity (&lt; 37 weeks) (HR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.46, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Prematurity (&lt; 37 weeks) vaccination in I trimester OR adjusted data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.92, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Prematurity (&lt; 37 weeks) vaccination in II/III trimester OR adjusted data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.87, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Neonatal death (OR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.40, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Seasonal vaccine ‐ safety ‐ pregnancy‐related outcomes ‐ pregnant women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Abortion (OR unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Congenital malformation (OR unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.08, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Prematurity (OR unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Prematurity (OR adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Neonatal death (OR unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Seasonal vaccine containing H1N1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Prematurity (37 weeks) vaccination in I trimester HR adjusted data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.76, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Prematurity (&lt; 37 weeks) vaccination in II trimester HR adjusted data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.21, 10.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Prematurity (&lt; 37 weeks) vaccination in III trimester HR adjusted data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.44, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Prematurity (&lt; 37 weeks) vaccination at any time during pregnancy HR adjusted data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.57, 5.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Effectiveness in newborns ‐ pregnant women (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.04, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Seasonal vaccine ‐ effectiveness ‐ ILI ‐ pregnant women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.04, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seasonal vaccine safety ‐ pregnancy‐related outcomes (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.36, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Abortion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.36, 1.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Inactivated parenteral influenza vaccine versus placebo ‐ case‐control studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Serious adverse events: Guillain‐Barré syndrome ‐ cohort studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Seasonal influenza vaccination and Guillain‐Barré syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.85, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 General population (adjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.83, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pregnant women (unadjusted data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.03, 15.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Serious adverse events: Guillain‐Barré syndrome ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 2009 to 2010 A/H1N1 ‐ general population (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 7 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.14, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At any time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.87, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 2009 to 2010 A/H1N1 ‐ general population (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.39, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 &lt; 7 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.35, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 &gt; 6 weeks (i.e. at any time)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.22, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Seasonal influenza vaccination general population (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.18, 10.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Serious adverse events: Guillain‐Barré syndrome ‐ case‐control studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza vaccination (seasonal) ‐ demyelinating diseases (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 General population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pregnant women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Influenza vaccination (H1N1) ‐ demyelinating diseases (unadjusted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.51, 8.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza vaccination (seasonal) ‐ general population ‐ demyelinating diseases (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Influenza vaccination (seasonal) ‐ general population ‐ multiple sclerosis (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Influenza vaccination (seasonal) ‐ general population ‐ optic neuritis (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Serious adverse events: demyelinating diseases (multiple sclerosis, optic neuritis) ‐ case‐control studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Seasonal influenza vaccine ‐ HR (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 General population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pregnant women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.68, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seasonal influenza vaccine (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 General population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pregnant women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.70, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Serious adverse events: immune thrombocytopenic purpura ‐ cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Seasonal influenza vaccine ‐ general population (adjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.43, 8.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.55, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seasonal influenza vaccine ‐ general population (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 &lt; 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.48, 6.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.59, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Serious adverse events: immune thrombocytopenic purpura ‐ case‐control studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza‐like illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Standard recommended parenteral ‐ non‐matching ‐ 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.57, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Standard recommended parenteral ‐ non‐matching ‐ 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.44, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Influenza <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Standard recommended parenteral ‐ non‐matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospitalisations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Standard recommended parenteral ‐ non‐matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.41, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.14, 7.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Standard recommended parenteral ‐ non‐matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.14, 7.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">1968 to 1969 pandemic: inactivated polyvalent parenteral influenza vaccine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza‐like illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.25, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 WHO recommended parenteral ‐ matching vaccine ‐ 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.23, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 WHO recommended parenteral ‐ matching vaccine ‐ 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.22, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Influenza <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 WHO recommended parenteral ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospitalisations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.13, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 WHO recommended parenteral ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.13, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.05, 6.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 WHO recommended parenteral ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.05, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Working days lost <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.60, ‐0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 WHO recommended parenteral ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.60, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Days ill <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.60, ‐0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 WHO recommended ‐ matching vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.60, ‐0.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">1968 to 1969 pandemic: inactivated monovalent parenteral influenza vaccine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">1968 to 1969 pandemic: inactivated polyvalent aerosol influenza vaccine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza‐like illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.46, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Inactivated polyvalent aerosol vaccine versus placebo ‐ non‐matching ‐ 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.32, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Inactivated polyvalent aerosol vaccine versus placebo ‐ non‐matching ‐ 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">1968 to 1969 pandemic: inactivated polyvalent aerosol influenza vaccine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">1968 to 1969 pandemic: inactivated monovalent aerosol influenza vaccine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza‐like illness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.32, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Inactivated monovalent aerosol vaccine versus placebo ‐ matching ‐ 1 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.17, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Inactivated monovalent aerosol vaccine versus placebo ‐ matching ‐ 2 doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.38, 0.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">1968 to 1969 pandemic: inactivated monovalent aerosol influenza vaccine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001269-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">1968 to 1969 pandemic: live aerosol influenza vaccine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Influenza cases (clinically defined without clear definition) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Non‐matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Complications (bronchitis, otitis, pneumonia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Non‐matching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">1968 to 1969 pandemic: live aerosol influenza vaccine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001269.pub6/references#CD001269-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001269.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001269-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001269-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001269-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001269-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001269-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001269-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001269-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001269-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD001269-note-0020">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD001269-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001269-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001269-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001269-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001269\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001269\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001269\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001269\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001269\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001269.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001269.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001269.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001269.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001269.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713862342"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001269.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713862346"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001269.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6097de92936e',t:'MTc0MDcxMzg2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 